U.S. patent application number 14/098317 was filed with the patent office on 2014-07-03 for drug cores for sustained release of therapeutic agents.
This patent application is currently assigned to Mati Therapeutics, Inc.. The applicant listed for this patent is Mati Therapeutics, Inc.. Invention is credited to Stephen Boyd, Eugene De Juan, JR., Hanson S. Gifford, Rachna Jain, Cary J. Reich, Robert W. Shimizu, Deepank Utkhede.
Application Number | 20140186420 14/098317 |
Document ID | / |
Family ID | 39874137 |
Filed Date | 2014-07-03 |
United States Patent
Application |
20140186420 |
Kind Code |
A1 |
Utkhede; Deepank ; et
al. |
July 3, 2014 |
DRUG CORES FOR SUSTAINED RELEASE OF THERAPEUTIC AGENTS
Abstract
A solid drug core insert can be manufactured by injecting a
liquid mixture comprising a therapeutic agent and a matrix
precursor into a sheath body. The injection can be conducted at
subambient temperatures. The mixture is cured to form a solid
drug-matrix core. The therapeutic agent can be a liquid at about
room temperature that forms a dispersion of droplets in the matrix
material. A surface of the solid drug core is exposed, for example
by cutting the tube, and the exposed surface of the solid drug core
releases therapeutic quantities of the therapeutic agent when
implanted into the patient. In some embodiments, the insert body
inhibits release of the therapeutic agent, for example with a
material substantially impermeable to the therapeutic agent, such
that the therapeutic quantities are released through the exposed
surface, thereby avoiding release of the therapeutic agent to
non-target tissues.
Inventors: |
Utkhede; Deepank; (Surrey,
CA) ; Shimizu; Robert W.; (Laguna Niguel, CA)
; Jain; Rachna; (Milpitas, CA) ; Boyd;
Stephen; (Murrieta, CA) ; Gifford; Hanson S.;
(Woodside, CA) ; De Juan, JR.; Eugene; (San
Francisco, CA) ; Reich; Cary J.; (Los Gatos,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Mati Therapeutics, Inc. |
Austin |
TX |
US |
|
|
Assignee: |
Mati Therapeutics, Inc.
Austin
TX
|
Family ID: |
39874137 |
Appl. No.: |
14/098317 |
Filed: |
December 5, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13367823 |
Feb 7, 2012 |
8628792 |
|
|
14098317 |
|
|
|
|
12231986 |
Sep 5, 2008 |
|
|
|
13367823 |
|
|
|
|
60970699 |
Sep 7, 2007 |
|
|
|
60970709 |
Sep 7, 2007 |
|
|
|
60970820 |
Sep 7, 2007 |
|
|
|
61049317 |
Apr 30, 2008 |
|
|
|
Current U.S.
Class: |
424/427 ;
514/530 |
Current CPC
Class: |
A61P 27/06 20180101;
A61P 27/02 20180101; A61K 47/34 20130101; A61P 25/04 20180101; A61F
9/0017 20130101; Y02A 50/395 20180101; A61F 2230/0069 20130101;
A61P 29/00 20180101; A61F 9/00772 20130101; A61K 9/0051 20130101;
A61P 43/00 20180101; A61P 37/08 20180101; A61P 31/10 20180101; A61L
2300/602 20130101; A61P 31/04 20180101; Y02A 50/30 20180101; A61L
2300/802 20130101; A61L 27/54 20130101; A61P 31/00 20180101; A61F
2250/0067 20130101; A61L 2300/41 20130101; A61K 31/5575
20130101 |
Class at
Publication: |
424/427 ;
514/530 |
International
Class: |
A61K 9/00 20060101
A61K009/00; A61K 31/5575 20060101 A61K031/5575 |
Claims
1. A drug insert for an implant body adapted for disposition within
or adjacent to a body cavity, tissue, duct or fluid of a patient,
wherein the drug insert comprises: a cured mixture comprising
latanoprost and a silicone matrix, wherein the latanoprost is
dispersed within the mixture as inclusions with an average diameter
of less than about 10 .mu.m; and an impermeable sheath body
partially covering the cured mixture to provide at least one
exposed surface.
2. The drug insert of claim 1, wherein the implant is adapted for
disposition in or adjacent to an eye of a patient.
3. The drug insert of claim 1, wherein the implant body comprises a
punctal plug adapted to be disposed within the punctum of the
patient.
4. The drug insert of claim 1, wherein the inclusions of
latanoprost are uniformly and homogeneously dispersed throughout
the cured mixture.
5. The drug insert of claim 1, wherein the amount of the
latanoprost in a volumetric portion of the cured mixture varies
from the amount of the latanoprost in any other equal volumetric
portion of the cured mixture by no greater than about 10%.
6. The drug insert of claim 1, wherein the amount of the
latanoprost in a volumetric portion of the cured mixture varies
from the amount of the latanoprost in any other equal volumetric
portion of the cured mixture by no greater than about 5%.
7. The drug insert of claim 1, further comprising a seal on one end
of the drug insert wherein a second end is the exposed surface.
8. The drug insert of claim 1, wherein the one end is sealed with a
UV-curable adhesive, a cyanoacrylate, an epoxy, by pinching, with a
heat weld, or with a cap.
9. The drug insert of claim 1, wherein the insert comprises about
0.1 wt % to about 50 wt % of the latanoprost.
10. The drug insert of claim 1, wherein the insert comprises about
10 wt % to about 50 wt % of the latanoprost.
11. The drug insert of claim 1, wherein the insert comprises about
20 wt % to about 50 wt % of the latanoprost.
12. The drug insert of claim 1, wherein the sheath body comprises
at least one of polyimide, PMMA, PET, stainless steel, or
titanium.
13. The drug insert of claim 1, wherein the drug insert is about
0.80 to about 1.0 mm in length.
14. The drug insert of claim 1, wherein the drug insert has a
diameter of about 0.2 to about 0.75 mm.
15. The drug insert of claim 1, wherein the average diameter of the
latanoprost inclusions are uniform in size and shape throughout the
cured mixture.
16. The drug insert of claim 1, wherein the drug insert is
configured to elute at least about 100 ng per day of the
latanoprost.
17. The drug insert of claim 1, wherein the drug insert is
configured to elute a therapeutic level of the latanoprost during a
treatment period of at least 20 days.
18. The drug insert of claim 1, wherein the cured mixture further
comprises a salt.
19. The drug insert of claim 1, wherein the inclusions of
latanoprost have an average diameter of less than about 7 .mu.m.
Description
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application is a continuation application under 35
U.S.C. .sctn.120 of U.S. patent application Ser. No. 12/231,986,
filed Sep. 5, 2008, which claims the benefit of priority under 35
U.S.C. .sctn.119(e) to U.S. Provisional Patent Application Ser.
Nos. 60/970,699, filed Sep. 7, 2007; 60/970,709, filed Sep. 7,
2007; 60/970,820, filed Sep. 7, 2007; and 61/049,317, filed Apr.
30, 2008, which are all incorporated herein by reference in their
entireties.
[0002] The subject matter of this application is related to that of
U.S. patent application Ser. No. 11/695,537, filed on Apr. 2, 2007,
published as U.S. Patent Application Publication No. 2007/0269487
on Nov. 22, 2007, which claims the benefit of U.S. Provisional
Application No. 60/871,864, filed on Dec. 26, 2006, the disclosures
of which are incorporated herein by reference in their
entireties.
[0003] The subject matter of this application is related to that of
U.S. Pat. App. No. 61/057,246, filed on May 30, 2008 and U.S. Pat.
App. No. 61/132,927, filed on Jun. 24, 2008, and U.S. patent
application Ser. No. 12/231,989, filed Sep. 8, 2008, entitled
"LACRIMAL IMPLANTS AND RELATED METHODS," and published as U.S.
Patent Application Publication No. 2009/0104248 on Apr. 23,
2009.
BACKGROUND
[0004] A variety of challenges face patients and physicians in the
area of drug delivery, for example, ocular drug delivery. In
particular, the repetitive nature of the therapies (multiple
injections, instilling multiple eye drop regimens per day), the
associated costs, and the lack of patient compliance may
significantly impact the efficacy of the therapies available,
leading to reduction in vision and many times blindness.
[0005] Patient compliance in taking the medications, for example,
instilling the eye drops, can be erratic, and in some cases,
patients may not follow the directed treatment regime. Lack of
compliance can include, failure to instill the drops, ineffective
technique (instilling less than required), excessive use of the
drops (leading to systemic side effects), and use of non-prescribed
drops or failure to follow the treatment regime requiring multiple
types of drops. Many of the medications may require the patient to
instill them up to 4 times a day.
[0006] In addition to compliance, the cost of at least some eye
drop medications is increasing, leading some patients on limited
incomes to be faced with the choice of buying basic necessities or
instead getting their prescriptions filled. Many times insurance
does not cover the total cost of the prescribed eye drop
medication, or in some cases eye drops containing multiple
different medications.
[0007] Further, in many cases, topically applied medications have a
peak ocular effect within about two hours, after which additional
applications of the medications should be performed to maintain the
therapeutic benefit. In addition, inconsistency in
self-administered or ingested medication regimes can result in a
suboptimal therapy. PCT Publication WO 06/014434 (Lazar), which is
incorporated herein by reference in its entirety, may be relevant
to these and/or other issues associated with eye drops.
[0008] One promising approach to ocular drug delivery is to place
an implant that releases a drug in tissue near the eye. Although
this approach can offer some improvement over eye drops, some
potential problems of this approach may include implantation of the
implant at the desired tissue location, retention of the implant at
the desired tissue location, and sustaining release of the drug at
the desired therapeutic level for an extended period of time. For
example in the case of glaucoma treatment, visits to the treating
physician can be months apart, and premature depletion and/or
premature release of a drug from an implant can result in
insufficient drug being delivered for a portion of the treatment
period. This can result in the patient potentially suffering a
reduction in vision or blindness.
[0009] In light of the above, it would be desirable to provide for
the manufacture of improved drug delivery implants that overcome at
least some of the above mentioned shortcomings.
SUMMARY
[0010] The present invention is directed to various embodiments of
drug inserts and drug cores containing therapeutic agents for use
in implant bodies adapted for disposition in a body tissue, fluid,
cavity, or duct. The implant bodies can be adapted to be disposed
in or adjacent to an eye of a patient. The implants release the
agent to the body, for example, into an eye or surrounding tissues,
or both, over a period of time, for treatment of a malcondition in
the patient for which use of the therapeutic agent is medically
indicated. The invention is also directed to various embodiments of
methods of manufacture of the drug inserts and drug cores, and to
methods of treatment of patients using implants containing the drug
inserts or drug inserts.
[0011] In various embodiments, the invention provides a drug insert
adapted for disposition within an implant, the implant being
adapted for disposition within or adjacent to an eye of a patient,
the drug insert comprising a drug core that can include a sheath
body partially covering the drug core, the drug core comprising a
therapeutic agent and a matrix wherein the matrix comprises a
polymer, the sheath body being disposed over a portion of the drug
core to control the release of the agent from said portion and so
as to define at least one exposed surface of the drug core adapted
to release the agent, or any combination thereof, when the implant
is inserted into the patient, wherein an amount of the therapeutic
agent in a volumetric portion of the drug core is similar to an
amount of the therapeutic agent in any other equal volumetric
portion of the drug core. For example, the therapeutic agent may be
uniformly and homogeneously dispersed throughout the matrix, or the
therapeutic agent at least in part forms solid or liquid inclusions
within the matrix. For example, the amount of the therapeutic agent
within the volumetric portion of the drug core may vary from the
amount of the therapeutic agent within any other equal volumetric
portion of the drug core by no greater than about 30%. For example,
the amount of the therapeutic agent within the volumetric portion
of the drug core varies from the amount of the therapeutic agent
within any other equal volumetric portion of the drug core by no
greater than about 20%. For example, the amount of the therapeutic
agent within the volumetric portion of the drug core varies from
the amount of the therapeutic agent within any other equal
volumetric portion of the drug core by no greater than about 10%.
For example, the amount of the therapeutic agent within the
volumetric portion of the drug core varies from the amount of the
therapeutic agent within any other equal volumetric portion of the
drug core by no greater than about 5%. For example, the amount of
the therapeutic agent within a volumetric portion of the drug core
is the same as the amount of the therapeutic agent within any other
equal volumetric portion of the drug core. In various embodiments,
the drug insert can be adapted to release the agent to the eye,
surrounding tissues, systemically, or any combination thereof,
and/or for providing sustained release of a therapeutic agent to
the eye or surrounding tissues, or systemically, or any combination
thereof.
[0012] In various embodiments, the invention provides a plurality
of the drug inserts as described above wherein each of the
plurality of the inserts comprises a similar amount of the agent
dispersed respectively therewithin. For example, the similar amount
of agent dispersed respectively therein can vary no greater than
about 30% therebetween. For example, the similar amount of agent
dispersed respectively therein can vary no greater than about 20%
therebetween. For example, the similar amount of agent dispersed
respectively therein can vary no greater than about 10%
therebetween. For example, the similar amount of agent dispersed
respectively therein can vary no greater than about 5%
therebetween.
[0013] In various embodiments, the invention provides a drug core
comprising a therapeutic agent and a matrix wherein the matrix
comprises a polymer, for disposition into a drug insert or an
implant, the drug insert or the implant being adapted for
disposition within or adjacent to an eye of a patient, wherein the
therapeutic agent is uniformly homogeneously dispersed throughout
the matrix, or the therapeutic agent at least in part forms solid
or liquid inclusions within the matrix; wherein an amount of the
therapeutic agent in a volumetric portion of the drug core is
similar to an amount of the therapeutic agent in any other equal
volumetric portion of the drug core. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 30%.
For example, the amount of the therapeutic agent in a volumetric
portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 20%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 10%.
For example, the amount of the therapeutic agent in a volumetric
portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 5%. For example, the amount of the
therapeutic agent within a volumetric portion of the drug core is
the same as the amount of the therapeutic agent within any other
equal volumetric portion of the drug core. In various embodiments,
the drug insert can be adapted to release the agent to the eye,
surrounding tissues, systemically, or any combination thereof,
and/or for providing sustained release of a therapeutic agent to
the eye or surrounding tissues, or systemically, or any combination
thereof.
[0014] In various embodiments, the invention provides an implant
for sustained delivery of a therapeutic agent to a patient, wherein
the entire implant comprises a drug core comprising a therapeutic
agent and a matrix, wherein the matrix comprises a polymer. A
porous or absorbent material can alternatively be used to make up
the entire implant or plug which can be saturated with the active
agent.
[0015] In various embodiments, the invention provides a filled
precursor sheath adapted for manufacture of a plurality of drug
inserts therefrom by division of the filled precursor sheath, each
drug insert being adapted for disposition within a respective
implant, the implant being adapted for disposition within or
adjacent to an eye of a patient, the filled precursor sheath
comprising a precursor sheath body and a precursor drug core
contained therewithin, the precursor drug core comprising a
therapeutic agent and a matrix wherein the matrix comprises a
polymer, wherein the therapeutic agent is uniformly and
homogeneously dispersed throughout the matrix, or the therapeutic
agent at least in part forms solid or liquid inclusions within the
matrix, wherein an amount of the therapeutic agent in a volumetric
portion of the precursor drug core is similar to an amount of the
therapeutic agent in any other equal volumetric portion of the
precursor drug core, the precursor sheath body being substantially
impermeable to the agent, each of the plurality of inserts divided
therefrom being adapted to release the agent, a respective sheath
body of each of the plurality of inserts divided from the filled
precursor sheath being disposed over a portion of a respective drug
core of each of the plurality of inserts to inhibit release of the
agent from said portion and so as to define at least one exposed
surface of the drug core adapted to release the agent, when the
insert is disposed in an implant and the implant is inserted into
the patient. For example, an amount of the therapeutic agent in a
volumetric portion of the precursor drug core can vary from an
amount of the therapeutic agent in any other equal volumetric
portion of the precursor drug core by no greater than about 30%.
For example, an amount of the therapeutic agent in a volumetric
portion of the precursor drug core can vary from an amount of the
therapeutic agent in any other equal volumetric portion of the
precursor drug core by no greater than about 20%. For example, an
amount of the therapeutic agent in a volumetric portion of the
precursor drug core can vary from an amount of the therapeutic
agent in any other equal volumetric portion of the precursor drug
core by no greater than about 10%. For example, an amount of the
therapeutic agent in a volumetric portion of the precursor drug
core can vary from an amount of the therapeutic agent in any other
equal volumetric portion of the precursor drug core by no greater
than about 5%. For example, the amount of the therapeutic agent
within a volumetric portion of the drug core is the same as the
amount of the therapeutic agent within any other equal volumetric
portion of the drug core. In various embodiments, the drug insert
can be adapted to release the agent to the eye, surrounding
tissues, systemically, or any combination thereof, and/or for
providing sustained release of a therapeutic agent to the eye or
surrounding tissues, or systemically, or any combination
thereof.
[0016] In various embodiments, the invention provides an implant
body for disposition in or adjacent to an eye of a patient, the
implant body comprising a channel therein adapted to receive a drug
insert such that an exposed surface of the drug insert will be
exposed to tear liquid when the drug insert is disposed within the
implant and when the implant is disposed in or adjacent to the eye,
the drug insert comprising a sheath body that is substantially
impermeable to the agent, containing therewithin a drug core
comprising a therapeutic agent and a matrix comprising a polymer,
wherein the therapeutic agent is uniformly and homogeneously
dispersed throughout the matrix, or the therapeutic agent at least
in part forms solid or liquid inclusions within the matrix wherein
an amount of the therapeutic agent in a volumetric portion of the
drug core is similar to an amount of the therapeutic agent in any
other equal volumetric portion of the drug core, the body
comprising a biocompatible material and being adapted to be
retained within or adjacent to the eye for a period of time. For
example, the amount of the therapeutic agent in a volumetric
portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 30%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 20%.
For example, the amount of the therapeutic agent in a volumetric
portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 10%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 5%.
For example, the amount of the therapeutic agent within a
volumetric portion of the drug core is the same as the amount of
the therapeutic agent within any other equal volumetric portion of
the drug core. In various embodiments, the drug insert can be
adapted to release the agent to the eye, surrounding tissues,
systemically, or any combination thereof, and/or for providing
sustained release of a therapeutic agent to the eye or surrounding
tissues, or systemically, or any combination thereof.
[0017] In various embodiments, the invention provides an implant
body for disposition in or adjacent to an eye of a patient, the
implant body comprising a channel therein adapted to receive a drug
core such that an exposed surface of the drug core will be exposed
to tear liquid when the drug core is disposed within the implant
and when the implant is disposed in or adjacent to the eye, the
drug core comprising a therapeutic agent and a matrix comprising a
polymer, wherein an amount of the therapeutic agent in a volumetric
portion of the drug core is similar to an amount of the therapeutic
agent in any equal volumetric portion of the drug core, wherein the
therapeutic agent is sufficiently soluble in the matrix such that
therapeutic quantities of the agent will be released from the
exposed surface of the drug core to tear liquid in contact with the
exposed surface when the implant body is disposed in or adjacent to
an eye, the body comprising a biocompatible material and being
adapted to be retained within or adjacent to the eye for a period
of time. For example, the amount of the therapeutic agent in a
volumetric portion of the drug core can vary from the amount of the
therapeutic agent in any equal volumetric portion of the drug core
by no greater than about 30%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any equal volumetric
portion of the drug core by no greater than about 20%. For example,
the amount of the therapeutic agent in a volumetric portion of the
drug core can vary from the amount of the therapeutic agent in any
equal volumetric portion of the drug core by no greater than about
10%. For example, the amount of the therapeutic agent in a
volumetric portion of the drug core can vary from the amount of the
therapeutic agent in any equal volumetric portion of the drug core
by no greater than about 5%. In various embodiments, the drug core
can be adapted to release the therapeutic agent to the eye,
surrounding tissues, systemically, or any combination thereof,
and/or for providing sustained release of a therapeutic agent to
the eye or surrounding tissues, or systemically, or any combination
thereof.
[0018] In various embodiments, the invention provides a method of
manufacturing a drug insert for an implant body adapted for
disposition within or adjacent to an eye of a patient, the insert
comprising a drug core comprising a therapeutic agent and a matrix
wherein the matrix comprises a polymer, wherein the therapeutic
agent is uniformly and homogeneously dispersed throughout the
matrix, or the therapeutic agent at least in part forms solid or
liquid inclusions within the matrix wherein an amount of the
therapeutic agent in a volumetric portion of the drug core is
similar to an amount of the therapeutic agent in any other equal
volumetric portion of the drug core, the sheath body being disposed
over a portion of the drug core to inhibit release of the agent
from said portion and so as to define at least one exposed surface
of the drug core adapted to release the agent when the implant is
inserted into the patient; the method comprising injecting, at a
subambient temperature of less than about 20.degree. C., a mixture
comprising a matrix precursor and the agent into the sheath body
such that the sheath body is substantially filled therewith; then,
curing the mixture comprising the matrix precursor within the
sheath body to form the drug insert such that a drug core having an
exposed surface is formed therein. In various embodiments, the drug
insert can be adapted to release the agent to the eye, surrounding
tissues, systemically, or any combination thereof, and/or for
providing sustained release of a therapeutic agent to the eye or
surrounding tissues, or systemically, or any combination
thereof.
[0019] In various embodiments, the invention provides a method of
manufacturing a drug insert for an implant body adapted for
disposition within or adjacent to an eye of a patient, the method
comprising injecting, at a subambient temperature of less than
about 20.degree. C., a mixture comprising a therapeutic agent and a
matrix precursor into a precursor sheath body, wherein the
therapeutic agent is uniformly and homogeneously dispersed
throughout the matrix, or the therapeutic agent at least in part
forms solid or liquid inclusions within the matrix, wherein an
amount of the therapeutic agent in a volumetric portion of the drug
core is similar to an amount of the therapeutic agent in any other
equal volumetric portion of the drug core, the precursor sheath
body being substantially impermeable to the agent, such that the
precursor sheath is substantially filled therewith to provide a
filled precursor sheath; then, curing the mixture such that a
precursor drug core is formed within the precursor sheath body, and
then, dividing the filled precursor sheath to form a plurality of
drug inserts therefrom, wherein each drug insert comprises a drug
core and a sheath body, the sheath body being disposed over a
portion of the drug core to inhibit release of the agent from said
portion and so as to define at least one exposed surface of the
drug core, when the insert is disposed with an implant and the
implant is inserted into the patient; each insert being adapted fit
within a respective implant body and to release, through the
exposed surface of the insert, therapeutic quantities of the agent
to tear liquid; wherein each of the plurality of drug inserts is of
substantially the same length, wherein an amount of the agent in
each of the plurality of inserts divided from the filled precursor
sheath is similar.
[0020] For example, the amount of the therapeutic agent in a
volumetric portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 30%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 20%.
For example, the amount of the therapeutic agent in a volumetric
portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 10%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 5%.
For example, the amount of the agent in each of the plurality of
inserts can vary by no greater than about 30% therebetween. For
example, the amount of the agent in each of the plurality of
inserts can vary by no greater than about 20% therebetween. For
example, the amount of the agent in each of the plurality of
inserts can vary by no greater than about 10% therebetween. For
example, the amount of the agent in each of the plurality of
inserts can vary by no greater than about 5% therebetween.
[0021] In further embodiments, the method of manufacturing a drug
insert further comprises, after the curing step as described
herein, extruding the drug core from the sheath body prior to or
after dividing the filled sheath body into a plurality of drug
insert, thereby forming the drug cores free of the sheath body
material.
[0022] In various embodiments, the above methods are employed to
manufacture an implant for sustained delivery of a therapeutic
agent to a patient, wherein the entire implant comprises a drug
core comprising a therapeutic agent and a matrix, wherein the
matrix comprises a polymer. A porous or absorbent material can
alternatively be used to make up the entire implant or plug which
can be saturated with the active agent. In other embodiments, a
therapeutic agent and a matrix as described herein are added to a
mold to form the drug core; the drug core is then cured, then used
as an implant for sustained delivery of the therapeutic agent to a
patient.
[0023] In various embodiments, the invention provides a drug insert
made by a method of the invention.
[0024] In various embodiments, the invention provides a method of
treating a malcondition in a patient in need thereof; comprising
disposing an implant comprising a drug insert of the invention, or
a drug core of the invention, or a drug core obtained by division
of a filled precursor sheath of the invention, or a drug implant of
the invention, or a drug insert prepared by the method of the
invention, wherein the therapeutic agent is adapted to treat the
malcondition, in or adjacent to an eye of the patient such that the
drug is released into a body tissue or fluid.
[0025] In various embodiments, the invention provides the use of a
drug insert of the invention, or a drug core of the invention, or a
drug core obtained by division of a filled precursor sheath of the
invention, or a drug implant of the invention, or a drug insert
prepared by the method of the invention, in the manufacture of an
implant adapted for treatment of a malcondition in a patient in
need thereof.
[0026] In various embodiments, the invention provides a drug insert
adapted for disposition within an punctal plug for providing
sustained release of a latanoprost to the eye for treatment of
glaucoma, the insert comprising a core and a sheath body partially
covering the core, the core comprising the latanoprost and a matrix
wherein the matrix comprises a silicone polymer, the latanoprost
being contained within the silicone as droplets thereof, wherein an
amount of the latanoprost in a volumetric portion of the drug core
is similar to an amount of the latanoprost in any other equal
volumetric portion of the drug core, the sheath body being disposed
over a portion of the core to inhibit release of the latanoprost
from said portion, an exposed surface of the core not covered by
the sheath body being adapted to release the latanoprost to the
eye.
[0027] In various embodiments, the invention provides a drug insert
adapted for disposition within an punctal plug for providing
sustained release of a cyclosporine to the eye for treatment of dry
eye or inflammation, the insert comprising a core and a sheath body
partially covering the core, the core comprising the cyclosporine
and a matrix wherein the matrix comprises a polyurethane polymer,
the cyclosporine being contained within the polyurethane, wherein
an amount of the cyclosporine in a volumetric portion of the drug
core is similar to an amount of the cyclosporine in any other equal
volumetric portion of the drug core, the sheath body being disposed
over a portion of the core to inhibit release of the cyclosporine
from said portion, an exposed surface of the core not covered by
the sheath body being adapted to release the cyclosporine to the
eye.
[0028] In various embodiments, the invention provides a drug insert
adapted for disposition within an implant, the implant being
adapted for disposition within or adjacent to a body cavity,
tissue, duct, or fluid, for providing sustained release of a
therapeutic agent to the cavity, duct, tissue, or surrounding
tissues or any combination thereof, the insert comprising a drug
core and a sheath body partially covering the drug core, the drug
core comprising a therapeutic agent and a matrix wherein the matrix
comprises a polymer, wherein the therapeutic agent is uniformly and
homogeneously dispersed throughout the matrix, or the therapeutic
agent at least in part forms solid or liquid inclusions within the
matrix, wherein an amount of the therapeutic agent in a volumetric
portion of the drug core is similar to an amount of the therapeutic
agent in any other equal volumetric portion of the drug core, the
sheath body being disposed over a portion of the drug core to
inhibit release of the agent from said portion and so as to define
at least one exposed surface of the drug core adapted to release
the agent to the cavity, duct, tissue, or surrounding tissues or
any combination thereof, when the implant is inserted into the
patient.
[0029] In various embodiments, the invention provides a drug insert
adapted for disposition within an implant, the implant being
adapted for disposition within or adjacent to an eye of a patient,
for providing sustained release of a therapeutic agent
systemically, the insert comprising a drug core and a sheath body
partially covering the drug core, the drug core comprising a
therapeutic agent and a matrix wherein the matrix comprises a
polymer, wherein the therapeutic agent is uniformly and
homogeneously dispersed throughout the matrix, or the therapeutic
agent at least in part forms solid or liquid inclusions within the
matrix, wherein an amount of the therapeutic agent in a volumetric
portion of the drug core is similar to an amount of the therapeutic
agent in any other equal volumetric portion of the drug core, the
sheath body being disposed over a portion of the drug core to
inhibit release of the agent from said portion and so as to define
at least one exposed surface of the drug core adapted to release
the agent systemically when the implant is inserted into the
patient.
[0030] In various embodiments, the invention provides a drug core
comprising a therapeutic agent and a matrix wherein the matrix
comprises a polymer, for disposition as or into a drug insert or an
implant, the drug insert or the implant being adapted for
disposition within or adjacent to a body cavity, tissue, duct, or
fluid, for providing sustained release of a therapeutic agent to
the cavity, duct, tissue, or surrounding tissues or any combination
thereof, wherein the therapeutic agent is uniformly homogeneously
dispersed throughout the matrix, or the therapeutic agent at least
in part forms solid or liquid inclusions within the matrix; wherein
an amount of the therapeutic agent in a volumetric portion of the
drug core is similar to an amount of the therapeutic agent in any
other equal volumetric portion of the drug core.
[0031] In various embodiments, the invention provides a drug core
comprising a therapeutic agent and a matrix wherein the matrix
comprises a polymer, for disposition as or into a drug insert or an
implant, the drug insert or the implant being adapted for
disposition within or adjacent to an eye of a patient for providing
sustained release of the therapeutic agent systemically, wherein
the therapeutic agent is uniformly homogeneously dispersed
throughout the matrix, or the therapeutic agent at least in part
forms solid or liquid inclusions within the matrix; wherein an
amount of the therapeutic agent in a volumetric portion of the drug
core is similar to an amount of the therapeutic agent in any other
equal volumetric portion of the drug core. The drug core may be
formed into an implant or drug insert by molding the matrix with
the therapeutic agent into an appropriate shape. The implant of
this form has no sheath or outer implant body or housing.
[0032] Although it is not intended to be a limitation of the
invention, it is believed the therapeutic agent transports through
the matrix to its surface whereupon the agent becomes dispersed,
dissolved or otherwise entrained with body fluid for delivery to
target tissue. The transport may be the result of and/or influenced
by diffusion, molecular interaction, domain formation and
transport, infusion of body fluid into the matrix or other
mechanisms. For delivery to the eye, therapeutic quantities of
agent transport to the exposed surface of the matrix whereupon tear
liquid will sweep away the agent for delivery to target tissue or
tissues.
[0033] To better illustrate the invention described herein, a
non-limiting list of exemplary aspects and embodiments of the
invention is provided as follows.
[0034] Aspect A1 concerns a drug insert adapted for disposition
within an implant, the implant being adapted for disposition within
or adjacent to a body cavity, tissue, duct, or fluid, the insert
comprising a drug core and a sheath body partially covering the
drug core, the drug core comprising a therapeutic agent and a
matrix, the matrix comprising a polymer, the sheath body being
disposed over a portion of the drug core to inhibit release of the
agent from said portion and so as to define at least one exposed
surface of the drug core adapted to release the agent to the
cavity, tissue, duct, or fluid, or any combination thereof when the
implant is inserted into the patient, and wherein an amount of the
therapeutic agent in a volumetric portion of the drug core is
similar to an amount of the therapeutic agent in any other equal
volumetric portion of the drug core.
[0035] Embodiment A2 concerns the drug insert of aspect A1 wherein
the amount of the therapeutic agent within the volumetric portion
of the drug core varies from the amount of the therapeutic agent
within any other equal volumetric portion of the drug core by no
greater than about 30%.
[0036] Embodiment A3 concerns the drug insert of aspect A1 wherein
the amount of the therapeutic agent within the volumetric portion
of the drug core varies from the amount of the therapeutic agent
within any other equal volumetric portion of the drug core by no
greater than about 20%.
[0037] Embodiment A4 concerns the drug insert of aspect A1 wherein
the amount of the therapeutic agent within the volumetric portion
of the drug core varies from the amount of the therapeutic agent
within any other equal volumetric portion of the drug core by no
greater than about 10%.
[0038] Embodiment A5 concerns the drug insert of aspect A1 wherein
the amount of the therapeutic agent within the volumetric portion
of the drug core varies from the amount of the therapeutic agent
within any other equal volumetric portion of the drug core by no
greater than about 5%.
[0039] Embodiment A6 concerns the drug insert of aspect A1 wherein
the implant is a punctal plug.
[0040] Embodiment A7 concerns a plurality of the drug inserts of
aspect A1 wherein each of the plurality of the inserts comprises a
similar concentration of the agent relative to the other inserts of
the plurality.
[0041] Embodiment A8 concerns the plurality of drug inserts of
embodiment A7 wherein the similar concentration of agent varies no
greater than about 30% therebetween.
[0042] Embodiment A9 concerns the plurality of drug inserts of
embodiment A7 wherein the similar concentration of agent varies no
greater than about 20% therebetween.
[0043] Embodiment A10 concerns the plurality of drug inserts of
embodiment A7 wherein the similar concentration of agent varies no
greater than about 10% therebetween.
[0044] Embodiment A11 concerns the plurality of drug inserts of
embodiment A7 wherein the similar concentration of agent varies no
greater than about 5% therebetween.
[0045] Embodiment A12 concerns the drug insert of aspect A1 wherein
the exposed surface is adapted to release therapeutic quantities of
the agent for a time period of at least several days into tear
liquid when the implant is inserted into the patient.
[0046] Embodiment A13 concerns the plurality of drug inserts of
embodiment A7 wherein the exposed surface of each of the plurality
of drug inserts is adapted to release therapeutic quantities of the
agent for a time period of at least several days into tear liquid
when the implant is inserted into the patient, wherein the
therapeutic quantity of the agent released by each of the plurality
of drug insert is similar.
[0047] Embodiment A14 concerns the plurality of embodiment A13,
wherein the therapeutic quantity of the agent released by each of
the plurality of the inserts varies by no greater than about 30%
therebetween.
[0048] Embodiment A15 concerns the plurality of embodiment A13,
wherein the therapeutic quantity of the agent released by each of
the plurality of the inserts varies by no greater than about 20%
therebetween.
[0049] Embodiment A16 concerns the plurality of embodiment A13,
wherein the therapeutic quantity of the agent released by each of
the plurality of the inserts varies by no greater than about 10%
therebetween.
[0050] Embodiment A17 concerns the plurality of embodiment A13,
wherein the therapeutic quantity of the agent released by each of
the plurality of the inserts varies by no greater than about 5%
therebetween.
[0051] Embodiment A18 concerns the drug insert of aspect A1 wherein
the drug core comprises about 0.1 wt % to about 50 wt % of the
agent.
[0052] Embodiment A19 concerns the drug insert of aspect A1 wherein
the matrix comprises a non-biodegradable silicone or a
polyurethane, or combination thereof.
[0053] Embodiment A20 concerns the drug insert of aspect A1 wherein
the sheath body comprises a polymer comprising at least one of
polyimide, PMMA, or PET, wherein the polymer is extruded or cast;
or a metal comprising stainless steel or titanium.
[0054] Embodiment A21 concerns the drug insert of aspect A1 wherein
the agent comprises a glaucoma medication, a muscarinic agent, a
beta blocker, an alpha agonist, a carbonic anhydrase inhibitor, a
prostaglandin or prostaglandin analog; an anti-inflammatory agent;
an anti-infective agent; a dry eye medication; or any combination
thereof.
[0055] Embodiment A22 concerns the drug insert of embodiment A21
wherein the anti-inflammatory agent comprises a steroid, a soft
steroid, or an NSAID and other compounds with analgesic
properties.
[0056] Embodiment A23 concerns the drug insert of embodiment A21
wherein the anti-infective agent comprises an antibiotic, an
antiviral, or an antimycotic.
[0057] Embodiment A24 concerns the drug insert of embodiment A21
wherein the dry eye medication comprises cyclosporine,
antihistamine, mast cell stabilizer such as olapatadine, a
demulcent, or sodium hyaluronate.
[0058] Embodiment A25 concerns the drug insert of aspect A1 wherein
the agent comprises latanoprost, and the amount of the agent in the
drug insert is about 10-50 .mu.g.
[0059] Embodiment A26 concerns the drug insert of aspect A1 wherein
the drug insert comprises a release rate modifying material
comprising an inert filler material, a salt, a surfactant, a
dispersant, a second polymer, an oligomer, or a combination
thereof.
[0060] Embodiment A27 concerns the drug insert of aspect A1 wherein
the drug core is substantially cylindrical in form, having an axis,
wherein the exposed surface of the drug core is disposed on one end
of the cylindrical form and a surface of the drug core covered by
the sheath body constitutes a remainder of the surface of the
cylindrical form.
[0061] Embodiment A28 concerns the drug insert of aspect A1 wherein
the agent is dissolved in the matrix within the drug core.
[0062] Embodiment A29 concerns the drug insert of embodiment A28
wherein the agent comprises cyclosporine and the matrix comprises
polyurethane.
[0063] Embodiment A30 concerns the drug insert of aspect A1 wherein
the agent is present at least in part as a plurality of solid or
liquid inclusions throughout the matrix, the inclusions comprising,
at a temperature of less than about 25.degree. C., droplets of the
agent of no greater than about 100 .mu.m diameter when the agent is
a liquid at less than about 25.degree. C., or particles of the
agent of no greater than about 100 .mu.m diameter when the agent is
a solid at less than about 25.degree. C.
[0064] Embodiment A31 concerns the drug insert of embodiment A30
wherein an average inclusion diameter and a size distribution of a
plurality of inclusion diameters within a population of inclusions
have an effect on a rate of release of the agent from the drug core
to the patient.
[0065] Embodiment A32 concerns the drug insert of embodiment A30
wherein the inclusions have an average diameter of less than about
20 .mu.m.
[0066] Embodiment A33 concerns the drug insert of embodiment A32
wherein a standard deviation of diameters of the inclusions is less
than about 8 .mu.m.
[0067] Embodiment A34 concerns the drug insert of embodiment A30
wherein the inclusions have an average diameter of less than about
15 .mu.m.
[0068] Embodiment A35 concerns the drug insert of embodiment A34
wherein a standard deviation of diameters of the inclusions is less
than about 6 .mu.m.
[0069] Embodiment A36 concerns the drug insert of embodiment A30
wherein the inclusions have an average diameter of less than about
10 .mu.m.
[0070] Embodiment A37 concerns the drug insert of embodiment A36
wherein a standard deviation of diameters of the inclusions is less
than about 4 .mu.m.
[0071] Embodiment A38 concerns the drug insert of embodiment A30
wherein a distribution of diameters of the inclusions is a
monodisperse distribution.
[0072] Embodiment A39 concerns the drug insert of embodiment A30
wherein the inclusions predominantly comprise a cross-sectional
size within a range from about 0.1 .mu.m to about 50 .mu.m.
[0073] Embodiment A40 concerns the drug insert of embodiment A30
wherein the agent forms inclusions in the matrix that are in a
liquid physical state at less than about 25.degree. C.
[0074] Embodiment A41 concerns the drug insert of embodiment A40
wherein substantially all the inclusions are droplets of the agent
of less than about 30 .mu.m in diameter within the matrix.
[0075] Embodiment A42 concerns the drug insert of embodiment A40
wherein the droplets have an average diameter of less than about 10
.mu.m.
[0076] Embodiment A43 concerns the drug insert of embodiment A42
wherein a standard deviation of diameters of the inclusions is less
than about 4 .mu.m.
[0077] Embodiment A44 concerns the drug insert of embodiment A40
wherein the agent is latanoprost.
[0078] Embodiment A45 concerns the drug insert of embodiment A30
wherein the agent forms inclusions in the matrix that are in a
solid physical state at less than about 25.degree. C.
[0079] Embodiment A46 concerns the drug insert of embodiment A45
wherein substantially all the inclusions are particles of the agent
of less than about 30 .mu.m in diameter within the matrix.
[0080] Embodiment A47 concerns the drug insert of embodiment A45
wherein an average particle diameter within the matrix is about
5-50 .mu.m.
[0081] Embodiment A48 concerns the drug insert of embodiment A45
wherein the agent is bimatoprost, olopatadine, or cyclosporine.
[0082] Embodiment A49 concerns the drug insert of aspect A1 wherein
the core comprises two or more therapeutic agents.
[0083] Embodiment A50 concerns the drug insert of aspect A1 wherein
the drug core comprises first and second drug cores.
[0084] Embodiment A51 concerns the drug insert of embodiment A50
wherein the drug insert comprises two drug cores disposed within
the sheath body, a first drug core comprising a first agent and a
first matrix, and a second drug core comprising a second agent and
a second matrix, wherein the first agent and the second agent are
different, and wherein the first matrix and the second matrix are
either the same or differ from each other; the implant body
comprising an aperture adapted to receive the first and the second
cores disposed within the sheath body, the drug cores being adapted
to be disposed, within the sheath, within the aperture of the
implant body.
[0085] Embodiment A52 concerns the drug insert of embodiment A50
wherein the first matrix and the second matrix differ from each
other with respect to at least one of a composition, an exposed
surface area, a surfactant, a crosslinker, an additive, a matrix
material, a formulation, a release rate modifying reagent, or a
stability.
[0086] Embodiment A53 concerns the drug insert of embodiment A50
wherein the first drug core and the second drug core are disposed
within the sheath body such that the first drug core has a surface
exposed directly to tear liquid and the second drug core does not
have a surface exposed directly to tear liquid when the drug insert
is disposed within the implant body and the implant body is
disposed in or adjacent to the eye of the patient.
[0087] Embodiment A54 concerns the drug insert of embodiment A50
wherein the first drug core and the second drug core are disposed
side by side within the sheath body.
[0088] Embodiment A55 concerns the drug insert of embodiment A50,
wherein the first drug core and the second drug core are each
cylindrical in shape and disposed with the sheath body, the first
drug core being positioned near a proximal end of an aperture in
the implant body and the second drug core being positioned near a
distal end of the aperture, when the drug insert is disposed within
the implant body.
[0089] Embodiment A56 concerns the drug insert of embodiment A50,
wherein the first drug core and the second drug core are each
cylindrical in shape provided that the first drug core has a first
central opening, the drug cores being positioned concentrically
within the sheath body within an aperture of the implant body
adapted to receive the drug insert, and the second drug core being
configured to fit within the first central opening of the first
drug core.
[0090] Embodiment A57 concerns the drug insert of embodiment A56
wherein the first and second drug cores are concentrically
positioned within the aperture of the implant body, the first drug
core having a first central opening exposing a first inner surface
and the second drug core having a second central opening exposing a
second inner surface, the second drug core being configured to fit
within the first central opening of the first drug core, and
wherein the aperture extends from a proximal end to a distal end of
the implant body thereby being adapted to allow tear liquid to pass
through the aperture and contact the first and second inner
surfaces of the first and second central openings and release the
first and second therapeutic agents into a canaliculus of the
patient when the implant body is inserted into a patient.
[0091] Embodiment A58 concerns the drug insert of embodiment A50
wherein the first therapeutic agent has a release profile wherein
the first agent is released at therapeutic levels throughout a
first time period and the second therapeutic agent has a second
release profile wherein the second agent is released at therapeutic
levels throughout a second time period.
[0092] Embodiment A59 concerns the drug insert of embodiment A58
wherein the first time period and the second time period are
between one week and five years.
[0093] Embodiment A60 concerns the drug insert of embodiment A58
wherein the first release profile and the second release profile
are substantially the same.
[0094] Embodiment A61 concerns the drug insert of embodiment A58
wherein the first release profile and the second release profile
are different.
[0095] Embodiment A62 concerns the drug insert of embodiment A50
wherein any inclusions in the first drug core and in the second
drug core respectively have an average diameter of less than about
20 .mu.m.
[0096] Embodiment A63 concerns the drug insert of embodiment A50
wherein any inclusions in the first drug core and in the second
drug core respectively have a standard deviation of diameters of
less than about 8 .mu.m.
[0097] Embodiment A64 concerns the drug insert of embodiment A50
wherein the implant body comprises a central bore that extends from
a proximal end to a distal end of the implant body so as to be
adapted to allow a tear liquid to pass through the implant body and
the first and second therapeutic agents are released into the tear
liquid into a canaliculus of the patient when the implant body is
disposed in or adjacent to the eye.
[0098] Embodiment A65 concerns the drug insert of embodiment A50
wherein the first agent provides a first effect and a side effect
to the patient, and the second agent provides a second effect that
mitigates or counters the side effect of the first agent.
[0099] Embodiment A66 concerns the drug insert of embodiment A50,
further comprising disposing a medication-impregnated porous
material within the first matrix, the second matrix, or both,
wherein the medication-impregnated porous material is adapted so as
to permit tear liquid to release the first agent, the second agent,
or both, from the medication-impregnated porous material at
therapeutic levels over a sustained period when a drug
core-containing implant is disposed within a punctum, and wherein
the medication-impregnated porous material is a gel material that
can swell from a first diameter to a second diameter when in
contact with tear liquid.
[0100] Embodiment A67 concerns the drug insert of embodiment A66
wherein in which the second diameter is about 50% greater than the
first diameter.
[0101] Embodiment A68 concerns the drug insert of embodiment A66
wherein the medication-impregnated porous material is a HEMA
hydrophilic polymer.
[0102] Embodiment A69 concerns the drug insert of aspect A1 wherein
the matrix comprises a polyurethane polymer or copolymer.
[0103] Embodiment A70 concerns the drug insert of embodiment A69
wherein the polyurethane polymer or copolymer comprises an
aliphatic polyurethane, an aromatic polyurethane, a polyurethane
hydrogel-forming material, a hydrophilic polyurethane, or a
combination thereof.
[0104] Embodiment A71 concerns the drug insert of embodiment A69
wherein the polyurethane polymer or copolymer comprises a hydrogel
adapted to swell when contacted with an aqueous medium and the
sheath body is adapted to be of sufficient elasticity to expand in
response thereto.
[0105] Embodiment A72 concerns the drug insert of embodiment A71
wherein the swelling is adapted to retain the implant body within a
punctal canal of the patient.
[0106] Embodiment A73 concerns the drug insert of embodiment A69
wherein the therapeutic agent comprises cyclosporine or
olopatadine, a prodrug or a derivative of cyclosporine or
olopatadine, or any combination thereof.
[0107] Embodiment A74 concerns the drug insert of embodiment A73
wherein a weight ratio of the cyclosporine or the olopatadine, or
the cyclosporine prodrug or derivative, or the olopatadine prodrug
or derivative, or the combination thereof, to the polyurethane
polymer or copolymer is about 1 wt % to about 70 wt %.
[0108] Embodiment A75 concerns the drug insert of aspect A1 wherein
a concentration of the agent in the core is similar in a portion of
the drug core proximate to the exposed surface, a portion distal to
the exposed surface, and a portion disposed between the proximate
portion and the distal portion.
[0109] Embodiment A76 concerns the drug insert of embodiment A75
wherein the proximal portion is in length at least about one tenth
a length of the drug core.
[0110] Embodiment A77 concerns the drug insert of aspect A1 wherein
the drug insert or the implant is adapted for disposition within or
adjacent to an eye of a patient.
[0111] Embodiment A78 concerns the drug insert of aspect A1
wherein: a) the therapeutic agent is uniformly and homogeneously
dispersed throughout the matrix; or b) the therapeutic agent at
least in part forms solid or liquid inclusions within the
matrix.
[0112] The drug insert aspects and embodiments of aspect A1 and
embodiments A2 through A76 can be combined in any manner, as long
as the combination is not internally inconsistent. For example,
embodiment A6 may be combined with any of embodiments A2 through
A5. These combinations are intended to provide the same concepts
and meanings as multiply-dependent claims have and also the
concepts and meanings that multiply-dependent claims upon other
multiply-dependent claims have, so that any and all combinations of
preceding and succeeding subject matter are included for this
aspect and embodiment set.
[0113] Aspect B1 concerns a drug core comprising a therapeutic
agent and a matrix for disposition into or as a drug insert or an
implant, the drug insert or the implant being adapted for
disposition within or adjacent to a body cavity, tissue, duct, or
fluid of a patient, the matrix comprising a polymer, wherein an
amount of the therapeutic agent in a volumetric portion of the drug
core is similar to an amount of the therapeutic agent in any other
equal volumetric portion of the drug core.
[0114] Embodiment B2 concerns a drug core of aspect B1 wherein the
drug insert or the implant is adapted for disposition within or
adjacent to an eye of a patient.
[0115] Embodiment B3 concerns a core of aspect B1 wherein: a) the
therapeutic agent is uniformly and homogeneously dispersed
throughout the matrix; or b) the therapeutic agent at least in part
forms solid or liquid inclusions within the matrix.
[0116] Embodiment B4 concerns the drug core of aspect B1, wherein
the amount of the therapeutic agent in a volumetric portion of the
drug core varies from the amount of the therapeutic agent in any
other equal volumetric portion of the drug core by no greater than
about 30%.
[0117] Embodiment B5 concerns the drug core of aspect B1, wherein
the amount of the therapeutic agent in a volumetric portion of the
drug core varies from the amount of the therapeutic agent in any
other equal volumetric portion of the drug core by no greater than
about 20%.
[0118] Embodiment B6 concerns the drug core of aspect B1, wherein
the amount of the therapeutic agent in a volumetric portion of the
drug core varies from the amount of the therapeutic agent in any
other equal volumetric portion of the drug core by no greater than
about 10%.
[0119] Embodiment B7 concerns the drug core of aspect B1, wherein
the amount of the therapeutic agent in a volumetric portion of the
drug core varies from the amount of the therapeutic agent in any
other equal volumetric portion of the drug core by no greater than
about 5%.
[0120] Embodiment B8 concerns the drug core of aspect B1, wherein
the therapeutic agent is uniformly homogeneously distributed
throughout the matrix.
[0121] Embodiment B9 concerns the drug core of aspect B1, wherein
the therapeutic agent at least in part forms solid or liquid
inclusions within the matrix.
[0122] Embodiment B10 concerns the drug core of aspect B1, wherein
the therapeutic agent at least in part forms solid or liquid
inclusions within the matrix, wherein the inclusions have an
average diameter of less than about 20 .mu.m.
[0123] Embodiment B11 concerns the drug core of embodiment B10
wherein a standard deviation of diameters of the inclusions is less
than about 8 .mu.m.
[0124] Embodiment B12 concerns the drug core of aspect B1, wherein
the therapeutic agent at least in part forms solid or liquid
inclusions within the matrix, wherein the inclusions have an
average diameter of less than about 10 .mu.m.
[0125] Embodiment B13 concerns the drug core of embodiment B12
wherein a standard deviation of diameters of the inclusions is less
than about 4 .mu.m.
[0126] Embodiment B14 concerns the drug core of aspect B1, wherein
the amounts of the therapeutic agent in equal volumetric portions
at about the proximal portion, at about the middle portion and at
about the distal portion of the drug core are similar.
[0127] Embodiment B15 concerns the drug core of embodiment B14,
wherein the amounts of the therapeutic agent vary by no greater
than about 30%.
[0128] Embodiment B16 concerns the drug core of embodiment B14,
wherein the amounts of the therapeutic agent vary by no greater
than about 20%.
[0129] Embodiment B17 concerns the drug core of embodiment B14,
wherein the amounts of the therapeutic agent vary by no greater
than about 10%.
[0130] Embodiment B18 concerns the drug core of embodiment B16,
wherein the amounts vary by no greater than about 5%.
[0131] Embodiment B19 concerns the drug core of aspect B1, wherein
the polymer comprises a non-biodegradable silicone or polyurethane,
or combination thereof.
[0132] Embodiment B20 concerns the drug core of aspect B1, wherein
the therapeutic agent comprises a glaucoma medication, a muscarinic
agent, a beta blocker, an alpha agonist, a carbonic anhydrase
inhibitor, a prostaglandin or prostaglandin analog; an
anti-inflammatory agent; an anti-infective agent; a dry eye
medication; or any combination thereof.
[0133] Embodiment B21 concerns the drug core of embodiment B20
wherein the anti-inflammatory agent comprises a steroid, a soft
steroid, or an NSAID and/or other compounds with analgesic
properties.
[0134] Embodiment B22 concerns the drug core of embodiment B20
wherein the anti-infective agent comprises an antibiotic, an
antiviral, or an antimycotic.
[0135] Embodiment B23 concerns the drug core of embodiment B20
wherein the dry eye medication comprises cyclosporine,
antihistamines and mast cell stabilizers, olapatadine, a demulcent,
or sodium hyaluronate.
[0136] Embodiment B24 concerns the drug core of aspect B1, wherein
the polymer comprises silicone.
[0137] Embodiment B25 concerns the drug core of aspect B1, wherein
the therapeutic agent comprises cyclosporine and the polymer
comprises a polyurethane.
[0138] Embodiment B26 concerns the drug core of aspect B1
comprising a release rate modifying material comprising an inert
filler material, a salt, a surfactant, a dispersant, a second
polymer, an oligomer, or a combination thereof.
[0139] Embodiment B27 concerns the drug core of aspect B1 disposed
within a sheath body.
[0140] Embodiment B28 concerns the drug core of aspect B1 which has
been formed into a shape of an implant body for disposition in or
adjacent to a body cavity, tissue, duct, or fluid of a patient.
[0141] The drug core aspects and embodiments of aspect B1 and
embodiments B2 through B28 can be combined in any manner, as long
as the combination is not internally inconsistent. For example,
embodiment B6 may be combined with any of embodiments B2 through
B5. These combinations are intended to provide the same concepts
and meanings as multiply-dependent claims have and also the
concepts and meanings that multiply-dependent claims upon other
multiply-dependent claims have, so that any and all combinations of
preceding and succeeding subject matter are included for this
aspect and embodiment set.
[0142] Aspect C1 concerns a filled precursor sheath comprising a
precursor sheath body containing a precursor drug core, the drug
core comprising a therapeutic agent and a matrix, the matrix
comprising a polymer, the precursor sheath body being substantially
impermeable to the agent, wherein an amount of the therapeutic
agent in a volumetric portion of the precursor drug core is similar
to an amount of the therapeutic agent in any other equal volumetric
portion of the precursor drug core.
[0143] Embodiment C2 concerns the filled precursor sheath of aspect
C1 adapted for manufacture of a plurality of drug inserts by
division of the filled precursor sheath, each drug insert being
adapted for disposition within a respective implant, the implant
being adapted for disposition within or adjacent a body cavity,
tissue, duct or fluid.
[0144] Embodiment C3 concerns the filled precursor sheath of aspect
C1 wherein the implant is adapted for disposition within or
adjacent to an eye of a patient.
[0145] Embodiment C4 concerns the precursor sheath of aspect C1
wherein an amount of the therapeutic agent in a volumetric portion
of the precursor drug core varies from an amount of the therapeutic
agent in any other equal volumetric portion of the precursor drug
core by no greater than about 30%.
[0146] Embodiment C5 concerns the precursor sheath of aspect C1
wherein an amount of the therapeutic agent in a volumetric portion
of the precursor drug core varies from an amount of the therapeutic
agent in any other equal volumetric portion of the precursor drug
core by no greater than about 20%.
[0147] Embodiment C6 concerns the precursor sheath of aspect C1
wherein an amount of the therapeutic agent in a volumetric portion
of the precursor drug core varies from an amount of the therapeutic
agent in any other equal volumetric portion of the precursor drug
core by no greater than about 10%.
[0148] Embodiment C7 concerns the precursor sheath of aspect C1
wherein an amount of the therapeutic agent in a volumetric portion
of the precursor drug core varies from an amount of the therapeutic
agent in any other equal volumetric portion of the precursor drug
core by no greater than about 5%.
[0149] Embodiment C8 concerns the precursor sheath of aspect C1
wherein the amount of the agent in a first insert of the plurality
of inserts is similar to the amount of agent in any other insert of
the plurality of inserts.
[0150] Embodiment C9 concerns the precursor sheath of embodiment C8
wherein the amount of the agent in the first insert varies by no
greater than about 30% compared with the amount of agent in any
other insert.
[0151] Embodiment C10 concerns the precursor sheath of embodiment
C8 wherein the amount of the agent in the first insert varies by no
greater than about 20% compared with the amount of agent in any
other insert.
[0152] Embodiment C11 concerns the precursor sheath of embodiment
C8 wherein the amount of the agent in the first insert varies by no
greater than about 10% compared with the amount of agent in any
other insert.
[0153] Embodiment C12 concerns the precursor sheath of embodiment
C8 wherein the amount of the agent in the first insert varies by no
greater than about 5% compared with the amount of agent in any
other insert.
[0154] Embodiment C13 concerns the precursor sheath of aspect C1
wherein the implant comprises a punctal plug and each of the
plurality of inserts is adapted for disposition within a respective
plurality thereof.
[0155] Embodiment C14 concerns the precursor sheath of embodiment
C13 wherein each exposed surface of each drug insert divided
therefrom is adapted to release therapeutic quantities of the agent
for a time period of at least several days into tear fluid, when
the insert is disposed within a punctal plug and the punctal plug
is disposed within a punctum of a patient.
[0156] Embodiment C15 concerns the precursor sheath of aspect C1
wherein the drug core comprises about 0.1 wt % to about 50 wt % of
the agent.
[0157] Embodiment C16 concerns the precursor sheath of aspect C1
wherein the matrix comprises a non-biodegradable silicone or a
polyurethane, or combination thereof.
[0158] Embodiment C17 concerns the precursor sheath of aspect C1
wherein the sheath body comprises a polymer comprising at least one
of polyimide, PMMA, PET, wherein the polymer is extruded or cast,
or stainless steel, or titanium.
[0159] Embodiment C18 concerns the precursor sheath of aspect C1
wherein the agent comprises wherein the agent comprises a glaucoma
medication, a muscarinic agent, a beta blocker, an alpha agonist, a
carbonic anhydrase inhibitor, a prostaglandin or prostaglandin
analog; an anti-inflammatory agent; an anti-infective agent; a dry
eye medication; or any combination thereof.
[0160] Embodiment C19 concerns the precursor sheath of embodiment
C18 wherein the anti-inflammatory agent comprises a steroid, a soft
steroid, or an NSAID and/or other compounds with analgesic
properties.
[0161] Embodiment C20 concerns the precursor sheath of embodiment
C18 wherein the anti-infective agent comprises an antibiotic, an
antiviral, or an antimycotic.
[0162] Embodiment C21 concerns the precursor sheath of embodiment
C18 wherein the dry eye medication comprises cyclosporine,
antihistamines and mast cell stabilizers, olapatadine, a demulcent,
or sodium hyaluronate.
[0163] Embodiment C22 concerns the precursor sheath of aspect C1
wherein the agent comprises latanoprost, and the amount of the
agent in each of the plurality of drug inserts is about 10-50
.mu.g.
[0164] Embodiment C23 concerns the precursor sheath of aspect C1
wherein the drug insert comprises a release rate modifying material
comprising an inert filler material, a salt, a surfactant, a
dispersant, a second polymer, an oligomer, or a combination
thereof.
[0165] Embodiment C24 concerns the precursor sheath of aspect C1
adapted for division by cutting with a blade or with a laser.
[0166] Embodiment C25 concerns the precursor sheath of aspect C1
wherein the agent is dissolved in the matrix.
[0167] Embodiment C26 concerns the precursor sheath of aspect C1
wherein the agent is dispersed as a plurality of solid or liquid
inclusions throughout the matrix, the inclusions comprising, at a
temperature of less than about 25.degree. C., droplets of the agent
of no greater than about 100 .mu.m diameter when the agent is a
liquid at less than about 25.degree. C., or particles of the agent
of no greater than about 100 .mu.m diameter when the agent is a
solid at less than about 25.degree. C.
[0168] Embodiment C27 concerns the precursor sheath of embodiment
C26 wherein the inclusions have an average diameter of less than
about 20 .mu.m.
[0169] Embodiment C28 concerns the precursor sheath of embodiment
C27 wherein a standard deviation of diameters of the inclusions is
less than about 8 .mu.m.
[0170] Embodiment C29 concerns the precursor sheath of embodiment
C26 wherein the inclusions have an average diameter of less than
about 10 .mu.m.
[0171] Embodiment C30 concerns the precursor sheath of embodiment
C29 wherein a standard deviation of diameters of the inclusions is
less than about 4 .mu.m.
[0172] Embodiment C31 concerns the precursor sheath of embodiment
C26 wherein a size distribution of diameters of the plurality of
inclusions is monodisperse.
[0173] Embodiment C32 concerns the precursor sheath of aspect C1
wherein: a) the therapeutic agent is uniformly and homogeneously
dispersed throughout the matrix; or b) the therapeutic agent at
least in part forms solid or liquid inclusions within the
matrix.
[0174] The filled precursor sheath aspects and embodiments of
aspect C1 and embodiments C2 through C32 can be combined in any
manner, as long as the combination is not internally inconsistent.
For example, embodiment C6 may be combined with any of embodiments
C2 through C5. These combinations are intended to provide the same
concepts and meanings as multiply-dependent claims have and also
the concepts and meanings that multiply-dependent claims upon other
multiply-dependent claims have, so that any and all combinations of
preceding and succeeding subject matter are included for this
aspect and embodiment set.
[0175] Aspect D1 concerns an implant body for disposition in or
adjacent to a body cavity, tissue, duct, or fluid of a patient, the
implant body comprising a channel therein adapted to receive a drug
insert such that an exposed surface of the insert will be exposed
to the body cavity, tissue, duct or fluid when the insert is
disposed within the implant and when the implant is disposed in or
adjacent to the body cavity, tissue, duct or fluid, the drug insert
comprising a sheath body that is substantially impermeable to the
agent, the sheath body containing a drug core comprising a
therapeutic agent and a matrix comprising a polymer, wherein an
amount of the therapeutic agent in a volumetric portion of the
precursor drug core is similar to an amount of the therapeutic
agent in any other equal volumetric portion of the precursor drug
core.
[0176] Embodiment D2 concerns an implant body of aspect D1 wherein
the implant is adapted for disposition within or adjacent to an eye
of a patient.
[0177] Embodiment D3 concerns the implant body of aspect D1,
wherein the amount of the therapeutic agent in a volumetric portion
of the drug core varies from the amount of the therapeutic agent in
any other equal volumetric portion of the drug core by no greater
than about 30%.
[0178] Embodiment D4 concerns the implant body of aspect D1,
wherein the amount of the therapeutic agent in a volumetric portion
of the drug core varies from the amount of the therapeutic agent in
any other equal volumetric portion of the drug core by no greater
than about 20%.
[0179] Embodiment D5 concerns the implant body of aspect D1,
wherein the amount of the therapeutic agent in a volumetric portion
of the drug core varies from the amount of the therapeutic agent in
any other equal volumetric portion of the drug core by no greater
than about 10%.
[0180] Embodiment D6 concerns the implant body of aspect D1,
wherein the amount of the therapeutic agent in a volumetric portion
of the drug core varies from the amount of the therapeutic agent in
any other equal volumetric portion of the drug core by no greater
than about 5%.
[0181] Embodiment D7 concerns the implant of aspect D1, wherein the
exposed surface is capable of releasing the therapeutic quantities
into at least one of a sclera, a cornea or a vitreous when disposed
in or adjacent to the eye of the patient.
[0182] Embodiment D8 concerns the implant of aspect D1 comprising a
punctal plug adapted for disposition within a punctum of a patient
for release of the agent into tear liquid.
[0183] Embodiment D9 concerns the implant of aspect D1, wherein the
therapeutic agent is soluble in the matrix.
[0184] Embodiment D10 concerns the implant of aspect D1 wherein the
therapeutic agent forms inclusions within the matrix but is
sufficiently soluble in or transportable through the matrix such
that when the implant is disposed adjacent to an eye, the exposed
surface is capable of releasing therapeutic quantities of the agent
to the tear liquid for a period of time when the implant is
disposed in or adjacent to the eye.
[0185] Embodiment D11 concerns the implant of aspect D1 wherein a
rate of release of the agent is determined in part by a
concentration of the agent that dissolves in the matrix.
[0186] Embodiment D12 concerns the implant of aspect D1 wherein the
matrix comprises a crosslinked water insoluble solid material that
contains the inclusions.
[0187] Embodiment D13 concerns the implant of embodiment D12
wherein the crosslinked water insoluble solid material comprises a
silicone or a polyurethane.
[0188] Embodiment D14 concerns the implant of aspect D1 wherein the
matrix further comprises an effective amount of a release rate
varying material, the release rate varying material comprising at
least one of a crosslinker, an inert filler material, a surfactant,
a dispersant, a second polymer, or an oligomer, or any combination
thereof.
[0189] Embodiment D15 concerns the implant of aspect D1 wherein the
drug core comprises from about 5% to about 50% of the therapeutic
agent.
[0190] Embodiment D16 concerns the implant of embodiment D10
wherein the inclusions of agent are in physical form liquid or
solid.
[0191] Embodiment D17 concerns the implant of aspect D1 wherein the
sheath body comprises a polymer comprising at least one of
polyimide, PMMA, PET, wherein the polymer is extruded or case, or
stainless steel, or titanium.
[0192] Embodiment D18 concerns the implant of aspect D1 wherein the
implant body comprises at least one of a silicone or a
hydrogel.
[0193] Embodiment D19 concerns the implant of aspect D1 wherein the
agent is dispersed as a plurality of solid or liquid inclusions
throughout the matrix, the inclusions comprising, at a temperature
of less than about 25.degree. C., droplets of the agent of no
greater than about 200 .mu.m diameter when the agent is a liquid at
less than about 25.degree. C., or particles of the agent of no
greater than about 200 .mu.m diameter when the agent is a solid at
less than about 25.degree. C.
[0194] Embodiment D20 concerns the implant of embodiment D19
wherein the inclusions have an average diameter of less than about
20 .mu.m.
[0195] Embodiment D21 concerns the implant of embodiment D20
wherein a standard deviation of diameters of the inclusions is less
than about 8 .mu.m.
[0196] Embodiment D22 concerns the implant of embodiment D19
wherein the inclusions have an average diameter of less than about
15 .mu.m.
[0197] Embodiment D23 concerns the implant of embodiment D22
wherein a standard deviation of diameters of the inclusions is less
than about 6 .mu.m.
[0198] Embodiment D24 concerns the implant of embodiment D19
wherein the inclusions have an average diameter of less than about
10 .mu.m.
[0199] Embodiment D25 concerns the implant of embodiment D24
wherein a standard deviation of diameters of the inclusions is less
than about 4 .mu.m.
[0200] Embodiment D26 concerns the implant of embodiment D19
wherein a size distribution of diameters of the plurality of
inclusions is monodisperse.
[0201] Embodiment D27 concerns the implant of embodiment D19
wherein the inclusions comprise a cross-sectional size within a
range from about 0.1 .mu.m to about 50 .mu.m.
[0202] Embodiment D28 concerns the implant of embodiment D19
wherein the agent forms inclusions in the matrix that are in a
liquid physical state at less than about 25.degree. C.
[0203] Embodiment D29 concerns the implant of embodiment D19
wherein the agent forms inclusions in the matrix that are in a
solid physical state at less than about 25.degree. C.
[0204] Embodiment D30 concerns the implant of aspect D1 wherein: a)
the therapeutic agent is uniformly and homogeneously dispersed
throughout the matrix; or b) the therapeutic agent at least in part
forms solid or liquid inclusions within the matrix.
[0205] The implant body aspects and embodiments of aspect D1 and
embodiments D2 through D30 can be combined in any manner, as long
as the combination is not internally inconsistent. For example,
embodiment D6 may be combined with any of embodiments D2 through
D5. These combinations are intended to provide the same concepts
and meanings as multiply-dependent claims have and also the
concepts and meanings that multiply-dependent claims upon other
multiply-dependent claims have, so that any and all combinations of
preceding and succeeding subject matter are included for this
aspect and embodiment set.
[0206] Aspect E1 concerns a method of manufacturing a drug insert
for an implant body adapted for disposition within or adjacent to a
body cavity, tissue, duct, or fluid of a patient, the insert
comprising a drug core and a sheath body partially covering the
drug core, the drug core comprising a therapeutic agent and a
matrix the matrix comprising a polymer, the sheath body being
disposed over a portion of the drug core to inhibit release of the
agent from said portion and so as to define at least one exposed
surface of the drug core adapted to release the agent when the
implant is inserted into the patient, the method comprising
injecting into the sheath body, at a temperature of less than about
25.degree. C., a mixture comprising a matrix precursor and the
therapeutic agent such that the sheath body is substantially filled
therewith; then, curing the mixture within the sheath body to form
within the sheath body the drug core wherein an amount of the
therapeutic agent in a volumetric portion of the drug core is
similar to an amount of the therapeutic agent in any other equal
volumetric portion of the drug core.
[0207] Aspect E2 concerns a method of manufacturing a drug insert
for an implant body adapted for disposition within or adjacent to a
body cavity, tissue, duct, or fluid of a patient, the method
comprising injecting into a precursor sheath body, at a temperature
of less than about 25.degree. C., a mixture comprising a
therapeutic agent and a precursor matrix such that the precursor
sheath is substantially filled therewith, the precursor sheath body
being substantially impermeable to the agent, curing the mixture in
the precursor sheath body to provide a cured, filled precursor
sheath body containing a precursor drug core; and dividing the
cured filled precursor sheath to form a plurality of drug inserts,
each drug insert being adapted to fit within a respective implant
body, wherein each drug insert comprises a drug core and a sheath
body, the sheath body being disposed over a portion of the drug
core to inhibit release of the agent from said portion and so as to
define at least one exposed surface of the drug core adapted to
release the agent when the insert is disposed with an implant and
the implant is inserted into the patient, and wherein an amount of
the therapeutic agent in a volumetric portion of the drug core is
similar to an amount of the therapeutic agent in any other equal
volumetric portion of the drug core.
[0208] Embodiment E3 concerns a method of manufacturing a drug
insert of aspect E2 wherein each of the plurality of drug inserts
is of substantially the same length, and wherein an amount of the
agent in a first insert of the plurality is similar to the amount
of agent in any other insert of the plurality.
[0209] Embodiment E4 concerns the method of manufacturing a drug
insert according to aspect E1, aspect E2, or embodiment E3 wherein
the implant is adapted for disposition in or adjacent to an eye of
a patient.
[0210] Embodiment E5 concerns the method of aspect E1 or E2 wherein
the amount of the therapeutic agent in a volumetric portion of the
drug core varies from the amount of the therapeutic agent in any
other equal volumetric portion of the drug core by no greater than
about 30%.
[0211] Embodiment E6 concerns the method of aspect E1 or E2 wherein
the amount of the therapeutic agent in a volumetric portion of the
drug core varies from the amount of the therapeutic agent in any
other equal volumetric portion of the drug core by no greater than
about 20%.
[0212] Embodiment E7 concerns the method of aspect E1 or E2 wherein
the amount of the therapeutic agent in a volumetric portion of the
drug core varies from the amount of the therapeutic agent in any
other equal volumetric portion of the drug core by no greater than
about 10%.
[0213] Embodiment E8 concerns the method of aspect E1 or E2 wherein
the amount of the therapeutic agent in a volumetric portion of the
drug core varies from the amount of the therapeutic agent in any
other equal volumetric portion of the drug core by no greater than
about 5%.
[0214] Embodiment E9 concerns the method of aspect E2 wherein the
amount of the agent in each of the plurality of inserts varies by
no greater than about 30% therebetween.
[0215] Embodiment E10 concerns the method of aspect E2 wherein the
amount of the agent in each of the plurality of inserts varies by
no greater than about 20% therebetween.
[0216] Embodiment E11 concerns the method of aspect E2 wherein the
amount of the agent in each of the plurality of inserts varies by
no greater than about 10% therebetween.
[0217] Embodiment E12 concerns the method of aspect E2 wherein the
amount of the agent in each of the plurality of inserts varies by
no greater than about 5% therebetween.
[0218] Embodiment E13 concerns the method of aspect E2 wherein
dividing the precursor insert comprises cutting the precursor
insert with a blade or with a laser.
[0219] Embodiment E14 concerns the method of aspect E1 or E2
wherein the implant comprises a punctal plug adapted to be disposed
within the punctum of the patient.
[0220] Embodiment E15 concerns the method of embodiment E14 wherein
the exposed surface is adapted to release therapeutic quantities of
the agent for a time period of at least several days into tear
fluid when the insert is disposed in the punctal plug and the
punctal plug is disposed within a punctum of a patient.
[0221] Embodiment E16 concerns the method of aspect E1 or E2
wherein the mixture further comprises a solvent in which the matrix
precursor and the agent are soluble, and wherein curing comprises
at least partial removal of the solvent following injection into
the sheath body or precursor sheath body respectively.
[0222] Embodiment E17 concerns the method of embodiment E16 wherein
curing comprises heating, vacuum treatment, or both.
[0223] Embodiment E18 concerns the method of embodiment E16 wherein
the solvent comprises a hydrocarbon, an ester, a halocarbon, an
alcohol, an amide, or a combination thereof.
[0224] Embodiment E19 concerns the method of embodiment E16 wherein
the solvent comprises a halocarbon and the agent comprises
cyclosporine.
[0225] Embodiment E20 concerns the method of aspect E1 or E2
wherein curing the mixture comprises heating the mixture to a
temperature, at a relative humidity, for a period of time.
[0226] Embodiment E21 concerns the method of embodiment E20 wherein
the temperature comprises a range from about 20.degree. C. to about
100.degree. C., the relative humidity comprises a range from about
40% to about 100%, and the period of time comprises a range from
about 1 minute to about 48 hours.
[0227] Embodiment E22 concerns the method of embodiment E21 wherein
the temperature is at least about 40.degree. C., the relative
humidity is at least about 80%, or both.
[0228] Embodiment E23 concerns the method of aspect E1 or E2
wherein curing comprises a step of polymerization or cross-linking,
or both, of the matrix precursor.
[0229] Embodiment E24 concerns the method of embodiment E23
comprising polymerization or cross-linking, or both, in the
presence of a catalyst.
[0230] Embodiment E25 concerns the method of embodiment E24 wherein
the catalyst comprises a tin compound or a platinum compound.
[0231] Embodiment E26 concerns the method of embodiment E24 wherein
the catalyst comprises at least one of a platinum with vinyl
hydride system or a tin with alkoxy system.
[0232] Embodiment E27 concerns the method of aspect E1 or E2
wherein the mixture is prepared by a method comprising
sonication.
[0233] Embodiment E28 concerns the method of aspect E1 or E2
wherein injecting comprises injecting under a pressure of at least
about 40 psi.
[0234] Embodiment E29 concerns the method of aspect E1 or E2
wherein the temperature comprises a temperature of about
-50.degree. C. to about 25.degree. C.
[0235] Embodiment E30 concerns the method of aspect E1 or E2
wherein the temperature comprises a temperature of about
-20.degree. C. to about 0.degree. C.
[0236] Embodiment E31 concerns the method of aspect E1 or E2
wherein the mixture is injected such that the sheath body or
precursor sheath body, respectively, is filled at a rate of no
greater than about 0.5 cm/sec.
[0237] Embodiment E32 concerns the method of aspect E1 or E2
wherein each drug insert is sealed at one end thereof, a second end
providing the exposed surface.
[0238] Embodiment E33 concerns the method of embodiment E32 wherein
each drug insert is sealed at one end thereof with a UV-curable
adhesive, a cyanoacrylate, an epoxy, by pinching, with a heat weld,
or with a cap.
[0239] Embodiment E34 concerns the method of embodiment E33 further
comprises irradiating the drug insert with a UV-curable adhesive
with UV light.
[0240] Embodiment E35 concerns the method of embodiment E33 further
comprising, after sealing one end thereof, inserting each drug
insert into a channel of an implant body adapted to receive the
insert therein.
[0241] Embodiment E36 concerns the method of aspect E1 or E2
wherein the insert comprises about 0.1 wt % to about 50 wt % of the
agent.
[0242] Embodiment E37 concerns the method of aspect E1 or E2
wherein the matrix comprises a non-biodegradable silicone or a
polyurethane.
[0243] Embodiment E38 concerns the method of aspect E1 or E2
wherein the sheath or precursor sheath comprises at least one of
polyimide, PMMA, PET, stainless steel, or titanium.
[0244] Embodiment E39 concerns the method of aspect E1 or E2
wherein the agent comprises a glaucoma medication, a muscarinic
agent, a beta blocker, an alpha agonist, a carbonic anhydrase
inhibitor, or a prostaglandin or prostaglandin analog; an
antiinflammatory agent; an anti-infective agent; a dry eye
medication; or any combination thereof.
[0245] Embodiment E40 concerns the method of embodiment E39 wherein
the anti-inflammatory agent comprises a steroid, a soft steroid, or
an NSAID and/or any other compound with analgesic properties.
[0246] Embodiment E41 concerns the method of embodiment E39 wherein
the anti-infective agent comprises an antibiotic, an antiviral, or
an antimicotic.
[0247] Embodiment E42 concerns the method of embodiment E39 wherein
the dry eye medication comprises cyclosporine, olapatadine,
delmulcents, or sodium hyaluronate.
[0248] Embodiment E43 concerns the method of aspect E1 or E2
wherein the agent comprises latanoprost, the matrix comprises
silicone or polyurethane, and the amount of the agent in each of
the plurality of drug inserts is about 10-50 .mu.g.
[0249] Embodiment E44 concerns the method of aspect E1 or E2
wherein the agent comprises cyclosporine, the matrix comprises
silicone or polyurethane, and a relative amount of the agent in
each of the plurality of drug inserts is ranges from about 1% to
about 50% of the core.
[0250] Embodiment E45 concerns the method of aspect E1 or E2
wherein the drug insert comprises a release rate modifying material
comprising an inert filler material, a salt, a surfactant, a
dispersant, a second polymer, an oligomer, or a combination
thereof.
[0251] Embodiment E46 concerns the method of aspect E1 or E2
wherein the drug core is substantially cylindrical in form, having
an axis, wherein a surface of the drug core is not covered by the
sheath is disposed on one end on the cylindrical form and is the
drug core covered by the sheath is disposed on a remainder of the
surface of the cylindrical form.
[0252] Embodiment E47 concerns the method of aspect E1 or E2
wherein the agent is dissolved in the matrix.
[0253] Embodiment E48 concerns the method of embodiment E47 wherein
the agent comprises cyclosporine and the matrix comprises
polyurethane.
[0254] Embodiment E49 concerns the method of aspect E1 or E2
wherein the agent is dispersed as a plurality of solid or liquid
inclusions within the matrix, the inclusions comprising, at a
temperature of less than about 25.degree. C., droplets of the agent
of no greater than about 200 .mu.m diameter when the agent is a
liquid at less than about 25.degree. C., or particles of the agent
of no greater than about 200 .mu.m diameter when the agent is a
solid at less than about 25.degree. C.
[0255] Embodiment E50 concerns the method of embodiment E49 wherein
the inclusions have an average diameter of less than about 20
.mu.m.
[0256] Embodiment E51 concerns the method of embodiment E50 wherein
a standard deviation of diameters of the inclusions is less than
about 8 .mu.m.
[0257] Embodiment E52 concerns the method of embodiment E49 wherein
the inclusions have an average diameter of less than about 15
.mu.m.
[0258] Embodiment E53 concerns the method of embodiment E52 wherein
a standard deviation of diameters of the inclusions is less than
about 6 .mu.m.
[0259] Embodiment E54 concerns the method of embodiment E49 wherein
the inclusions wherein the inclusions have an average diameter of
less than about 10 .mu.m.
[0260] Embodiment E55 concerns the method of embodiment E54 wherein
a standard deviation of diameters of the inclusions is less than
about 4 .mu.m.
[0261] Embodiment E56 concerns the method of embodiment E49 wherein
a distribution of diameters of the inclusions is a monodisperse
distribution.
[0262] Embodiment E57 concerns the method of embodiment E49 wherein
the mixture is prepared by a process comprising sonication.
[0263] Embodiment E58 concerns the method of embodiment E49 wherein
the inclusions comprise a cross-sectional size within a range from
about 0.1 .mu.m to about 50 .mu.m.
[0264] Embodiment E59 concerns the method of embodiment E49 wherein
the agent forms inclusions within the matrix that are in physical
state a liquid at less than about 25.degree. C.
[0265] Embodiment E60 concerns the method of embodiment E59 wherein
substantially all the inclusions are droplets of the agent of less
than about 50 .mu.m in diameter within the matrix.
[0266] Embodiment E61 concerns the method of embodiment E59 wherein
an average droplet diameter within the matrix is about 5-50
.mu.m.
[0267] Embodiment E62 concerns the method of embodiment E59 wherein
the agent is latanoprost.
[0268] Embodiment E63 concerns the method of embodiment E49 wherein
the physical state of the agent is a solid at less than about
25.degree. C.
[0269] Embodiment E64 concerns the method of embodiment E63 wherein
the agent forms inclusions in the matrix and the physical state of
the inclusions is a solid at less than about 25.degree. C.
[0270] Embodiment E65 concerns the method of embodiment E63 wherein
substantially all the inclusions are particles of the agent of less
than about 50 .mu.m in diameter within the matrix.
[0271] Embodiment E66 concerns the method of embodiment E63 wherein
an average particle diameter within the matrix is about 5-50
.mu.m.
[0272] Embodiment E67 concerns the method of embodiment E63 wherein
the agent is bimatoprost, olopatadine, or cyclosporine.
[0273] Embodiment E68 concerns the method of aspect E1 or E2
wherein each drug insert comprises two or more therapeutic
agents.
[0274] Embodiment E69 concerns the method of aspect E1 or E2
wherein each drug core comprises first and second drug cores.
[0275] Embodiment E70 concerns the method of embodiment E69 wherein
the first and second drug cores are positioned side by side and
together form a cylinder which is the drug core within the sheath
body.
[0276] Embodiment E71 concerns the method of embodiment E69 wherein
the drug core comprises two drug cores, a first drug core
comprising a first agent and a first matrix, and a second drug core
comprising a second agent and a second matrix, wherein the first
agent and the second agent are different, and wherein the first
matrix and the second matrix are either the same or differ from
each other, the implant body comprising an aperture adapted to
receive the drug insert comprising the first and the second drug
cores, the method further comprising disposing the drug cores
within the insert prior to disposing the insert within the aperture
of the implant body.
[0277] Embodiment E72 concerns the method of embodiment E71 wherein
the first matrix and the second matrix differ from each other with
respect to at least one of a composition, an exposed surface area,
a surfactant, a crosslinker, an additive, a matrix material, a
formulation, or a stability.
[0278] Embodiment E73 concerns the method of embodiment E71 wherein
the first drug core and the second drug core are disposed within
the sheath such that the first drug core has a surface exposed
directly to tear liquid and the second drug core has a surface
exposed the first drug core.
[0279] Embodiment E74 concerns the method of embodiment E71 wherein
the first drug core and the second drug core are disposed side by
side within the sheath.
[0280] Embodiment E75 concerns the method of embodiment E71 wherein
the first drug core and the second drug core are each cylindrical
in shape and disposed with the drug core, the first drug core being
positioned near a proximal end of an aperture in the implant body
adapted to receive the drug core and the second drug core being
positioned near a distal end of the aperture.
[0281] Embodiment E76 concerns the method of embodiment E71 wherein
the first drug core and the second drug core are each cylindrical
in shape and are positioned concentrically within an aperture of
the implant body adapted to receive the drug cores, the first drug
core having a first central opening and the second drug core being
configured to fit within the first central opening of the first
drug core.
[0282] Embodiment E77 concerns the method of embodiment E71 wherein
the first and second drug cores are concentrically positioned
within the aperture, the first drug core having a first central
opening exposing a first inner surface and the second drug core
having a second central opening exposing a second inner surface,
the second drug core being configured to fit within the first
central opening of the first drug core, and wherein the aperture
extends from a proximal end to a distal end of the implantable body
adapted to allow a tear or tear film fluid to pass through the
aperture and contact the first and second inner surfaces of the
first and second central openings and release the first and second
therapeutic agents into a canaliculus.
[0283] Embodiment E78 concerns the method of embodiment E71 wherein
the insert is adapted such that when it is implanted the first
therapeutic agent releases at therapeutic levels throughout a first
time period and the second therapeutic agent releases at
therapeutic levels throughout a second time period.
[0284] Embodiment E79 concerns the method of embodiment E71 wherein
the first therapeutic agent releases at therapeutic levels
throughout a first time period and the second therapeutic agent
releases at therapeutic levels throughout a second time period.
[0285] Embodiment E80 concerns the method of embodiment E79 wherein
the first time period and the second time period are between one
week and five years.
[0286] Embodiment E81 concerns the method of embodiment E79 wherein
the first time period and the second time period are substantially
the same.
[0287] Embodiment E82 concerns the method of embodiment E79 wherein
the first time period and the second timer period are
different.
[0288] Embodiment E83 concerns the method of embodiment E71 further
comprising disposing a head coupled to the implant body covering
the aperture, the head being permeable to the first and second
therapeutic agents.
[0289] Embodiment E84 concerns the method of embodiment E71,
wherein the therapeutic levels are drop administered quantities or
less.
[0290] Embodiment E85 concerns the method of embodiment E71,
wherein the therapeutic levels are less than 10% of drop
administered quantities.
[0291] Embodiment E86 concerns the method of embodiment E71,
further comprising disposing a medication-impregnated porous
material within the first matrix, the second matrix, or both, the
medication-impregnated porous material being adapted such that tear
liquid releases the first agent, the second agent, or both,
therefrom at therapeutic levels over a sustained period when a drug
core-containing implant is disposed within a punctum, wherein the
medication-impregnated porous material is a gel material that can
swell from a first diameter to a second diameter.
[0292] Embodiment E87 concerns the method of embodiment E86 wherein
in which the second diameter is about 50% greater than the first
diameter.
[0293] Embodiment E88 concerns the method of embodiment E86 wherein
the medication-impregnated porous material is a HEMA hydrophilic
polymer.
[0294] Embodiment E89 concerns the method of embodiment E71 wherein
the implant body comprises a central bore that extends from a
proximal end to a distal end of the implant body adapted to allow a
tear liquid to pass through the implant body and release the first
and second therapeutic agents into a canaliculus.
[0295] Embodiment E90 concerns the method of embodiment E71 wherein
the first agent provides a first effect and a side effect to the
patient, and the second agent provides a second effect that
mitigates or counters the side effect of the first agent.
[0296] Embodiment E91 concerns the method of aspect E1 or E2
wherein the matrix comprises a polyurethane polymer or
copolymer.
[0297] Embodiment E92 concerns the method of embodiment E91 wherein
the polyurethane polymer or copolymer comprises an aliphatic
polyurethane, an aromatic polyurethane, a polyurethane
hydrogel-forming material, a hydrophilic polyurethane, or a
combination thereof.
[0298] Embodiment E93 concerns the method of embodiment E91 wherein
the polyurethane polymer or copolymer comprises a hydrogel adapted
to swell when contacted with an aqueous medium and the sheath is
adapted to be of sufficient elasticity to expand in response
thereto.
[0299] Embodiment E94 concerns the method of embodiment E93 wherein
the swelling is adapted to retain the plug within the punctal
canal.
[0300] Embodiment E95 concerns the method of embodiment E91 wherein
the therapeutic agent comprises cyclosporine or olopatadine, a
prodrug or a derivative of cyclosporine or olopatadine or any
combination thereof.
[0301] Embodiment E96 concerns the method of embodiment E95 wherein
a weight ratio of the cyclosporine or the olopatadine or the
cyclosporine prodrug or derivative, or the olopatadine prodrug or
derivative, or the combination thereof, to the polyurethane polymer
or copolymer is about 1 wt % to about 70 wt %.
[0302] Embodiment E97 concerns the method of embodiment E95 wherein
the polyurethane polymer or copolymer, and a quantity or a
concentration of the cyclosporine or olopatadine, or the prodrug or
derivative of cyclosporine or olopatadine, or combination thereof,
therein, is selected to provide a release profile of the agent into
tear liquid of the patient.
[0303] Embodiment E98 concerns the method of embodiment E91 wherein
the drug core further comprises a second therapeutic agent.
[0304] Embodiment E99 concerns the method of embodiment E91,
comprising forming the mixture by melting and mixing the
polyurethane polymer or copolymer and the therapeutic agent.
[0305] Embodiment E100 concerns the method of embodiment E99
wherein the therapeutic agent is in molten form in the mixture.
[0306] Embodiment E101 concerns the method of embodiment E99
wherein the therapeutic agent is in solid form in the mixture.
[0307] Embodiment E102 concerns the drug insert made by a method of
aspect E1 or E2.
[0308] Embodiment E103 concerns the method of aspect E1 or E2,
wherein the temperature comprises a temperature of less than about
25.degree. C.
[0309] Embodiment E104 concerns the method of aspect E1 or E2,
wherein the temperature comprises a temperature of less than about
15.degree. C.
[0310] Embodiment E105 concerns the method of aspect E1 or E2,
wherein the temperature comprises a temperature of less than about
10.degree. C.
[0311] Embodiment E106 concerns the method of aspect E1 or E2,
wherein the temperature comprises a temperature of less than about
5.degree. C.
[0312] Embodiment E107 concerns the method of aspect E1 or E2
wherein: a) the therapeutic agent is uniformly and homogeneously
dispersed throughout the matrix; or b) the therapeutic agent at
least in part forms solid or liquid inclusions within the
matrix.
[0313] The method of manufacturing aspects and embodiments of
aspects E1 and E2 and embodiments E3 through E107 can be combined
in any manner, as long as the combination is not internally
inconsistent. For example, embodiment E6 may be combined with any
of embodiments E3 through E5. These combinations are intended to
provide the same concepts and meanings as multiply-dependent claims
have and also the concepts and meanings that multiply-dependent
claims upon other multiply-dependent claims have, so that any and
all combinations of preceding and succeeding subject matter are
included for this aspect and embodiment set.
[0314] Aspect F1 concerns a method of treating a malcondition in a
patient in need thereof, comprising disposing in the patient an
implant comprising a drug insert of any one of aspect A1 and
embodiments A2-A78 or a drug core of any one of aspect B1 and
embodiments B2-B28, or a drug core obtained by division of a filled
precursor sheath of any one of aspect C1 and embodiments C2-C32, or
a drug implant of any one of aspect D1 and embodiments D2-D30, or a
drug insert of embodiment E102, wherein the therapeutic agent is
adapted to treat the malcondition, in or adjacent to an eye of the
patient such that the drug is released into a body tissue or
fluid.
[0315] Embodiment F2 concerns the method of aspect F1 wherein the
malcondition comprises glaucoma, and the agent is a prostaglandin
analog.
[0316] Embodiment F3 concerns the method of embodiment F2 wherein
the matrix comprises a non-biodegradable silicone or polyurethane
polymer.
[0317] Embodiment F4 concerns the method of embodiment F2 wherein
the prostaglandin analog is latanoprost.
[0318] Embodiment F5 concerns the method of aspect F1 wherein the
malcondition comprises dry eye or eye inflammation and the agent is
cyclosporine or olopatadine or a prodrug or derivative of
cyclosporine or olopatadine.
[0319] Embodiment F6 concerns the method of embodiment F5 wherein
the matrix comprises polyurethane.
[0320] Aspect G1 concerns a drug insert adapted for disposition
within a lacrimal implant for providing sustained release of
latanoprost to an eye of a patient in need of treatment of
glaucoma, the drug insert comprising a drug core and a sheath body
partially covering the drug core, the drug core comprising
latanoprost and a matrix, the matrix comprising a silicone polymer,
the sheath body being disposed over a portion of the drug core to
inhibit release of the latanoprost from that portion and so as to
define at least one exposed surface of the drug core not covered by
the sheath body thereby being adapted to release the latanoprost to
the eye, wherein an amount of the latanoprost in a volumetric
portion of the drug core is similar to an amount of the latanoprost
in any other equal volumetric portion of the drug core.
[0321] Embodiment G2 concerns the drug insert of aspect G1 wherein
the amount of the latanoprost in a volumetric portion of the drug
core varies from the amount of the latanoprost in any other equal
volumetric portion of the drug core by no greater than about
30%.
[0322] Embodiment G3 concerns the drug insert of aspect G1 wherein
the amount of the latanoprost in a volumetric portion of the drug
core varies from the amount of the latanoprost in any other equal
volumetric portion of the drug core by no greater than about
20%.
[0323] Embodiment G4 concerns the drug insert of aspect G1 wherein
the amount of the latanoprost in a volumetric portion of the drug
core varies from the amount of the latanoprost in any other equal
volumetric portion of the drug core by no greater than about
10%.
[0324] Embodiment G5 concerns the drug insert of aspect G1 wherein
the amount of the latanoprost in a volumetric portion of the drug
core varies from the amount of the latanoprost in any other equal
volumetric portion of the drug core by no greater than about
5%.
[0325] Embodiment G6 concerns the drug insert of aspect G1, wherein
the latanoprost is dispersed within the silicone as droplets
thereof.
[0326] The drug insert aspects and embodiments of aspect G1 and
embodiments G2 through G6 can be combined in any manner, as long as
the combination is not internally inconsistent. For example,
embodiment G6 may be combined with any of embodiments G2 through
G5. These combinations are intended to provide the same concepts
and meanings as multiply-dependent claims have and also the
concepts and meanings that multiply-dependent claims upon other
multiply-dependent claims have, so that any and all combinations of
preceding and succeeding subject matter are included for an aspect
and embodiment set.
[0327] Aspect H1 concerns a drug insert adapted for disposition
within an punctal plug for providing sustained release of a
cyclosporine to the eye for treatment of dry eye or inflammation,
the insert comprising a drug core and a sheath body partially
covering the core, the drug core comprising the cyclosporine and a
matrix, the matrix comprising a polyurethane polymer, the sheath
body being disposed over a portion of the core to inhibit release
of the cyclosporine from said portion and so as to define at least
one exposed surface of the drug core not covered by the sheath body
being adapted to release the cyclosporine to the eye, wherein an
amount of the cyclosporine in a volumetric portion of the drug core
is similar to an amount of the cyclosporine in any other equal
volumetric portion of the drug core.
[0328] Embodiment H2 concerns the drug insert of aspect H1 wherein
the amount of the cyclosporine in a volumetric portion of the drug
core varies from the amount of the cyclosporine in any other equal
volumetric portion of the drug core by no greater than about
30%.
[0329] Embodiment H3 concerns the drug insert of aspect H1 wherein
the amount of the cyclosporine in a volumetric portion of the drug
core varies from the amount of the cyclosporine in any other equal
volumetric portion of the drug core by no greater than about
20%.
[0330] Embodiment H4 concerns the drug insert of aspect H1 wherein
the amount of the cyclosporine in a volumetric portion of the drug
core varies from the amount of the cyclosporine in any other equal
volumetric portion of the drug core by no greater than about
10%.
[0331] Embodiment H5 concerns the drug insert of aspect H1 wherein
the amount of the cyclosporine in a volumetric portion of the drug
core varies from the amount of the cyclosporine in any other equal
volumetric portion of the drug core by no greater than about
5%.
[0332] Embodiment H6 concerns the drug insert of aspect H1, wherein
the cyclosporine is dissolved within the polyurethane.
[0333] The drug insert aspects and embodiments of aspect H1 and
embodiments H2 through H6 can be combined in any manner, as long as
the combination is not internally inconsistent. For example,
embodiment 1-16 may be combined with any of embodiments H2 through
H5. These combinations are intended to provide the same concepts
and meanings as multiply-dependent claims have and also the
concepts and meanings that multiply-dependent claims upon other
multiply-dependent claims have, so that any and all combinations of
preceding and succeeding subject matter are included for an aspect
and embodiment set.
[0334] Further aspects and embodiments include the following.
[0335] The drug insert of any one of aspect A1 and embodiments
A1-A78, or the drug core of any one of aspect B1 and embodiments
B2-B28, or the drug core obtained by division of a filled precursor
sheath of any one of aspects C1 and embodiments C2-C32, or the drug
implant of any one of aspect D1 and embodiments D2-D30, or the drug
insert of embodiment E102, adapted for providing sustained release
of a therapeutic agent to the eye or surrounding tissues, or
systemically, or any combination thereof.
[0336] A drug core of any of aspect A1 and embodiments A2-A78 which
has been formed into a shape of an implant body for disposition in
or adjacent to a body cavity, tissue, duct, or fluid of a
patient.
[0337] Another aspect of the invention concerns the use of a drug
insert of any one of aspect A1 and embodiments A2-A78, or a drug
core of any one of aspect B1 or embodiments B2-B28, or a drug core
obtained by division of a filled precursor sheath of any one of
aspect C1 or embodiments C2-C32, or a drug implant of any one of
aspect D1 or embodiments D2-D30, or a drug insert of E102, in the
manufacture of an implant adapted for treatment of a malcondition
in a patient in need thereof.
[0338] Another aspect of the invention concerns an implant
comprising a polymer and a therapeutic agent disposed therein,
wherein an amount of the therapeutic agent in a volumetric portion
of the implant is similar to an amount of the therapeutic agent in
any other equal volumetric portion of the implant.
[0339] A further aspect of the invention concerns a method of
manufacturing an implant comprising a polymer and a therapeutic
agent disposed therein, wherein an amount of the therapeutic agent
in a volumetric portion of the implant is similar to an amount of
the therapeutic agent in any other equal volumetric portion of the
implant, in which the method comprises injecting a mixture
comprising a polymer and a therapeutic agent into a mold, the
method comprising injecting said mixture at a temperature less than
about 25.degree. C.
BRIEF DESCRIPTION OF THE DRAWINGS
[0340] FIG. 1A shows a top cross sectional view of a sustained
release implant to treat an optical defect of an eye, according to
an embodiment of the present invention.
[0341] FIG. 1B shows a side cross sectional view of the sustained
release implant of FIG. 1A.
[0342] FIG. 1C shows a perspective view of a sustained release
implant with a coil retention structure, according to an embodiment
of the present invention.
[0343] FIG. 1D shows a perspective view of a sustained release
implant with a retention structure comprising struts, according to
an embodiment of the present invention.
[0344] FIG. 1E shows a perspective view of a sustained release
implant with a cage retention structure, according to an embodiment
of the present invention.
[0345] FIG. 1F shows a perspective view of a sustained release
implant comprising a core and sheath, according to an embodiment of
the present invention.
[0346] FIG. 1G schematically illustrates a sustained release
implant comprising a flow restricting retention element, a core and
a sheath, according to an embodiment of the present invention.
[0347] FIG. 2A shows a cross sectional view of a sustained release
implant with core comprising an enlarged exposed surface area,
according to an embodiment of the present invention.
[0348] FIG. 2B shows a cross sectional view of a sustained release
implant with a core comprising an enlarged exposed surface area,
according to an embodiment of the present invention.
[0349] FIGS. 2C and 2D show perspective view and cross sectional
views, respectively, of a sustained release implant with a core
comprising a reduced exposed surface area, according to an
embodiment of the present invention.
[0350] FIG. 2E shows a cross sectional view of a sustained release
implant with a core comprising an enlarged exposed surface area
with an indentation and castellation, according to an embodiment of
the present invention.
[0351] FIG. 2F shows a perspective view of a sustained release
implant comprising a core with folds, according to an embodiment of
the present invention.
[0352] FIG. 2G shows a perspective view of a sustained release
implant with a core comprising a channel with an internal surface,
according to an embodiment of the present invention.
[0353] FIG. 2H shows a perspective view of a sustained release
implant with a core comprising porous channels to increase drug
migration, according to an embodiment of the invention.
[0354] FIG. 2I shows a perspective view of a sustained release
implant with a convex exposed drug core surface, according to an
embodiment of the present invention.
[0355] FIG. 2J shows a side view of a sustained release implant
with a core comprising an exposed surface area with several soft
brush-like members extending therefrom, according to an embodiment
of the present invention.
[0356] FIG. 2K shows a side view of a sustained release implant
with a drug core comprising a convex exposed surface and a
retention structure, according to an embodiment of the present
invention.
[0357] FIG. 2L shows a side view of a sustained release implant
with a drug core comprising a concave indented surface to increase
exposed surface area of the core, according to an embodiment of the
present invention.
[0358] FIG. 2M shows a side view of a sustained release implant
with a drug core comprising a concave surface with a channel formed
therein to increase an exposed surface area of the core, according
to an embodiment of the present invention.
[0359] FIGS. 3A and 3B show an implant comprising a silicone body,
a drug core and retention structures, according to embodiments of
the present invention.
[0360] FIG. 3C shows insertion of the implant as in FIG. 3A into an
upper canaliculus of an eye.
[0361] FIG. 3D shows an implant as in FIG. 3A in an expanded
profile configuration following implantation in the canaliculus of
the eye.
[0362] FIG. 4A shows a drug core insert suitable for use with an
implant, according to embodiments of the present invention.
[0363] FIG. 4B shows an of implant suitable for use with a drug
core insert, according to embodiments of the present invention.
[0364] FIG. 4C shows an annular drug core insert suitable for use
with an implant for systemic delivery of a therapeutic agent,
according to embodiments of the present invention.
[0365] FIG. 4D shows an of implant suitable for use with a drug
core insert as in FIG. 4C.
[0366] FIGS. 4E and 4F show a side cross-sectional view and an end
view, respectively, of a drug core inserts with two drug cores,
according to embodiments of the present invention.
[0367] FIGS. 5A to 5C schematically illustrate replacement of a
drug core and a sheath body, according to an embodiment of the
present invention.
[0368] FIGS. 5D and 5E show an implant comprising a filament that
extends from a drug core insert for removal the drug core insert
from the implant, according to embodiments of the present
invention.
[0369] FIG. 5F shows an implant comprising a filament that extends
along a drug core insert bonded to a distal end of the drug core
insert for removal of the drug core insert from a body of the
implant, according to embodiments of the present invention.
[0370] FIG. 6A shows a method of manufacturing a punctal plug,
according to embodiments of the present invention.
[0371] FIG. 6B shows a method of manufacturing a hydrogel rod in
accordance with the method of FIG. 6A.
[0372] FIG. 6C shows a method of molding a silicone plug in
accordance with the method of FIG. 6A.
[0373] FIG. 6D shows a method of assembling the punctal plug
component in accordance with the method of in FIG. 6A.
[0374] FIG. 6E shows a method of manufacturing a drug core insert,
in accordance with the method of in FIG. 6A.
[0375] FIG. 6F shows method 690 of final assembly in accordance
with method 600 of FIG. 6A.
[0376] FIGS. 7A and 7B show elution data of latanoprost at day 1
and day 14, respectively, for the three core diameters of 0.006,
0.012 and 0.025 inches and three Latanoprost concentrations of
approximately 5%, 11% and 18%, according to embodiments of the
present invention.
[0377] FIG. 7C shows elution data for Latanoprost from 0.32 mm
diameter, 0.95 mm long drug cores with concentrations of 5, 10 and
20% and drug weights of 3.5, 7 and 14 .mu.g, respectively,
according to embodiments of the present invention.
[0378] FIGS. 7D and 7E show dependence of the rate of elution on
exposed surface area of the drug core for the three core diameters
and the three concentrations as in FIGS. 7A and 7B Latanoprost at
day 1 and day 14, respectively, according to embodiments of the
present invention.
[0379] FIG. 8 shows elution profiles of cyclosporine from drug
cores into a buffer solution with surfactant and a buffer solution
with surfactant, according to embodiments of the present
invention.
[0380] FIG. 9 shows normalized elution profiles in nano-grams per
device per day over 100 days for bulk sample of silicone with 1%
Bimatoprost, according to embodiments of the present invention.
[0381] FIG. 10 shows profiles of elution of Latanoprost from the
cores for four formulations of Latanoprost, according to
embodiments of the present invention.
[0382] FIG. 11A shows the effect on elution of material and
crosslinking on drug cores with 20% latanoprost, according to
embodiments of the present invention.
[0383] FIG. 11B shows the effect of drug concentration on the
elution of latanoprost, according to embodiments of the present
invention.
[0384] FIG. 11C shows the effect of covering one end of the drug
core insert, according to embodiments of the present invention.
[0385] FIG. 12 shows the elution of fluorescein and the effect of
surfactant on fluorescein elution, according to embodiments of the
present invention.
[0386] FIG. 13 shows the elution of sterilized and non-sterilized
drug cores, according to embodiments of the present invention.
[0387] FIG. 14 shows the effect of salt on the elution of
therapeutic agent, according to embodiments of the present
invention.
[0388] FIGS. 15 A-D shows scanning electron micrographs of
longitudinal sections of a silicone/latanoprost drug insert
prepared by a method of the invention; A, B,=extrusion at ambient
and superambient temperatures; C, D=extrusion at subambient
temperatures.
[0389] FIG. 16 shows a plot of latanoprost content per 1 mm section
of a filled precursor sheath prepared by an extrusion method which
was carried out at about 0 degrees, about -25, about 40, and room
temperatures.
[0390] FIG. 17 shows an implant comprising a silicone body, a drug
core and retention structures, according to embodiments of the
present invention.
[0391] FIG. 18A shows a sectional view of a sustained release
implant having a first drug core with a first therapeutic agent and
a second drug core with a second therapeutic agent to treat an eye,
the first and second drug cores being in a concentric
configuration, according to an embodiment of the present
invention.
[0392] FIG. 18B shows a side cross-sectional view of the sustained
release implant of FIG. 18A.
[0393] FIG. 19A shows a sectional view of a sustained release
implant having a first drug core with a first therapeutic agent and
a second drug core with a second therapeutic agent to treat an eye,
the first and second drug cores being in a side by side
configuration, according to an embodiment of the present
invention.
[0394] FIG. 19B shows a side cross-sectional view of the sustained
release implant of FIG. 19A.
[0395] FIG. 20A shows a sectional view of a sustained release
implant having a first drug core with a first therapeutic agent and
a second drug core with a second therapeutic agent to treat an eye,
the first and second drug cores being in a concentric configuration
with a hollow center to allow fluid flow through the implant,
according to an embodiment of the present invention.
[0396] FIG. 20B shows a side cross-sectional view of the sustained
release implant of FIG. 20A.
[0397] FIG. 21 schematically illustrates a lacrimal insert in the
shape of a punctal plug for use in a therapeutic implant.
[0398] FIG. 22 shows one embodiment of a therapeutic implant to
treat an eye having a punctal plug and a sustained release implant
having a drug core with a first therapeutic agent and a second
therapeutic agent.
[0399] FIGS. 23-25 show different embodiments of therapeutic
implants to treat an eye having a punctual plug and a sustained
release implant having a first drug core with a first therapeutic
agent and a second drug core having a second therapeutic agent.
[0400] FIGS. 26A-26C show different embodiments of therapeutic
implants to treat an eye that encompass punctual plugs made of a
medication-impregnable porous material having with two therapeutic
agents.
[0401] FIG. 27 shows therapeutic implants containing first and
second therapeutic agents as applied to the eye.
[0402] FIG. 28 shows various core elements that are combinable into
a cylindrical shaped drug core.
[0403] FIGS. 29A-29D show different embodiments of a cylindrical
shaped drug core using the core elements of FIG. 28.
[0404] FIGS. 30A and 30B show other embodiments of a cylindrical
shaped drug core assembled from core elements of different
shapes.
[0405] FIG. 31 shows a sectional view of a sustained release
implant having a first drug core with a first therapeutic agent and
a second drug core with a second therapeutic agents to treat an
eye, the first and second drug cores being in a stacked
configuration, according to an embodiment of the present
invention.
[0406] FIG. 32 shows one embodiment of a therapeutic implant to
treat an eye having a punctal plug and a sustained release implant
having a first drug core with a first therapeutic agent and a
second drug core having a second therapeutic agent, the first and
second drug cores being in a stacked configuration, according to an
embodiment of the present invention.
[0407] FIG. 33 shows one embodiment of a therapeutic implant to
treat a body condition, the implant having a first therapeutic
agent and a second therapeutic agent.
[0408] FIGS. 34 and 35 show anatomical tissue structures of the eye
suitable for use with implants, according to embodiments of the
present invention.
[0409] FIG. 36 shows one embodiment of the implant having the bent
design.
DETAILED DESCRIPTION
Definitions
[0410] Unless otherwise indicated, the words and phrases presented
in this document have their ordinary meanings to one of skill in
the art. Such ordinary meanings can be obtained by reference to
their use in the art and by reference to general and scientific
dictionaries, for example, Webster's Third New International
Dictionary, Merriam-Webster Inc, Springfield, Mass., 1993, The
American Heritage Dictionary of the English Language, Houghton
Mifflin, Boston Mass., 1981, and Hawley's Condensed Chemical
Dictionary, 14.sup.th edition, Wiley Europe, 2002.
[0411] The following explanations of certain terms are meant to be
illustrative rather than exhaustive. These terms have their
ordinary meanings given by usage in the art and in addition include
the following explanations.
[0412] As used herein, the term "about" refers to a variation of 10
percent of the value specified; for example about 50 percent
carries a variation from 45 to 55 percent.
[0413] As used herein, the term "and/or" refers to any one of the
items, any combination of the items, or all of the items with which
this term is associated.
[0414] As used herein, the singular forms "a," "an," and "the"
include plural reference unless the context clearly dictates
otherwise.
[0415] "Subject" or "patient" as used herein, includes mammals such
as humans, non-human primates, rats, mice, dogs, cats, horses, cows
and pigs.
[0416] A "therapeutic agent" is a medicinal compound or mixture
thereof that is effective and medically indicated for treatment of
a malcondition in a patient.
[0417] "Treating" or "treatment" within the meaning herein refers
to an alleviation of symptoms associated with a disorder or
disease, or inhibition of further progression or worsening of those
symptoms, or prevention or prophylaxis of the disease or disorder.
Similarly, as used herein, an "effective amount" in the context of
a therapeutic agent, or a "therapeutically effective amount" of a
therapeutic agent refers to an amount of the agent that alleviates,
in whole or in part, symptoms associated with the disorder or
condition, or halts or slows further progression or worsening of
those symptoms, or prevents or provides prophylaxis for the
disorder or condition. In particular, an "effective amount" refers
to an amount effective, at dosages and for periods of time
necessary, to achieve the desired therapeutic result. A
therapeutically effective amount is also one in which any toxic or
detrimental effects of compounds of the invention are outweighed by
the therapeutically beneficial effects. When the term "effective
amount" is used in the context of a functional material, such as an
effective amount of a dispersant, what is meant is that the amount
of the functional material used is effective to achieve the desired
result.
[0418] An "implant" as the term is used herein refers to a physical
device adapted for insertion within or adjacent to a portion of a
patient's body, not necessarily by surgical emplacement. For
example, insertion of an implant such as a punctal plug through the
punctum into the canaliculus of the eye of a patient need not
involve surgical intervention, similarly with the emplacement of a
device adapted to be held under an eyelid in contact with the orb
of the eye. An implant is formed of biocompatible materials to the
extent the materials actually come in contact with body tissues or
fluids when disposed in their operative location. As defined
herein, an implant is adapted to receive a "drug insert", that is,
a structure that contains the therapeutic agent to be administered
to the particular patient for treatment of the particular
condition, and which is adapted to release the therapeutic agent to
the target tissues or organs over a period of time. Release of
therapeutic quantities of an agent over a period of time is
referred to as "sustained release" or "controlled release", as is
well known in the art.
[0419] By the terms "eye and surrounding tissues" is meant not just
the orb of the eye, but surrounding conjunctival membranes, tear
ducts, canaliculi (ducts draining tear liquid to the sinus),
eyelids, and associated body structures.
[0420] A "polymer" as the term is used herein, refers to an organic
macromolecule containing one or more repeating units, as is well
known in the art. A "copolymer" refers to a polymer in which there
are at least two types of repeating units included. A copolymer can
be a block copolymer, in which there are segments containing
multiple repeating units of one type, bonded to segments containing
multiple repeating units of a second type. A "polymer" or
"polymeric material" can be a silicone, a polyurethane, a
polyamide, a polyester, a polysaccharide, a polyimide, or the like,
or any copolymer thereof. When a polymeric material is to come in
contact with a body tissue or fluid, the polymeric material is
biocompatible.
[0421] A "matrix" is a material comprising an organic polymer in
which the therapeutic agent is dispersed, the combination of which
materials, referred to as a "core", serves as the reservoir of the
agent from which the agent is released over a period of time.
[0422] The term "precursor" as used in the context of this
invention and as applied to any particular item means an
intermediate or forerunner or prior article, device, item, or
compound that is subsequently manipulated to form a final article,
device, item or compound, or the like. For example, a "precursor
sheath" is the elongated tube that, when filled with matrix and
then cut, forms the sheath of the insert. In another example in the
language used herein, a "matrix precursor" is "cured" to form the
matrix. The matrix precursor can itself be a polymer, and can be
cured, for example, by crosslinking. Or, the matrix precursor can
be a polymer dissolved in a solvent, and curing includes removal of
the solvent to provide the polymeric matrix material. Or, the
matrix precursor can be a monomer, and curing can involve
polymerization of the monomer, and can also involve removal of a
solvent, and crosslinking of a polymer formed by polymerization. In
a further example, a precursor drug core is a cured matrix
containing the therapeutic agent that can be cut into appropriate
lengths to form a drug core. A typical application of the precursor
drug core is the filled precursor sheath. The filled precursor
sheath is a precursor sheath body containing the precursor drug
core that can be cut into appropriate lengths thereby producing a
drug insert of the invention.
[0423] The terms "agent", "therapeutic agent", or "drug" as used
herein refer to a medicinal material, a compound or a mixture
thereof, suitable and medically indicated for treatment of a
malcondition in a patient. The agent can be in a solid physical
form or a liquid physical form at about room temperature or at
about body temperature, depending on the melting point of the
material. Examples of therapeutic agents are provided herein; for
treatment of malconditions of the eye, specific examples of types
or classes of agents that can be included in the inventive inserts
include a glaucoma medication, a muscarinic agent, a beta blocker,
an alpha agonist, a carbonic anhydrase inhibitor, or a
prostaglandin or prostaglandin analog; an antiinflammatory agent;
an anti-infective agent; a dry eye medication; or any combination
thereof. More specifically, an example of a glaucoma medication is
a prostaglandin or a prostaglandin analog. An example of a
muscarinic agent is pilocarpine. An example of a beta blocked is
betaxolol. An example of an alpha agonist is brimonidine. Examples
of a carbonic anhydrase inhibitor are dorzolamide or brinzolamide.
Examples of an antiinflammatory agent include a steroid, a soft
steroid, or an non-steroidal antiinflammatory drug (NSAID) such as
ibuprofen. An example of an analgesic includes, salicylic acid and
acetaminophen. An antibiotic (antibacterial) can be a beta-lactam
antibiotic, a macrocyclic antibiotic such as erythromycin, a
fluoroquinolone, or the like. An antiviral compound can be a
reverse transcriptase inhibitor or a viral protease inhibitor. An
antimycotic can be a triazole antifungal compound. A dry eye
medication can be cyclosporine, olapatadine, a delmulcent, or
sodium hyaluronate.
[0424] In various embodiments, the therapeutic agent is contained
in the matrix such that an amount of the therapeutic agent in a
volumetric portion of the drug core is similar to an amount of the
therapeutic agent in any other equal volumetric portion of the drug
core. For example, the amount of the therapeutic agent in a
volumetric portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 30%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 20%.
For example, the amount of the therapeutic agent in a volumetric
portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 10%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 5%. In
addition, the concentration of the therapeutic agent in a
volumetric portion of the drug core can be the same as any other
equal volumetric portion of the drug core, in certain embodiments
including those embodiments wherein the agent is present as a
uniform, homogeneous dispersion and in embodiments wherein the
agent is present in solid or liquid inclusions throughout the
matrix.
[0425] The agent can be dissolved in the matrix in some
embodiments, when the chemical identities of the agent and the
matrix, and the concentration of the agent in the matrix, are such
that dissolution is achieved. For example, as is known in the art,
certain lipophilic steroid derivatives can dissolve at significant
concentrations in silicones. In this event, the agent is referred
to as being "dissolved" in the polymer, or as being uniformly,
homogeneously dispersed throughout the matrix or "dispersed at a
molecular level" in the polymer, just as a compound can be
dissolved in a solvent, to form a "solid solution" of the agent in
the polymeric material of the matrix.
[0426] In other embodiments, the agent does not completely dissolve
in the matrix, but is present as domains or "inclusions" of the
agent within the polymeric matrix. The inclusions can be liquid or
solid at about room temperature or at about the temperature of the
human body. After the matrix precursor has been cured to form the
matrix, the inclusions are non-uniformly distributed in the
now-solid or near solid matrix, and are thus prevented at least to
some extent from recombining with each other, such as by liquid
droplet accretion. This form is referred to as a "heterogeneous"
distribution of the agent in the matrix. When inclusions of the
agent are present, it is believed that a certain proportion of the
agent may also be dissolved in the matrix. However, dissolution is
not necessary for operation and function of the invention.
Furthermore, the heterogeneous distribution of the agent with the
matrix can be managed on a macroscopic level as discussed in
connection with the definition of the terms "concentration" and
"similar" given below.
[0427] A "concentration" of a therapeutic agent, as the term is
used herein, refers to a concentration of the agent within a
macroscopic portion of the matrix-agent core, that is controlled to
have a degree of reproducibility from sample to sample of the core.
A concentration of the agent in a macroscopic portion of the core
can vary, but only within limits, relative to that in any other
equal macroscopic portion of the core. The term does not relate to
concentrations at the molecular level, where discontinuous and/or
irregular domains or inclusions of the agent in concentrated form
may be present, but rather refers to bulk concentrations of the
agent in volumes of the core that are greater than at least about
0.1 mm.sup.3, for example, a cubic sample of core about 100 .mu.m
on a side, or a 0.1 mm thick slice of a core with cross-sectional
area of about 1 mm.sup.2.
[0428] The term "similar", as in a "similar" concentration of a
therapeutic agent, means that within a defined margin, the
quantity, such as the concentration of the agent, for example in
units of .mu.g/mm.sup.3, only varies within a certain degree from
measurement to measurement. The degree of variation is controlled
or regulated to provide a degree of uniformity of core material,
such that pluralities of cores or inserts are medically suitable in
that the dose of the agent they can provide to the tissue is within
certain limits from sample to sample. For example, a "similar"
concentration between two equal volumes of core material, or
between two inserts prepared by from a filled precursor sheath, can
vary by no greater than about 30%, or can vary by no greater than
about 20%, or can vary by no greater than about 10%, or can vary by
no greater than about 5%. The term "similar" also includes solid
solutions and uniform homogeneous dispersions, defined herein.
These concern situations where the concentration of the therapeutic
agent is the same in different portions of the core or between a
plurality of cores. This is a subcategory of the more general
category "similar."
[0429] The inclusions can be of various sizes, and various
distributions of sizes of a plurality of the inclusions are
possible, as are defined herein. When it is stated that the
inclusions are no greater than about 100 .mu.m in diameter, what is
meant is that the largest inclusion observed within a drug insert
of the invention has a greatest dimension of no greater than about
100 .mu.m. When a particular size distribution of inclusions is
recited, what is meant is that a predominant proportion of all the
inclusions are of the stated dimension. When an average size or
"average diameter" of inclusions within a population of inclusions
is stated, what is meant is a numerical average of the greatest
dimensions of all the inclusions. When a "standard deviation" of
the distribution of inclusion diameters with in a population of
inclusions is stated, what is meant that the distribution of
inclusion diameters is normal or near normal, and that the standard
deviation is a measure of the spread of the values, as is well
known in the art. A small standard deviation relative to the
average diameter denotes a tight distribution of inclusion
diameters, a feature of various embodiments of the present
invention.
[0430] In various embodiments, the inclusions can have an average
diameter of less than about 20 .mu.m, and a standard deviation of
diameters of the inclusions is less than about 8 .mu.m. Or, the
inclusions can have an average diameter of less than about 15
.mu.m, and a standard deviation of diameters of the inclusions is
less than about 6 .mu.m. Or, the inclusions can have an average
diameter of less than about 10 .mu.m, and a standard deviation of
diameters of the inclusions is less than about 4 .mu.m. A relative
uniformity of inclusion size distribution, and a relative
uniformity of the amount of agent dispersed per unit volume of the
core within the insert, are features of various embodiments
according to the present invention.
[0431] The size distribution of inclusion diameters can be
monodisperse, and can be tightly so. By "monodisperse" is meant
herein that the size distribution of the diameters of the plurality
of inclusions is relatively tightly clustered around the average
inclusion diameter, even if the distribution is not a normal
distribution. For example, the distribution can have a fairly sharp
upper size limit of inclusions of greater than average diameter,
but can trail off in the distribution of inclusions of less than
average diameter. Nevertheless, the size distribution can be
tightly clustered, or monodisperse.
[0432] A "polyurethane" refers to a variety of polymer or copolymer
containing repeating units bonded covalently through urethane,
i.e., carbamate, bonds, --N--C(O)--O-- wherein the N and 0 atoms
are attached to an organic radical. The organic radical can be
aliphatic, aromatic, or mixed; can contain other functional groups.
Each radical, other than the radicals at the ends of the molecular
chains, is bonded via two (or more) urethane groups to other
radicals. A polyurethane polymer contains only urethane-type groups
joining the repeating units. A polyurethane copolymer, such as a
polyurethane-silicone copolymer or a polyurethane-carbonate
copolymer, contains urethane and other types of groups joining the
repeating units, i.e., silicone and carbonate type groups
respectively.
[0433] A polyurethane-silicone copolymer contains segments of
polyurethane chains and segments of silicone chains, as is well
known in the art. A polyurethane-carbonate copolymer contains
urethane segments and carbonate (--O--C(O)O--) segments. An example
of a polyurethane-carbonate copolymer is Carbothane TPU.RTM.
(Lubrizol).
[0434] A `hydrogel" as the term is used herein refers to a
polymeric material that has absorbed greater than 100 wt %, for
example up to 500-2000 wt %, of water within the polymeric
structure and has consequently swelled substantially in physical
size. A hydrogel possesses physical integrity, has tensile
strength, and is not substantially fluid. A "hydrogel-forming
polymer" is a polymeric material capable of forming a hydrogel upon
contact with water. Examples include TG-500 and TG-2000.
[0435] "TG-500" and "TG-2000" are polyurethane hydrogel-forming
polymers manufactured by the Thermedics Polymer Products division
of Lubrizol Advanced Materials, Inc., of Wilmington, Mass. They are
described by the manufacturer as aliphatic, polyether based
thermoplastic polyurethanes capable of forming hydrogels. Such
hydrogel-forming polymers can absorb greater than 100 wt %, for
example up to 500-2000 wt % of water, and consequently swell in
physical dimensions.
[0436] A "hydrophilic polymer" is a polymer that can be wetted by
water, i.e., does not have a water-repellant surface. A hydrophilic
polymer can absorb water to a small degree, for example about 0-100
wt % of water, but does not greatly swell in volume as does a
hydrogel-forming polymer.
[0437] "Cyclosporine" is an immunosuppressant drug widely used in
post-allogeneic organ transplant to reduce the activity of the
patient's immune system and so the risk of organ rejection. It has
been studied in transplants of skin, heart, kidney, lung, pancreas,
bone marrow and small intestine. Initially isolated from a
Norwegian soil sample, Cyclosporin A, the main form of the drug, is
a cyclic nonribosomal peptide of 11 amino acids (an undecapeptide)
produced by the fungus Tolypocladium inflatum Gams. The structure
of cyclosporine is:
##STR00001##
[0438] "Olopatadine", the structure of which is shown below, is a
NSAID that can be administered in the form of a hydrochloride
salt:
##STR00002##
[0439] A "prodrug" is a substance, for example, that releases a
therapeutic agent such as cyclosporine or olopatidine, or a
biologically active derivative of either of these substances, when
administered to a mammal. A prodrug can be a chemical derivative
that contains a bond that is cleavable by an endogenous enzyme of
the mammalian circulatory system such as an esterase or a
phosphatase. For example, an amide NH of cyclosporine can be
substituted with an ester group, providing a carbamate of structure
ROC(O)N-cyclosporine. An endogenous esterase can cleave the ester
bond, yielding an N-carboxyamide, which can spontaneously
decarboxylate to yield cyclosporine. An ester of olopatidine, which
can be cleaved by an endogenous esterase to yield olopatidine, is
an example of an olopatidine prodrug. By formation of prodrugs, the
polarity (hydrophobicity/hydrophilicity) of cyclosporine or
olopatidine can be modified.
[0440] A "derivative" is a substance chemically allied to the
therapeutic agent, and retaining at least some of the therapeutic
agent's biological activity, but which need not be metabolized to
the agent itself in the mammalian body to provide the desired
beneficial result.
[0441] A "release profile", as in a "defined release profile",
refers to a rate of release as a function of time of the
therapeutic agent from an inventive plug into the eye, which can be
defined or determined by selection of a particular polyurethane
polymer or copolymer for a particular therapeutic agent. The
release profile will in turn govern both the concentration of the
agent in the eye and surrounding tissue over the time period during
which the plug releases the agent.
DETAILED DESCRIPTION
[0442] The present invention is directed to various embodiments of
drug inserts and drug cores containing therapeutic agents for use
in implant bodies adapted for disposition in a body tissue, fluid,
cavity, or duct. The implant bodies can be adapted to be disposed
in or adjacent to an eye of a patient. The implants release the
agent to the body, for example, into an eye or surrounding tissues,
or both, over a period of time, for treatment of a malcondition in
the patient for which use of the therapeutic agent is medically
indicated. The invention is also directed to various embodiments of
methods of manufacture of the drug inserts, and to methods of
treatment of patients using implants containing the drug
inserts.
[0443] In various embodiments, the invention provides a drug core
adapted for disposition within a sheath and hence within an
implant. The implant is adapted for disposition within or adjacent
to an eye of a patient, for providing sustained release of a
therapeutic agent to the eye or surrounding tissues or both.
[0444] The drug core comprises a therapeutic agent and a matrix
wherein the matrix comprises a polymer, wherein an amount of the
therapeutic agent in a volumetric portion of the drug core is
similar to an amount of the therapeutic agent in any other equal
volumetric portion of the drug core.
[0445] The insert comprises a drug core and a sheath body partially
covering the drug core. For example, the amount of the therapeutic
agent within the volumetric portion of the drug core varies from
the amount of the therapeutic agent within any other equal
volumetric portion of the drug core by less than about 30%. For
example, the amount of the therapeutic agent within the volumetric
portion of the drug core varies from the amount of the therapeutic
agent within any other equal volumetric portion of the drug core by
less than about 20%. For example, the amount of the therapeutic
agent within the volumetric portion of the drug core varies from
the amount of the therapeutic agent within any other equal
volumetric portion of the drug core by less than about 10%. For
example, the amount of the therapeutic agent within the volumetric
portion of the drug core varies from the amount of the therapeutic
agent within any other equal volumetric portion of the drug core by
less than about 5%.
[0446] The sheath body is disposed over a portion of the drug core
to inhibit release of the agent from said portion and so as to
define at least one exposed surface of the drug core adapted to
release the agent to the eye or surrounding tissues, or both, when
the implant is inserted into the patient.
[0447] In various embodiments, the invention provides a plurality
of the drug inserts as described above wherein each of the
plurality of the inserts comprises a similar amount of the agent
dispersed respectively therewithin For example, the similar amount
of agent dispersed respectively therein can vary no greater than
about 30% therebetween. For example, the similar amount of agent
dispersed respectively therein can vary no greater than about 20%
therebetween. For example, the similar amount of agent dispersed
respectively therein can vary no greater than about 10%
therebetween. For example, the similar amount of agent dispersed
respectively therein can vary no greater than about 5%
therebetween.
[0448] The exposed surface of the core is adapted to release
therapeutic quantities of the agent into body tissues or fluids,
for example into tear liquid, for a time period of at least several
days into tear liquid when the implant is inserted into the
patient. The sheath, which is impermeable to the agent, serves to
block, at least in part, exposure of non-target tissues to the
agent. For example, when the drug insert is disposed within an
implant inserted into the canaliculus of the eye, the sheath acts
to inhibit the release of the agent to the therapeutic target,
e.g., the eye, while blocking release to non-target tissue, such as
the interior of the canaliculus, or the nasal sinus.
[0449] In an embodiment, the drug core can be substantially
cylindrical in form, having an axis, wherein the exposed surface of
the drug core is disposed on one end of the cylindrical form and a
surface of the drug core covered by the sheath body constitutes a
remainder of the surface of the cylindrical form.
[0450] In a plurality of drug inserts of the invention, the
therapeutic quantity of the agent released by each of the drug
inserts is similar from one insert to another. For example, among a
plurality of drug inserts of the invention, the therapeutic
quantity of the agent released by each of the plurality of the
inserts can vary by no greater than about 30% therebetween, or by
no greater than about 20% therebetween, or by no greater than about
10% therebetween, or by no greater than about 5% therebetween. In
some embodiments, among a plurality of drug inserts of the
invention, the therapeutic quantity of the agent released by each
of the plurality of the inserts can be the same.
[0451] The drug core or drug insert can have various relative
contents of the therapeutic agent therein. For example, the drug
core can include about 0.1 wt % to about 50 wt % of the agent. The
agent is dispersed within the matrix, the matrix comprising a
polymer, to form a composite material that can be disposed within
the sheath. For example, the matrix can be formed of a
non-biodegradable silicone or a polyurethane, or combination
thereof. The sheath is formed of a substantially drug-impermeable
substance to block release of the agent except through an exposed
surface. It can be formed of any suitable biocompatible material,
such as a polymer comprising at least one of polyimide, PMMA, or
PET, wherein the polymer is extruded or cast; or a metal comprising
stainless steel or titanium.
[0452] A therapeutic agent for use in the inventive insert or core
can include anti-glaucoma medications, (e.g. adrenergic agonists,
adrenergic antagonists (beta blockers), carbonic anhydrase
inhibitors (CAIs, systemic and topical), parasympathomimetics,
prostaglandins such as latanoprost, and hypotensive lipids, and
combinations thereof), antimicrobial agent (e.g., antibiotic,
antiviral, antiparasitic, antimycotic, etc.), a corticosteroid or
other anti-inflammatory (e.g., an NSAID or other analgesic and pain
management compounds) such as cyclosporine or olopatidine, a
decongestant (e.g., vasoconstrictor), an agent that prevents of
modifies an allergic response (e.g., an antihistamine, cytokine
inhibitor, leucotriene inhibitor, IgE inhibitor, immunomodulator
such as cyclosporine), a mast cell stabilizer, cycloplegic,
mydriatic or the like.
[0453] Examples of agents further include, but are not limited to,
thrombin inhibitors; antithrombogenic agents; thrombolytic agents;
fibrinolytic agents; vasospasm inhibitors; vasodilators;
antihypertensive agents; antimicrobial agents, such as antibiotics
(such as tetracycline, chlortetracycline, bacitracin, neomycin,
polymyxin, gramicidin, cephalexin, oxytetracycline,
chloramphenicol, rifampicin, ciprofloxacin, tobramycin, gentamycin,
erythromycin, penicillin, sulfonamides, sulfadiazine,
sulfacetamide, sulfamethizole, sulfisoxazole, nitrofurazone, sodium
propionate), antifungals (such as amphotericin B and miconazole),
and antivirals (such as idoxuridine trifluorothymidine, acyclovir,
gancyclovir, interferon); inhibitors of surface glycoprotein
receptors; antiplatelet agents; antimitotics; microtubule
inhibitors; anti-secretory agents; active inhibitors; remodeling
inhibitors; antisense nucleotides; anti-metabolites;
antiproliferatives (including antiangiogenesis agents); anticancer
chemotherapeutic agents; anti-inflammatories (such as cyclosporine,
olopatidine, hydrocortisone, hydrocortisone acetate, dexamethasone
21-phosphate, fluocinolone, medrysone, methylprednisolone,
prednisolone 21-phosphate, prednisolone acetate, fluoromethalone,
betamethasone, triamcinolone, triamcinolone acetonide); non
steroidal anti-inflammatories (NSAIDs) (such as salicylate,
indomethacin, ibuprofen, diclofenac, flurbiprofen, piroxicam
indomethacin, ibuprofen, naxopren, piroxicam and nabumetone).
Examples of such anti-inflammatory steroids contemplated for use
with the present punctum plugs, include triamcinolone acetonide and
corticosteroids that include, for example, triamcinolone,
dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone,
and derivatives thereof); antiallergenics (such as sodium
chromoglycate, antazoline, methapyriline, chlorpheniramine,
cetrizine, pyrilamine, prophenpyridamine); anti proliferative
agents (such as 1,3-cis retinoic acid, 5-fluorouracil, taxol,
rapamycin, mitomycin C and cisplatin); decongestants (such as
phenylephrine, naphazoline, tetrahydrazoline); miotics and
anti-cholinesterase (such as pilocarpine, salicylate, carbachol,
acetylcholine chloride, physostigmine, eserine, diisopropyl
fluorophosphate, phospholine iodine, demecarium bromide);
antineoplastics (such as carmustine, cisplatin, fluorouracil);
immunological drugs (such as vaccines and immune stimulants);
hormonal agents (such as estrogens, estradiol, progestational,
progesterone, insulin, calcitonin, parathyroid hormone, peptide and
vasopressin hypothalamus releasing factor); immunosuppressive
agents, growth hormone antagonists, growth factors (such as
epidermal growth factor, fibroblast growth factor, platelet derived
growth factor, transforming growth factor beta, somatotrapin,
fibronectin); inhibitors of angiogenesis (such as angiostatin,
anecortave acetate, thrombospondin, anti-VEGF antibody); dopamine
agonists; radiotherapeutic agents; peptides; proteins; enzymes;
extracellular matrix; components; ACE inhibitors; free radical
scavengers; chelators; antioxidants; anti polymerases; photodynamic
therapy agents; gene therapy agents; and other therapeutic agents
such as prostaglandins, antiprostaglandins, prostaglandin
precursors, including antiglaucoma drugs including beta-blockers
such as timolol, betaxolol, levobunolol, atenolol, and
prostaglandin analogues such as bimatoprost, travoprost,
latanoprost etc; carbonic anhydrase inhibitors such as
acetazolamide, dorzolamide, brinzolamide, methazolamide,
dichlorphenamide, diamox; and neuroprotectants such as lubezole,
nimodipine and related compounds; and parasympathomimetrics such as
pilocarpine, carbachol, physostigmine and the like.
[0454] Additional agents that can be used with the present implants
include, but are not limited to, drugs that have been approved
under Section 505 of the United States Federal Food, Drug, and
Cosmetic Act or under the Public Health Service Act, some of which
can be found at the U.S. Food and Drug Administration (FDA) website
http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index. The
present punctum plugs can also be used with drugs listed in the
Orange Book, either in paper or in electronic form, which can be
found at the FDA Orange Book website
(http://www.fda.gov/cder/ob/)), that has or records the same date
as, earlier date than, or later date than, the filing date of this
patent document. For example, these drugs can include, among
others, dorzolamide, olopatadine, travoprost, bimatoprost,
cyclosporin, brimonidine, moxifloxacin, tobramycin, brinzolamide,
aciclovir timolol maleate, ketorolac tromethamine, prednisolone
acetate, sodium hyaluronate, nepafenac, bromfenac, diclofenac,
flurbiprofen, suprofenac, binoxan, patanol,
dexamethasone/tobramycin combination, moxifloxacin, or
acyclovir.
[0455] In various embodiments, a agent can be cyclosporine, or a
prodrug or derivative thereof, or olopatidine, or a prodrug or
derivative thereof, and, optionally, a second agent selected from
the above-listed therapeutic agents.
[0456] In various embodiments, the agent can be a prostaglandin
analog, such as latanoprost, bimatoprost, or travoprost, and the
amount of the agent in the drug insert can be about 10-50
.mu.g.
[0457] In various embodiments, the therapeutic agent is contained
in the matrix such that an amount of the therapeutic agent in a
volumetric portion of the drug core is similar to an amount of the
therapeutic agent in any other equal volumetric portion of the drug
core. For example, the amount of the therapeutic agent in a
volumetric portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 30%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 20%.
For example, the amount of the therapeutic agent in a volumetric
portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 10%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 5%. In
addition, the concentration of the therapeutic agent in a
volumetric portion of the drug core can be the same as any other
equal volumetric portion of the drug core, in certain embodiments
including those embodiments wherein the agent is present as a
uniform, homogeneous dispersion and in embodiments wherein the
agent is present in solid or liquid inclusions throughout the
matrix.
[0458] In various embodiments, the agent can be dissolved in the
matrix within the drug core, i.e., at an effective concentration
for use as with an implant, wherein the agent is sufficiently
soluble in the polymer such that no inclusions or concentrated
domains of the agent are present. This is known in the art as a
solid solution, i.e. a uniform, homogeneous dispersion on the
molecular level, wherein the solid polymer plays the role of a
solvent, and no liquid solvent is present. For example, when the
agent comprises cyclosporine and the matrix comprises polyurethane,
a solid solution is formed at useful concentrations of the
cyclosporine in the insert. This solubility is believed to result,
at least in part, from interaction of the abundant amide bonds
found in the cyclosporine molecule, which is a cyclic peptide, with
the amide-like urethane bonds of the polyurethane polymer.
[0459] In various embodiments, the agent is insufficiently soluble
in the matrix to form a solid solution. In these embodiments, the
agent can be distributed at least in part as a plurality of solid
or liquid inclusions throughout the matrix, the inclusions
comprising, at a temperature of about 20.degree. C., droplets of
the agent of no greater than about 100 .mu.m diameter when the
agent is a liquid at about 20.degree. C., or particles of the agent
of no greater than about 100 .mu.m diameter when the agent is a
solid at about 20.degree. C.; wherein the inclusions of the agent
are dispersed throughout each drug core.
[0460] As discussed above, the size and size distribution of the
inclusions can have an effect on a rate of release of the agent
from the drug core to the patient. For example, smaller, more
uniform inclusions can serve to infuse the bulk matrix with the
agent more effectively, at a higher rate, due to a more favorable
surface area to volume ratio. Accordingly, inventive methods
provide for control or regulation of the average inclusion diameter
or the distribution of inclusion diameters. For example, the
inclusions can have an average diameter of less than about 20
.mu.m. Inclusions of this average diameter can have a standard
deviation of diameters of the inclusions of less than about 8
.mu.m. For example, the inclusions can have an average diameter of
less than about 15 .mu.m. Inclusions of this average diameter can
have a standard deviation of diameters of the inclusions of less
than about 6 .mu.m. Or, the inclusions can have an average diameter
of less than about 10 .mu.m. Inclusions of this average diameter
can have a standard deviation of diameters of the inclusions of
less than about 4 .mu.m. In various embodiments, the distribution
of diameters of the inclusions can be a monodisperse distribution.
In various embodiments, the inclusions predominantly comprise a
cross-sectional size within a range from about 0.1 .mu.m to about
50 .mu.m. It is believed that tight, or monodisperse, distributions
of inclusion diameter are favorable from the point of view of
therapeutic aspects of the drug core or a drug insert containing
the core.
[0461] Various embodiments of the invention also provide a drug
core or an insert containing a drug core wherein the agent forms
inclusions in the matrix that are in a liquid physical state at
about 20.degree. C. For example, substantially all the inclusions
can be droplets of the agent of less than about 30 .mu.m in
diameter within the matrix. And, the droplets can have an average
diameter of less than about 10 .mu.m, or can have a standard
deviation of diameters of the inclusions is less than about 4
.mu.m. An example of an agent in a liquid physical state at about
20.degree. C. is latanoprost.
[0462] Various embodiments of the invention also provide a drug
core or an insert containing a drug core wherein the agent forms
inclusions in the matrix that are in a solid physical state at
about 20.degree. C. For example, substantially all the inclusions
can be particles of the agent of less than about 30 .mu.m in
diameter within the matrix. For example, an average particle
diameter within the matrix can be about 5-50 .mu.m. Examples of
agents in a solid physical state at about 20.degree. C. include
bimatoprost, olopatadine, or cyclosporine.
[0463] In various embodiments the drug insert or drug core can
comprise two or more therapeutic agents, or can comprise a
plurality of drug cores. Such a plurality of drug cores can also be
termed a plurality of drug sub-cores which together form the total
drug core. In this context first and second drug cores can also be
termed first and second drug sub-cores for clarity purposes. For
example, a drug insert of the invention can include two drug cores
disposed within the sheath body, a first drug core comprising a
first agent and a first matrix, and a second drug core comprising a
second agent and a second matrix, wherein the first agent and the
second agent are different, and wherein the first matrix and the
second matrix are either the same or differ from each other; the
implant body comprising an aperture adapted to receive the first
and the second cores disposed within the sheath body, the drug
cores being adapted to be disposed, within the sheath, within the
aperture of the implant body. The first matrix and the second
matrix can differ from each other with respect to at least one of a
composition, an exposed surface area, a surfactant, a crosslinker,
an additive, a matrix material, a formulation, a release rate
modifying reagent, or a stability. The first drug core and the
second drug core can be disposed within the sheath body such that
the first drug core has a surface exposed directly to tear liquid
and the second drug core does not have a surface exposed directly
to tear liquid when the drug insert is disposed within the implant
body and the implant body is disposed in or adjacent to the eye of
the patient. Or, the first drug core and the second drug core can
be disposed side by side within the sheath body. Or, the first drug
core and the second drug core can each be cylindrical in shape and
be disposed with the sheath body, the first drug core being
positioned near a proximal end of an aperture in the implant body
and the second drug core being positioned near a distal end of the
aperture, when the drug insert is disposed within the implant body.
Or, the first drug core and the second drug core can each be
cylindrical in shape provided that the first drug core has a first
central opening, the drug cores being positioned concentrically
within the sheath body within an aperture of the implant body
adapted to receive the drug insert, and the second drug core being
configured to fit within the first central opening of the first
drug core. Or, the first and second drug cores can be
concentrically positioned within the aperture of the implant body,
the first drug core having a first central opening exposing a first
inner surface and the second drug core having a second central
opening exposing a second inner surface, the second drug core being
configured to fit within the first central opening of the first
drug core, and wherein the aperture extends from a proximal end to
a distal end of the implant body thereby being adapted to allow
tear liquid to pass through the aperture and contact the first and
second inner surfaces of the first and second central openings and
release the first and second therapeutic agents into a canaliculus
of the patient when the implant body is inserted into a
patient.
[0464] In various embodiments, the first therapeutic agent can have
a release profile wherein the first agent is released at
therapeutic levels throughout a first time period and the second
therapeutic agent can have a second release profile wherein the
second agent is released at therapeutic levels throughout a second
time period. For example, the first time period and the second time
period can be between one week and five years. The first release
profile and the second release profile can be substantially the
same, or can be different.
[0465] In various embodiments, the first agent can provides a first
effect and a side effect to the patient, and the second agent can
provide a second effect that mitigates or counters the side effect
of the first agent.
[0466] In various embodiments, any inclusions in the first drug
core and in the second drug core respectively have an average
diameter of less than about 20 .mu.m, and can have a standard
deviation of diameters of less than about 8 .mu.m.
[0467] In various embodiments, the implant body can comprise a
central bore that extends from a proximal end to a distal end of
the implant body so as to be adapted to allow a tear liquid to pass
through the implant body such that the first and second therapeutic
agents are released into the tear liquid into a canaliculus of the
patient when the implant body is disposed in or adjacent to the
eye.
[0468] In various embodiments, the drug insert or the drug core can
further include a medication-impregnated porous material within the
first matrix, the second matrix, or both, wherein the
medication-impregnated porous material is adapted so as to permit
tear liquid to release the first agent, the second agent, or both,
from the medication-impregnated porous material at therapeutic
levels over a sustained period when a drug core-containing implant
is disposed within a punctum or within a lacrimal canaliculus, and
wherein the medication-impregnated porous material is a gel
material that can swell from a first diameter to a second diameter
when in contact with tear liquid. The second diameter can be about
50% greater than the first diameter. An example of a suitable
material for the medication-impregnated porous material is a
hydroxyethylmethacrylate (HEMA) hydrophilic polymer.
[0469] In various embodiments, the drug insert or drug core can
comprise a polyurethane polymer or copolymer. For example, the
polyurethane polymer or copolymer can be an aliphatic polyurethane,
an aromatic polyurethane, a polyurethane hydrogel-forming material,
a hydrophilic polyurethane, or a combination thereof. In various
embodiments, the polyurethane polymer or copolymer can include a
hydrogel adapted to swell when contacted with an aqueous medium and
the sheath body is adapted to be of sufficient elasticity to expand
in response thereto. For example, the swelling can be adapted to
retain the implant body within a duct, such as within a punctal
canal, of the patient.
[0470] In various embodiments, when the matrix comprises a
polyurethane, the therapeutic agent comprises cyclosporine or
olopatadine, a prodrug or a derivative of cyclosporine or
olopatadine, or any combination thereof. For example, the
cyclosporine or the olopatadine, or the cyclosporine prodrug or
derivative, or the olopatadine prodrug or derivative, or the
combination thereof, can be present in a weight ratio to the
polyurethane polymer or copolymer of about 1 wt % to about 70 wt %.
A concentration of the cyclosporine in the core can be similar in a
portion of the drug core proximate to the exposed surface, a
portion distal to the exposed surface, and a portion disposed
between the proximate portion and the distal portion. For example,
the proximal portion can be in length at least about one tenth a
length of the drug core.
[0471] In various embodiments, the invention provides a drug core
comprising a therapeutic agent and a matrix wherein the matrix
comprises a polymer, for disposition into a drug insert or an
implant. The drug insert or the implant is adapted for disposition
within or adjacent to an eye of a patient for providing sustained
release of the therapeutic agent to the eye or surrounding tissues
or both. The therapeutic agent is contained in the matrix such that
an amount of the therapeutic agent in a volumetric portion of the
drug core is similar to an amount of the therapeutic agent in any
other equal volumetric portion of the drug core. For example, the
therapeutic agent may be either uniformly homogeneously dispersed
throughout the matrix such as in a solid solution, or the
therapeutic agent at least in part forms solid or liquid inclusions
within the matrix. For example, the amount of the therapeutic agent
in a volumetric portion of the drug core can vary from the amount
of the therapeutic agent in any other equal volumetric portion of
the drug core by no greater than about 30%. For example, the amount
of the therapeutic agent in a volumetric portion of the drug core
can vary from the amount of the therapeutic agent in any other
equal volumetric portion of the drug core by no greater than about
20%. For example, the amount of the therapeutic agent in a
volumetric portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 10%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 5%.
For example, the amount of the therapeutic agent in a volumetric
portion of the drug core can be the same as the amount of
therapeutic agent in any other equal volumetric portion of the drug
core.
[0472] In various embodiments of the inventive drug insert for an
implant for disposition in or adjacent to a patient's eye, the
implant can be a lacrimal implant insertable into a lacrimal
canaliculus, which is commonly referred to as a punctal plug, i.e.,
an implant adapted to insertion through a punctum of the eye to
reside within the canaliculus of the eye, wherein the drug insert
can come in contact with tear liquid and thereby release the
therapeutic agent for contact with the eye or surrounding tissues
or both.
[0473] In various embodiments, the core of the insert comprising
the agent and a matrix, the matrix comprising a polymeric material,
is surrounded by a sheath body. The sheath body is substantially
impermeable to the agent, such that the agent is released to the
tear liquid only through an exposed surface of the core that comes
in contact with the tear liquid. The agent contained within the
core serves as a reservoir in order to release therapeutic
quantities or concentrations of the agent over a period of time,
which can range from days to months. For example, in treatment of
glaucoma, the drug insert can contain a prostaglandin analog such
as latanoprost.
[0474] The drug core is adapted to be disposed within a larger
structure, an implant, which is in turn adapted for disposition
within the body tissue, cavity, or duct. In various embodiments,
the implant can be a punctal plug adapted for emplacement within
the canaliculus of the eye, that is, within the duct(s) that drain
tears from the surface of the eye.
[0475] For example, various embodiments of the drug cores can be
used in implants, such as punctal plugs, adapted for placement near
the eye to treat a patient suffering from a malcondition of the eye
through the release of one or more drugs from the core within the
implant onto the surface of the eye, such as by diffusion into tear
fluids. Although specific reference is made to punctal plugs with
drug delivery capabilities for use within the canaliculus of the
eye, various embodiments of the implants may be useful for
sustained release of the drug and treatment of other structures
near and/or within the eye, for example the sclera, the
conjunctiva, the cul-de-sac of the eyelid, the trabecular meshwork,
the ciliary body, the cornea, the choroid, the suprachoroidal
space, the sclera, the vitreous humor, aqueous humor and retina.
Also, the inventive implants with their cores can be used for
release of therapeutic agents into tissues, body cavities, or
ducts, other than an eye or adjacent structures. In various
embodiments, the drug cores can be used for sustained release of
therapeutic agents into the ears and/or Eustachian tubes, nasal
and/or sinus cavities, urethra, skin, gastrointestinal tract
(including colon, bowel duct, and the like), and in or near joints
such as knee, finger, and intervertebral joints.
[0476] In various embodiments, a drug core comprising a composite
of a therapeutic agent and a matrix is partially contained within
or surrounded by a sheath, the sheath being substantially
impermeable to the agent. The sheath can cover part, but not all,
of the surface of the core comprising the drug and the matrix
material, the core having an exposed surface such that the
therapeutic agent can be released therethrough. The drug core and
its sheath together are adapted for inclusion within an implant
structure that is itself adapted for implantation within a body of
a patient, such as within a body cavity, tissue, duct, or fluid.
For example, the implant can be an ocular implant, adapted for
disposition in or around the eye, such as a punctal plug, adapted
to disposition within the canaliculus of the eye such that the
agent can be released through the punctum of the eye to contact the
orb and surrounding tissues.
[0477] The sheath can be composed of any suitable biocompatible
material which is substantially impermeable to the therapeutic
agent. For example, the sheath can be an impermeable polymeric
material such as a polyimide, polymethylmethacrylate, or a
polyester such as PET, or a biocompatible metal such as stainless
steel or titanium, or an inorganic glass, such as formed from
silicon oxide. The agent can be any therapeutic substance capable
of at least some diffusion through the matrix, which comprises a
polymer, such that the agent can be released into a body tissue or
fluid. A matrix can comprise a polymeric material, for example, the
matrix can include a silicone, a polyurethane, or any
non-biodegradable polymer wherein the agent has at least sufficient
solubility to diffuse therethrough. The matrix can comprise other
materials, including but not limited to other types of polymers
such as polyolefins, polyamides, polyesters, polyvinyl alcohol or
acetate, ethylene-vinyl acetate copolymers, polysaccharides such as
cellulose or chitin, or the like, provided the material is
biocompatible. Accordingly, selection of a material for the matrix
can be made at least in part based on the agent selected for the
particular application intended, such that a sufficient degree of
solubility of the agent in the matrix can be achieved for a
therapeutic level of the agent in the target tissue can be
maintained over a period of time.
[0478] Other substances, such as release rate modifying substances
such as surfactants, dispersants, fillers, other polymers and
oligomers, and the like, can be included with the matrix in the
core.
[0479] The substantially impermeable sheath prevents the diffusion
of the agent therethrough. Accordingly, the agent diffuses into
surrounding body fluids, tissues, etc. largely via that portion of
the core that is not covered by the sheath. The rate of diffusion
of the agent into the surrounding body fluids, tissues, etc. is
governed at least in part by the rate of diffusion of the agent
through the matrix. Once a molecule of the agent reaches the
exposed surface of the composite in contact with the environment,
it can diffuse into the surrounding fluid or tissue. In certain
embodiments, the therapeutic agent can initially be released into a
tissue structure adjacent to the target, for example into a punctum
of a patient located near the target ocular tissues, from where it
can diffuse to the site of action.
[0480] In various embodiments, the agent can be soluble or
substantially insoluble in the polymeric matrix material. In
embodiments wherein the agent is soluble at the concentration used
in the polymeric matrix material, the drug core comprises a
homogeneous composite wherein the agent is dispersed at a molecular
level within the polymeric matrix material. For example, a highly
lipophilic agent such as ethynodiol diacetate can dissolve at
significant concentrations in silicone polymer, such that a core
can be a homogeneous dispersion of the agent in the matrix at the
molecular level. For example, cyclosporine, a cyclic peptide
analog, can dissolve in significant concentrations in polyurethane,
a polymer that contains linkages resembling amide bonds. When a
homogeneous dispersion of the agent in the matrix is present, the
rate of release of the agent from the exposed surface of the core
into the body fluid or tissue can be controlled by the rate of
diffusion or transport of the agent through the matrix. In
embodiments wherein the agent is soluble in the polymeric matrix
material, the rate of release of the agent into the body tissue or
fluid can be determined at least in part by the concentration of
the agent dissolved in the matrix of the core. In various
embodiments, the concentration of therapeutic agent dissolved in
the matrix can be a saturation concentration The kinetics of such
release can be zero order, first order, or a fractional order
between zero and first orders.
[0481] In embodiments wherein the agent is only partially or
sparingly soluble or insoluble in the matrix at the concentration
used, the core comprises a heterogeneous composition wherein the
drug substance is dispersed as solid or liquid inclusions
throughout the polymeric matrix material. Where some solubility,
however slight, exists, a certain amount of the drug will be
dissolved in the matrix. In various embodiments, the inclusions can
range in size from about 0.1 .mu.m to about 100 .mu.m. When
inclusions of the agent in the matrix are present, the agent may be
at least slightly soluble in the matrix to enable at least some
diffusion of the agent from an inclusion to an exposed surface of
the drug core such that the agent can further diffuse into body
fluid or tissue, for example, the agent can diffuse into tear
fluid. When the agent is insoluble in the matrix, the agent will
form domains or inclusions as a separate phase within the matrix
that may cooperate to enable microchannels for transport of drug to
the matrix surface. In various embodiments, the agent can be
transported via channels or pores in the matrix, which can be
permeated by the body fluid. In various embodiments, the agent can
be transported through pores or channels present in the matrix.
[0482] The agent is present in the core, dispersed in the matrix,
in a concentration. The concentration is a concentration of the
agent within a macroscopic portion of the matrix-agent core, that
is controlled to be similar from sample to sample of the core. A
similar concentration of the agent in a macroscopic portion of the
core can vary, but only within limits, relative to that in any
other equal macroscopic portion of the core. The term does not
relate to concentrations at the molecular level, where domains or
inclusions of the agent in concentrated form may be present, but
rather refers to bulk concentrations of the agent in volumes of the
core that are greater than at least about 0.1 mm.sup.3, for
example, a cubic sample of core about 100 .mu.m on a side, or a 0.1
mm thick slice of a core with cross-sectional area of about 1
mm.sup.2. The concentration can vary within no greater than about
30%, or no greater than about 20%, or no greater than about 10%, or
no greater than about 5%.
[0483] In various embodiments, the inclusions can have an average
diameter of less than about 20 .mu.m, or less than about 15 .mu.m,
or less than about 10 .mu.m. The distribution of diameters of the
inclusions can be monodisperse, that is, relatively tightly grouped
around the average diameter. If the distribution of inclusion
diameters is a normal or near-normal distribution, and the
monodispersity can be expressed in terms of a standard deviation, a
standard deviation of diameters of the inclusions can be less than
about 8 or less than about 6 .mu.m, or less than about 4 .mu.m.
[0484] Although it is not intended to be a limitation of the
invention, the factors controlling the rate of release of the agent
from the matrix to the patient, such as the release of an ocular
drug into tear liquid, are believed to be complex and dependent on
many variables. For example, a drug and a matrix material may
together define a saturation concentration of the drug in that
matrix. For some drug-matrix combinations, high concentrations of
the drug can dissolve in the matrix. For others, a saturation
concentration is lower. For still others, no solubility exists, and
separate domain phases often manage rate of release. Another
possible factor is the rate of mass transfer from inclusions to the
surface of the matrix. Yet another possible factor is the rate of
diffusion of the agent from the matrix into a body fluid, such as
tear liquid.
[0485] A rate of release of the therapeutic agent at therapeutic
quantities can be determined at least in part by a concentration of
therapeutic agent in the matrix of the drug core. The therapeutic
agent can be capable of sufficiently dissolving into the matrix
from the inclusions, if present, so as to maintain the
concentration of therapeutic agent dissolved in the matrix such
that the rate of release is within a therapeutic window for the
extended period. This can lead to a desirable zero order rate of
release of the agent, as substantial reservoirs of the agent are
present in the inclusions, while the limited solubility of the
agent in the matrix is rate-determining in bringing the agent to
the exposed surface of the core, where it can be released in tear
fluids or other media. In embodiments wherein the agent is
insoluble and forms inclusions in the matrix material, the rate of
release of the agent into the body tissue or fluid can be
determined at least in part by the concentration of the agent as it
diffuses from the inclusions through separate domains in the matrix
material to the point of exposure to the body tissue or fluid.
[0486] In various embodiment, the matrix includes a release rate
varying material in a quantity sufficient to release the
therapeutic agent from the drug core at the therapeutic quantities
for an extended period when implanted for use. The release rate
modifying material can include an inert filler material, a salt, a
surfactant, a dispersant, a second polymer, an oligomer, or a
combination thereof. For example, the core can include a surfactant
or a dispersant material, or a filler, an oligomer, another
polymer, or the like, in addition to the one or more drugs and the
polymeric matrix material. Examples include polymers such as
polyethyleneglycols (PEGs), sodium alginate, low molecular weight
silicones or polyurethanes, etc. Non-polymeric additives can
include hydrophilic solvents such as ethylene glycol or
glycerol.
[0487] In various embodiments, the core comprises from about 5% to
about 50% of the drug. Depending on the drug, and the rate of
release of the drug from the polymer selected for the matrix, the
concentration can control the period of time over which therapeutic
quantities of the drug are released into body fluid, such as tear
liquid.
[0488] In various embodiments, as discussed above, the core can
include two or more drugs. In certain embodiments, both drugs are
substantially soluble in the matrix material. In other embodiments,
a first drug is substantially soluble in the matrix material and a
second drug forms inclusions within the matrix material. In some
embodiments, the implant comprise a single drug core with two
therapeutic agents mixed within a matrix. In other embodiments, the
implant comprise two drug cores, each with a single therapeutic
agent.
[0489] In some embodiments, the second drug can be a counteractive
agent to avoid a side effect of the first therapeutic agent. In one
example, the first drug can be a cycloplegic drug, i.e., one that
blocks accommodation (focusing) of the eye, e.g., atropine or
scopolamine, and the second therapeutic agent cab be at least one
of an anti-glaucoma drug or a miotic drug, selected to reduce the
known glaucoma-inducing side effect of cycloplegic drugs or to
cause pupil contraction counteracting the known mydriatic effects
of atropine or scopolamine. The anti-glaucoma drug may comprise at
least one of a sympathomimetic, a parasympathomimetic, a beta
blocking agent, a carbonic anhydrase inhibitor, or prostaglandin
analogue. In another example, the first therapeutic agent may be a
steroid and the second therapeutic agent may be an antibiotic,
wherein the steroids compromise the immune response, but the
antibiotics provides protection against infection. In another
example, the first therapeutic agent may be pilocarpine and the
second therapeutic agent may be non-steroidal anti-inflammatory
drug (NSAID). An analgesic may be a good compliment for the
treatment.
[0490] In specific embodiments, the core insert comprises a single
drug-matrix composite having two drugs contained therein. In other
embodiments, the core insert comprises two separate drug-matrix
composites ("subcores" or first and second cores), disposed
adjacent to each other within the sheath. The two separate
composites can be disposed in a concentric spatial configuration,
in a sector configuration, or otherwise, provided that exposed
surfaces of both composites are exposed to body tissue or fluid
when disposed within the body tissue, cavity, or duct of the
patient.
[0491] In some embodiments the therapeutic agents can be released
with a profile that corresponds to a kinetic order of therapeutic
agents release and the order can be within a range from about zero
to about one. In specific embodiments, the range is from about zero
to about one half, for example from about zero to about one
quarter. The therapeutic agents may be released with a profile that
corresponds to a kinetic order of therapeutic agents release and
the order is within a range from about zero to about one half for
at least about a month after the structure is inserted, for example
the order can be within the range at least about 3 months after the
structure is inserted.
[0492] In various embodiments, the invention provides a filled
precursor sheath adapted for manufacture of a plurality of drug
inserts therefrom by division of the filled precursor sheath, each
drug insert being adapted for disposition within a respective
implant, the implant being adapted for disposition within or
adjacent to an eye of a patient, for providing sustained release of
a therapeutic agent to the eye or surrounding tissues or both. The
filled precursor sheath comprises a precursor sheath body and a
precursor drug core contained therewithin, the precursor drug core
comprising a therapeutic agent and a matrix wherein the matrix
comprises a polymer and a therapeutic agent. In the precursor drug
cores, an amount of the therapeutic agent in a volumetric portion
of the precursor drug core is similar to an amount of the
therapeutic agent in any other equal volumetric portion of the
precursor drug core. The precursor sheath body is substantially
impermeable to the agent. Each of the plurality of inserts divided
therefrom is adapted to release the agent to the eye or surrounding
tissues, or both, when in contact with tear liquid. A respective
sheath body of each of the plurality of inserts divided from the
filled precursor sheath is disposed over a portion of a respective
drug core of each of the plurality of inserts to inhibit release of
the agent from said portion and so as to define at least one
exposed surface of the drug core adapted to release the agent to
the eye or surrounding tissues, or both, when the insert is
disposed in an implant and the implant is inserted into the
patient. For example, an amount of the therapeutic agent in a
volumetric portion of the precursor drug core can vary from an
amount of the therapeutic agent in any other equal volumetric
portion of the precursor drug core by no greater than about 30%.
For example, an amount of the therapeutic agent in a volumetric
portion of the precursor drug core can vary from an amount of the
therapeutic agent in any other equal volumetric portion of the
precursor drug core by no greater than about 20%. For example, an
amount of the therapeutic agent in a volumetric portion of the
precursor drug core can vary from an amount of the therapeutic
agent in any other equal volumetric portion of the precursor drug
core by no greater than about 10%. For example, an amount of the
therapeutic agent in a volumetric portion of the precursor drug
core can vary from an amount of the therapeutic agent in any other
equal volumetric portion of the precursor drug core by no greater
than about 5%.
[0493] In various embodiments, the filled precursor sheath can be
adapted to provide any of the above-discussed drug inserts by
division of the filled precursor sheath. In various embodiments,
the precursor sheath can be divided by cutting with a blade or with
a laser, or the like.
[0494] In various embodiments, the invention provides an implant
body for disposition in or adjacent to an eye of a patient for
release of a therapeutic agent over a period of time to the eye or
surrounding tissues, or both. The implant body comprises a channel
therein adapted to receive a drug insert such that an exposed
surface of the insert will be exposed to tear liquid when the
insert is disposed within the implant and when the implant is
disposed in or adjacent to the eye. The drug insert comprises a
sheath body that is substantially impermeable to the agent,
containing therewithin a drug core comprising a therapeutic agent
and a matrix comprising a polymer, wherein an amount of the
therapeutic agent in a volumetric portion of the drug core is
similar to an amount of the therapeutic agent in any other equal
volumetric portion of the drug core. The implant body comprises a
biocompatible material and being adapted to be retained within or
adjacent to the eye for a period of time. For example, the amount
of the therapeutic agent in a volumetric portion of the drug core
can vary from the amount of the therapeutic agent in any other
equal volumetric portion of the drug core by no greater than about
30%. For example, the amount of the therapeutic agent in a
volumetric portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 20%. For example, the amount of the
therapeutic agent in a volumetric portion of the drug core can vary
from the amount of the therapeutic agent in any other equal
volumetric portion of the drug core by no greater than about 10%.
For example, the amount of the therapeutic agent in a volumetric
portion of the drug core can vary from the amount of the
therapeutic agent in any other equal volumetric portion of the drug
core by no greater than about 5%.
[0495] In various embodiments, an exposed surface of the drug core
contained within the implant is capable of releasing the
therapeutic quantities into at least one of a sclera, a cornea or a
vitreous when disposed in or adjacent to the eye of the patient.
For example, the implant can be a punctal plug adapted for
disposition within a punctum of a patient for release of the agent
into tear liquid.
[0496] In various embodiments of the inventive methods described
above, the mixture can further comprise a solvent in which the
matrix precursor and the agent are soluble, and curing can comprise
at least partial removal of the solvent following injection into
the sheath body or precursor sheath body respectively. Curing can
involve heating, vacuum treatment, or both. The solvent can be a
hydrocarbon, an ester, a halocarbon, an alcohol, an amide, or a
combination thereof. For example, when the agent is cyclosporine,
the solvent can be a halocarbon.
[0497] In various embodiments, curing the mixture can comprise
heating the mixture to a temperature, at a relative humidity, for a
period of time. For example, the temperature can include a range
from about 20 degrees C. to about 100 degrees C., the relative
humidity can include a range from about 40% to about 100%, and the
period of time can include a range from about 1 minute to about 48
hours. More specifically, the temperature can be at least about
40.degree. C., the relative humidity can be at least about 80%, or
both. In various embodiments, curing can include a step of
polymerization or cross-linking, or both, of the matrix, the matrix
precursor, or both. For example, polymerization or cross-linking,
or both, can be carried out in the presence of a catalyst. For
instance, the catalyst can be a tin compound or a platinum
compound, such as a platinum with vinyl hydride catalyst system or
a tin with alkoxy catalyst system.
[0498] In various embodiments, the mixture can be prepared by a
method comprising sonication. The matrix precursor and the agent
can be mixed to provide a thoroughly dispersed emulsion-like
composite, wherein the agent, if insoluble or slightly soluble in
the matrix precursor, is dispersed in small particles or
droplets.
[0499] In various embodiments, the step of injecting the mixture
into the sheath can be carried out under a pressure of at least
about 40 psi. The mixture can be injected such that the sheath body
or precursor sheath body, respectively, is filled at a rate of no
greater than about 0.5 cm/sec.
[0500] The injection or extrusion of the mixture including the
agent and the matrix precursor or matrix can be carried out at room
temperature (20.degree. C.), or above room temperature, or can be
carried out at subambient temperatures of less than 20.degree. C.
For example, the injection can be carried out wherein the
subambient temperature comprises a temperature of about -50.degree.
C. to about 20.degree. C., or wherein the subambient temperature
comprises a temperature of about -20.degree. C. to about 0.degree.
C.
[0501] As discussed below, FIGS. 15 and 16 provide graphical
evidence of the advantages of subambient extrusion, both in terms
of uniformity of inclusion diameter, and in terms of uniformity of
distribution of the therapeutic agent throughout the length of a
filled precursor sheath. FIG. 15 shows electron micrographs of
cryogenically section portions of a drug core wherein the extrusion
was carried out at various temperatures. As can be seen, the
average diameter of the included droplets of latanoprost is smaller
when the extrusion is carried out at 0.degree. C. or -25.degree. C.
than when the extrusion is carried out at 25.degree. C. or at
40.degree. C.
[0502] In a parallel experiment, described in Examples 12 and 13,
average inclusion diameters; and diameter size distributions, were
determined for extrusions carried out at room temperature and at
-5.degree. C. for a latanoprost-silicone mixture:
[0503] Cold extrusion (-5.degree. C.): 0.006.+-.0.002 mm (n=40
inclusion),
[0504] Room temp (22.degree. C.): 0.019.+-.0.019 mm (n=40
inclusion),
showing that the cold extrusion technique produced inclusions of
smaller average diameter and of more uniform size than when the
extrusion was carried out at ambient temperature.
[0505] FIG. 16 shows graphically the content of latanoprost in a 10
can precursor sheath filled with the latanoprost-silicone mixture,
as discussed in Examples 12 and 13. As can be seen, cold extrusion
at -25.degree. C. and 0.degree. C. (squares) unexpectedly produced
a more uniform distribution of therapeutic agent latanoprost in the
silicone matrix, after curing, along the entire length of the 10 cm
precursor sheath, which was subsequently divided into 1 mm
sections, and the latanoprost content of each sections (drug
insert) determined. Extrusions carried out at room temperature
(circles) and at 40.degree. C. (triangles) were significantly more
variable. The results are significant in terms of manufacturing
medically useful devices, as it is desirable to maintain a uniform
content of the therapeutic agent among a plurality of drug inserts
manufactured by this method.
[0506] In various embodiments, each drug insert can be sealed at
one end thereof, the second end thereby providing the exposed
surface for release of the agent when the insert is disposed within
an implant and inserted into a patient. Each drug insert can be
sealed at one end thereof using a UV-curable adhesive, a
cyanoacrylate, an epoxy, by pinching, with a heat weld, or with a
cap. When a UV-curable adhesive is used, curing is carried out by
irradiation with UV light.
[0507] In various embodiments, the inventive methods further
comprise, after sealing one end thereof, inserting each drug insert
into a channel of a respective implant body adapted to receive the
insert therein.
[0508] In various embodiments, when the drug core comprises two
drug cores, a first drug core comprising a first agent and a first
matrix, and a second drug core comprising a second agent and a
second matrix, wherein the first agent and the second agent are
different, and wherein the first matrix and the second matrix are
either the same or differ from each other, the implant body
comprising an aperture adapted to receive the drug insert
comprising the first and the second drug cores, the method can
further comprise disposing the drug cores within the insert prior
to disposing the insert comprising the drug cores within the
aperture of the implant body.
[0509] In various embodiments, where the therapeutic agent
comprises cyclosporine or olopatadine, a prodrug or a derivative of
cyclosporine or olopatadine or any combination thereof, the matrix
includes polyurethane, and a weight ratio of the cyclosporine or
the olopatadine or the cyclosporine prodrug or derivative, or the
olopatadine prodrug or derivative, or the combination thereof, to
the polyurethane polymer or copolymer is about 1 wt % to about 70
wt %, the method can include forming the mixture by melting and
mixing the polyurethane polymer or copolymer and the therapeutic
agent. The therapeutic agent can be in molten form in the mixture,
or can be in solid form in the mixture.
[0510] In some embodiments, the matrix comprises an inert filler
material mixed with the therapeutic agent such that the exposed
surface releases the therapeutic agent at therapeutic quantities
for a sustained period of time.
[0511] In some embodiments, a salt is mixed with the matrix
precursor such that the exposed surface of the matrix, after
curing, releases the therapeutic agent at therapeutic quantities
for a sustained period of time.
[0512] In some embodiments, a surfactant is mixed with the matrix
precursor such that the exposed surface of the matrix, after
curing, releases the therapeutic agent at therapeutic quantities
for a sustained period of time.
[0513] In some embodiments a second polymer or an oligomer is mixed
with the matrix precursor, and after curing to form the matrix, the
presence of the second polymer or oligomer can serve to vary the
rate of release of the therapeutic agent.
[0514] Various embodiments of the invention provide a punctum plug
for insertion into a punctal canal of a patient, the plug
comprising a drug core having a distal end and a proximal end, at
least the distal end of the drug core having a cross section
suitable for insertion through a punctum, the drug core comprising
a polyurethane polymer or copolymer comprising a therapeutic agent
deliverable into the eye or surrounding tissues; and a
substantially impermeable sheath disposed over a portion of the
drug core to define at least one exposed surface of the drug core,
at least one exposed surface of the drug core being located near
the proximal end to contact a tear or tear film fluid of a patient
and release the therapeutic agent at therapeutic levels over a
sustained period when the plug is implanted for use within the
punctal canal of the patient. The inventive plug includes a core,
in which the therapeutic agent is contained, that is formed from a
polyurethane polymer or copolymer. The polyurethane polymer or
copolymer of the core can be an aliphatic polyurethane, an aromatic
polyurethane, a polyurethane hydrogel-forming material, a
hydrophilic polyurethane, or a combination thereof. For example,
the core can be formed of the polyurethane hydrogel-forming
material TG-500 or TG-2000 aliphatic, polyether based thermoplastic
polyurethanes capable of forming hydrogels. Such hydrogel-forming
polymers can absorb greater than 100 wt %, for example up to
500-2000 wt % of water, and consequently swell in physical
dimensions. Alternatively, the core can be formed of a hydrophilic
polyurethane such as Pursil, which swells much less, to the extent
of about 20-100%, upon contact with an aqueous medium. Other
examples include Lubrizol products including Tecophilic grades such
as HP-60D20, HP-60D35, HP-60D60, or HP-93A100.
[0515] In various embodiments, the therapeutic agent can comprise
cyclosporine, or a prodrug or a derivative of cyclosporine.
Cyclosporine, as is well-known in the art, is an immunomodulator,
and can be used in the treatment of dry eye and inflammations of
the eye, such as those resulting from an allergic response. The
weight ratio of the cyclosporine or the cyclosporine prodrug or
derivative, respectively, to the polyurethane polymer or copolymer
can be about 1 wt % up to as high as about 70 wt %, or even
greater. The rate of the release of the cyclosporine, or its
prodrug or derivative, can be controlled by selection of the
specific kind of polyurethane for the core and by modulating the
polarity (hydrophobicity/hydrophilicity) of the therapeutic agent.
Cyclosporine is a rather hydrophobic compound, but can be rendered
more hydrophilic by incorporation of functional groups, such as
groups that can be cleaved in vivo by endogenous enzymes like
esterases, wherein the functional groups incorporated have
hydrophilic moieties included.
[0516] In various embodiments, the therapeutic agent can be
olopatidine, or a prodrug or a derivative of olopatidine. For
instance, the agent can be olopatidine hydrochloride, also known as
patanol. Used to treat allergic conjunctivitis (itching eyes),
olopatadine inhibits the release of histamine from mast cells. It
is a relatively selective histamine H1 antagonist that inhibits the
in vivo and in vitro type 1 immediate hypersensitivity reaction
including inhibition of histamine induced effects on human
conjunctival epithelial cells.
[0517] The plug further includes a substantially impermeable
sheath, to limit the zone or region of release of the therapeutic
agent to the at least one exposed surface of the drug core,
disposed immediately adjacent to the punctum of the eye such that
the therapeutic agent is readily contacted by tear fluid and can
thus diffuse over the surface of the eye. For example, cyclosporine
can be released into the tear fluid to assist in treatment of the
eye for dryness or for inflammation, such as caused by an allergic
reaction. The sheath can also be adapted to provide a second
exposed surface of the drug core is located near the distal end of
the plug to release the therapeutic agent into the punctal canal,
if such is desired. For example, a second therapeutic agent can be
included, such as an antibiotic for treatment of infections of the
punctal canal.
[0518] The sheath can be of sufficient elasticity or flexibility
that when the core is adapted to swell when in contact with an
aqueous medium, such as when the core is constructed of a
hydrophilic or hydrogel-forming polyurethane polymer or copolymer,
that the sheath can expand in response to the swelling of the
hydrophilic or hydrogel-forming polyurethane polymer or copolymer.
The swelling is adapted to assist in retaining the plug within the
punctal canal.
[0519] The core can further contain a second bioactive agent, such
as are listed below, such as for treatment of a secondary condition
or to assist in treatment of the condition, for example, for which
administration of cyclosporine or olopatidine, or both, is
medically indicated.
[0520] The lacrimal implant can be any suitable shape adapted for
insertion into the punctal canal of the eye. For example, the
implant can be substantially cylindrical at the time of insertion
into the canal, prior to swelling of any hydrogel-forming core of
the plug. Or, the implant can be of a conical shape, or can be bent
in the form of an "L", or can have any other shape which can be
disposed within the punctal canal of a patient's eye such that the
therapeutic agent can be released from the core into the tear fluid
bathing the eye. Accordingly, the core of the implant, when the
implant is disposed within the punctal canal, has access to the
opening of the punctum such that the agent can diffuse into the
tear fluid and thereby bathe the eye surface. In various
embodiments, the core has access to the interior of the punctal
canal for release of the agent thereto.
[0521] For example, the implant can be a shape termed the
"bent-design" as disclosed in a patent application filed
concurrently with this application. Or, the implant can be a design
referred to as the "H-design", as disclosed in a patent application
filed concurrently with this application. Or, the implant can be
what is termed the "skeleton" design as disclosed in a patent
application filed concurrently with this application.
[0522] In various embodiments, a method of manufacture of the
inventive implant, comprising melting and mixing the polyurethane
polymer or copolymer and adding the therapeutic agent to form a
mixed melt, then, either casting the mixed melt within the sheath,
or, casting the mixed melt to form the core, then disposing the
sheath around the core, is provided.
[0523] The polyurethane selected to form the core of the implant
can be thermoplastic such that the implant can be manufactured by a
melt extrusion or casting process. For example, a melt of the core
polyurethane can be prepared and the therapeutic agent can be
incorporated therein. In various embodiments, the agent can melt at
a temperature around the melting point of a suitable polyurethane
polymer or copolymer, and the agent can itself be incorporated in a
molten state, provided the melting point is at a temperature at or
below the decomposition temperature of the polyurethane, and the
melting point of the polyurethane is below a temperature at which
the agent undergoes significant thermal decomposition. For example,
cyclosporine melts at about 135.degree. C., while TG-500 melts at
about 170.degree. C. and TG-2000 melts at about 115.degree. C.
Thus, a mixed melt can be prepared at about 135.degree. C., or
higher with TG-2000 wherein both the cyclosporine and the
polyurethane core material are both in a molten state. A higher
melting material like TG-500 can be used when the cyclosporine is
stable for the time period it is held at the elevated temperate in
the process used.
[0524] In various embodiments, the agent does not melt in the
molten polyurethane, but is dispersed as a solid, which in be in
the form of a fine powder, such as a microparticulate form. For
example, olopatidine, which melts in excess of 200.degree. C., can
be dispersed in solid form in a melt of a polyurethane. The
polyurethane melt containing the solid agent is then cast,
optionally within a sheath, to provide the inventive plug.
[0525] Thus, melt mixing processes can be cast to form an inventive
implant. For example, the mixed melt can be cast into a mold
already lined with a higher melting sheath material, which can be a
polyurethane that is not substantially permeable to diffusion of
the cyclosporine. In this way the sheathed implant can be prepared.
Alternatively, the core can be case in a mold, then the sheath
material coated or cast on the surface of the implant, except for
regions where the core material is to be left exposed. Or, the
sheath material can be cast to cover the entire implant, then a
portion removed to expose the core material in at least one
location near the proximal end, where the cyclosporine can readily
come into contact with tear fluid and thereby diffuse into the
eye.
[0526] In various embodiments, a method of manufacture of the
inventive implant, comprising dissolving the polyurethane polymer
or copolymer and mixing in the therapeutic agent in a solvent to
form a mixed solution, then, either casting the mixed solution
within the sheath, then removing the solvent, or, casting the mixed
solution to form the core, then removing the solvent, then
disposing the sheath around the core, is provided.
[0527] The polyurethane selected to form the core of the implant
can be soluble in an organic solvent, such as dichloromethane or
tetrahydrofuran. Many therapeutic agent, for example, cyclosporine,
are also soluble in many organic solvents, including
dichloromethane or tetrahydrofuran. In this way a mixed solution
can be prepared. This solution can then be used to cast the core of
the implant, with removal of the solvent. The solvent can be
removed by evaporation, which can be carried out under ambient
conditions, or can involve the application of heat, reduced
atmospheric pressure, or both. After removal of the solvent, the
sheath can be coated or cast around the core, either leaving an
exposed section of the core, or removing a portion of the sheath to
provide an exposed section.
[0528] In various embodiments, a method of manufacture of an
inventive implant comprises dissolving the polyurethane polymer or
copolymer in a solvent, then adding a therapeutic agent in solid
form, the agent being substantially insoluble in the solvent, then
removing the solvent to cast the core. The solid form of the agent
can be a fine powder, such as a microparticulate form, to provide
for a favorable surface area/mass ratio. In various embodiments the
implant comprises a dispersion of a solid form of the agent in the
polyurethane polymer or copolymer.
[0529] The polyurethane polymer or copolymer making up the core can
be an aliphatic polyurethane, an aromatic polyurethane, a
polyurethane hydrogel-forming material, a hydrophilic polyurethane,
or a combination thereof. The particular polyurethane used for the
therapeutic agent can be selected to control the release profile of
the agent over time.
[0530] The inventive implant can be used to treat a malcondition of
the eye or of surrounding tissue. For example, the implant
incorporating cyclosporine or olopatidine, or both, can be used to
treat an eye malcondition involving dry eye or eye inflammation.
The therapeutic agent can be released into the eye, as well as into
surrounding tissue such as the interior of the punctal canal, over
a period of time. The period of time can be about 1 week to about 6
months. When a swelling polyurethane is used, the swelling of the
implant can be used to secure the plug within the punctal canal for
the full time period over which the drug is adapted to be
released.
[0531] In various embodiments, the invention provides a drug insert
made by a method of the invention.
[0532] In various embodiments, the invention provides a method of
treating a malcondition in a patient in need thereof, comprising
disposing an implant comprising a drug insert of the invention, or
a drug core of the invention, or a drug core obtained by division
of a filled precursor sheath of the invention, or a drug implant of
the invention, or a drug insert prepared by the method of the
invention, wherein the therapeutic agent is adapted to treat the
malcondition, in or adjacent to an eye of the patient such that the
drug is released into a body tissue or fluid.
[0533] In various embodiments, the invention provides the use of a
drug insert of the invention, or a drug core of the invention, or a
drug core obtained by division of a filled precursor sheath of the
invention, or a drug implant of the invention, or a drug insert
prepared by the method of the invention, in the manufacture of an
implant adapted for treatment of a malcondition in a patient in
need thereof.
[0534] In various embodiments, the invention provides a drug insert
adapted for disposition within an punctal plug for providing
sustained release of a latanoprost to the eye for treatment of
glaucoma, the insert comprising a core and a sheath body partially
covering the core, the core comprising the latanoprost and a matrix
wherein the matrix comprises a silicone polymer, the latanoprost
being dispersed within the silicone as droplets thereof, wherein an
amount of the latanoprost in a volumetric portion of the drug core
is similar to an amount of the latanoprost in any other equal
volumetric portion of the drug core, the sheath body being disposed
over a portion of the core to inhibit release of the latanoprost
from said portion, an exposed surface of the core not covered by
the sheath body being adapted to release the latanoprost to the
eye.
[0535] In various embodiments, the invention provides a drug insert
adapted for disposition within an punctal plug for providing
sustained release of a cyclosporine to the eye for treatment of dry
eye or inflammation, the insert comprising a core and a sheath body
partially covering the core, the core comprising the cyclosporine
and a matrix wherein the matrix comprises a polyurethane polymer,
the cyclosporine being dissolved within the polyurethane, wherein
an amount of the cyclosporine in a volumetric portion of the drug
core is similar to an amount of the cyclosporine in any other equal
volumetric portion of the drug core, the sheath body being disposed
over a portion of the core to inhibit release of the cyclosporine
from said portion, an exposed surface of the core not covered by
the sheath body being adapted to release the cyclosporine to the
eye.
DISCUSSION OF THE FIGURES
[0536] FIG. 1A shows a top cross sectional view of a sustained
release implant 100 to treat an optical defect of an eye, according
to embodiments of the present invention. Implant 100 includes a
drug core 110. Drug core 110 is an implantable structure that
retains a therapeutic agent. Drug core 110 comprises a matrix 170
that contains inclusions 160 of therapeutic agent. Inclusions 160
will often comprise a concentrated form of the therapeutic agent,
for example a crystalline form of the therapeutic agent, and the
therapeutic agent may over time dissolve into matrix 170 of drug
core 110. Matrix 170 can comprise a silicone matrix or the like,
and the mixture of therapeutic agent within matrix 170 can be
non-homogeneous. In many embodiments, the non-homogenous mixture
comprises a silicone matrix portion that is saturated with the
therapeutic agent and an inclusions portion comprising inclusions
of the therapeutic agent, such that the non-homogenous mixture
comprises a multiphase non-homogenous mixture.
[0537] In some embodiments, inclusions 160 comprise droplets of an
oil of the therapeutic agent, for example Latanoprost oil. In some
embodiments, inclusions 160 may comprise particles of the
therapeutic agent, for example solid Bimatoprost particles in
crystalline form. In many embodiments, matrix 170 encapsulates
inclusions 160, and inclusions 160 may comprise microparticles have
dimensions from about 1 .mu.m to about 100 .mu.m. The encapsulated
inclusions dissolve into the surrounding solid matrix, for example
silicone, that encapsulates the micro particles such that matrix
170 is substantially saturated with the therapeutic agent while the
therapeutic agent is released from the core.
[0538] Drug core 110 is surrounded by a sheath body 120. Sheath
body 120 is can be substantially impermeable to the therapeutic
agent, so that the therapeutic agent is often released from an
exposed surface on an end of drug core 110 that is not covered with
sheath body 120. A retention structure 130 is connected to drug
core 110 and sheath body 120. Retention structure 130 is shaped to
retain the implant in a hollow tissue structure, for example, a
punctum of a canaliculus as described above.
[0539] An occlusive element 140 is disposed on and around retention
structure 130. Occlusive element 140 is impermeable to tear flow
and occludes the hollow tissue structure and may also serve to
protect tissues of the tissue structure from retention structure
130 by providing a more benign tissue-engaging surface. Sheath body
120 includes a sheath body portion 150 that connects to retention
structure 130 to retain sheath body 120 and drug core 110. Sheath
body portion 150 can include a stop to limit movement of sheath
body 120 and drug core 110. In many embodiments, sheath body
portion 150 can be formed with a bulbous tip 150B. Bulbous tip 150B
can comprise a convex rounded external portion that provides
atraumatic entry upon introduction into the canaliculus. In many
embodiments, sheath body portion 150B can be integral with
occlusive element 140.
[0540] FIG. 1B shows a side cross sectional view of the sustained
release implant of FIG. 1A. Drug core 110 is cylindrical and shown
with a circular cross-section. Sheath body 120 comprises an annular
portion disposed on drug core 110. Retention structure 130
comprises several longitudinal struts 131. Longitudinal struts 131
are connected together near the ends of the retention structure.
Although longitudinal struts are shown, circumferential struts can
also be used. Occlusive element 140 is supported by and disposed
over longitudinal struts 131 of retention structure 130 and may
comprise a radially expandable membrane or the like.
[0541] FIG. 1C shows a perspective view of a sustained release
implant 102 with a coil retention structure 132, according to an
embodiment of the present invention. Retention structure 132
comprises a coil and retains a drug core 112. A lumen, for example
channel 112C, may extend through the drug core 112 to permit tear
flow through the lumen for the delivery of therapeutic agent for
nasal and systemic applications of the therapeutic agent. In
addition or in combination with channel 112C, retention structure
132 and core 112 can be sized to permit tear flow around the drug
core and sheath body while the retention element holds tissue of
the canaliculus away from the drug core. Drug core 112 may be
partially covered. The sheath body comprises a first component 122A
that covers a first end of drug cove 112 and a second component
122B that covers a second end of the drug core. An occlusive
element can be placed over the retention structure and/or the
retention structure can be dip coated as described above.
[0542] FIG. 1D shows a perspective view of a sustained release
implant 104 with a retention structure 134 comprising struts,
according to an embodiment of the present invention. Retention
structure 134 comprises longitudinal struts and retains a drug core
114. Drug core 114 is covered with a sheath body 124 over most of
drug core 114. The drug core releases therapeutic agent through an
exposed end and sheath body 124 is annular over most of the drug
core as described above. An occlusive element can be placed over
the retention structure or the retention structure can be dip
coated as described above. A protrusion that can be engaged with an
instrument, for example a hook, a loop, a suture, or ring 124R, can
extend from sheath body 124 to permit removal of the drug core and
sheath body together so as to facilitate replacement of the sheath
body and drug core while the retention structure remains implanted
in the canaliculus. In some embodiments, a protrusion that can be
engaged with an instrument comprising hook, a loop, a suture or a
ring, can extend from retention structure 134 to permit removal of
the sustained release implant by removing the retention structure
with the protrusion, drug core and sheath body.
[0543] FIG. 1E shows a perspective view of a sustained release
implant 106 with a cage retention structure 136, according to an
embodiment of the present invention. Retention structure 136
comprises several connected strands of metal and retains a drug
core 116. Drug core 116 is covered with a sheath body 126 over most
of drug core 116. The drug core releases therapeutic agent through
an exposed end and sheath body 126 is annular over most of the drug
core as described above. An occlusive element can be placed over
the retention structure or the retention structure can be dip
coated as described above.
[0544] FIG. 1F shows a perspective view of a sustained release
implant comprising a core and sheath, according to an embodiment of
the present invention. Drug core 118 is covered with a sheath body
128 over most of drug core 118. The drug core releases therapeutic
agent through an exposed end and sheath body 128 is annular over
most of the drug core as described above. The rate of therapeutic
agent release is controlled by the surface area of the exposed drug
core and materials included within drug core 118. In many
embodiments, the rate of elution of the therapeutic agent is
strongly and substantially related to the exposed surface area of
the drug core and weakly dependent on the concentration of drug
disposed in the inclusions in the drug core. For circular exposed
surfaces the rate of elution is strongly dependent on the diameter
of the exposed surface, for example the diameter of an exposed drug
core surface near an end of a cylindrical drug core. Such an
implant can be implanted in ocular tissues, for example below
conjunctival tissue layer 9 of the eye and either above sclera
tissue layer 8, as shown in FIG. 1F, or only partially within the
scleral tissue layer so as not to penetrate the scleral tissue. It
should be noted that drug core 118 can be used with any of the
retention structures and occlusive elements as described
herein.
[0545] In an embodiment, the drug core is implanted between sclera
8 and conjunctiva 9 without sheath body 128. In this embodiment
without the sheath body, the physical characteristics of the drug
core can be adjusted to compensate for the increased exposed
surface of drug core, for example by reducing the concentration of
dissolved therapeutic agent in the drug core matrix as described
herein.
[0546] FIG. 1G schematically illustrates a sustained release
implant 180 comprising a flow restricting retention structure 186,
a core 182 and a sheath 184, according to an embodiment of the
present invention. Sheath body 184 can at least partially cover
drug core 182. Drug core 182 may contain inclusions of the
therapeutic agent therein to provide a sustained release of the
therapeutic agent. Drug core 182 can include an exposed convex
surface area 182A. Exposed convex surface area 182A may provide an
increased surface area to release the therapeutic agent. An
occlusive element 188 can be disposed over retention structure 186
to block the flow of tear through the canaliculus. In many
embodiments, retention structure 186 can be located within
occlusive structure 188 to provide the occlusive element integrated
with the retention structure. Flow restricting retention structure
186 and occlusive element 188 can be sized to block tear flow
through the canaliculus.
[0547] The cores and sheath bodies described herein can be
implanted in a variety of tissues in several ways. Many of the
cores and sheaths described herein, in particular the structures
described with reference to FIGS. 2A to 2J can be implanted alone
as punctal plugs. Alternatively, many of the cores and sheath
bodies described herein can comprise a drug core, sheath body,
and/or the like so as to be implanted with the retention structures
and occlusive elements described herein.
[0548] FIG. 2A shows a cross sectional view of a sustained release
implant 200 with core comprising an enlarged exposed surface area,
according to an embodiment of the present invention. A drug core
210 is covered with a sheath body 220. Sheath body 220 includes an
opening 220A. Opening 220 has a diameter that approximates the
maximum cross sectional diameter of drug core 210. Drug core 210
includes an exposed surface 210E, also referred to as an active
surface. Exposed surface 210E includes 3 surfaces: an annular
surface 210A, a cylindrical surface 210B and an end surface 210C.
Annular surface 210A has an outer diameter that approximates the
maximum cross sectional diameter of core 210 and an inner diameter
that approximates the outer diameter of cylindrical surface 210B.
End surface 210C has a diameter that matches the diameter of
cylindrical surface 210B. The surface area of exposed surface 210E
is the sum of the areas of annular surface 210A, cylindrical
surface 210B and end surface 210C. The surface area may be
increased by the size of cylindrical surface area 210B that extends
longitudinally along an axis of core 210.
[0549] FIG. 2B shows a cross sectional view of a sustained release
implant 202 with a core 212 comprising an enlarged exposed surface
area 212A, according to an embodiment of the present invention. A
sheath body 222 extends over core 212. The treatment agent can be
released from the core as described above. Exposed surface area
212A is approximately conical, can be ellipsoidal or spherical, and
extends outward from the sheath body to increase the exposed
surface area of drug core 212.
[0550] FIGS. 2C and 2D show perspective and cross sectional views,
respectively, of a sustained release implant 204 with a drug core
214 comprising a reduced exposed surface area 214A, according to an
embodiment of the present invention. Drug core 214 is enclosed
within a sheath body 224. Sheath body 22 includes an annular end
portion 224A that defines an opening through which drug core 214
extends. Drug core 214 includes an exposed surface 214A that
releases the therapeutic agent. Exposed surface 214A has a diameter
214D that is less than a maximum dimension, for example a maximum
diameter, across drug core 214.
[0551] FIG. 2E shows a cross sectional view of a sustained release
implant 206 with a drug core 216 comprising an enlarged exposed
surface area 216A with castellation extending therefrom, according
to an embodiment of the present invention. The castellation
includes several spaced apart fingers 216F to provide increased
surface area of the exposed surface 216A. In addition to increased
surface area provided by castellation, drug core 216 may also
include an indentation 216I. Indentation 216I may have the shape of
an inverted cone. Core 216 is covered with a sheath body 226.
Sheath body 226 is open on one end to provide an exposed surface
216A on drug core 216. Sheath body 226 also includes fingers and
has a castellation pattern that matches core 216.
[0552] FIG. 2F shows a perspective view of a sustained release
implant 250 comprising a core with folds, according to an
embodiment of the present invention Implant 250 includes a core 260
and a sheath body 270. Core 260 has an exposed surface 260A on the
end of the core that permits drug migration to the surrounding tear
or tear film fluid. Core 260 also includes folds 260F. Folds 260F
increase the surface area of core that is exposed to the
surrounding fluid tear or tear film fluid. With this increase in
exposed surface area, folds 260F increase migration of the
therapeutic agent from core 260 into the tear or tear film fluid
and target treatment area. Folds 260F are formed so that a channel
260C is formed in core 260. Channel 260C connects to the end of the
core to an opening in exposed surface 260A and provides for the
migration of treatment agent. Thus, the total exposed surface area
of core 260 includes exposed surface 260A that is directly exposed
to the tear or tear film fluid and the surfaces of folds 260F that
are exposed to the tear or tear film fluids via connection of
channel 260C with exposed surface 260A and the tear or tear film
fluid.
[0553] FIG. 2G shows a perspective view of a sustained release
implant with a core comprising a channel with an internal surface,
according to an embodiment of the present invention. Implant 252
includes a core 262 and sheath body 272. Core 262 has an exposed
surface 262A on the end of the core that permits drug migration to
the surrounding tear or tear film fluid. Core 262 also includes a
channel 262C. Channel 262C increases the surface area of the
channel with an internal surface 262P formed on the inside of the
channel against the core. In some embodiment, the internal exposed
surface may also be porous. Channel 262C extends to the end of the
core near exposed surface 262A of the core. The surface area of
core that is exposed to the surrounding tear or tear film fluid can
include the inside of core 262 that is exposed to channel 262C.
This increase in exposed surface area can increase migration of the
therapeutic agent from core 262 into the tear or tear film fluid
and target treatment area. Thus, the total exposed surface area of
core 262 can include exposed surface 260A that is directly exposed
to the tear or tear film fluid and internal surface 262P that is
exposed to the tear or tear film fluids via connection of channel
262C with exposed surface 262A and the tear or tear film fluid.
[0554] FIG. 2H shows a perspective view of a sustained release
implant 254 with a core 264 comprising channels to increase drug
migration, according to an embodiment of the invention. Implant 254
includes core 264 and sheath body 274. Exposed surface 264A is
located on the end of core 264, although the exposed surface can be
positioned at other locations. Exposed surface 264 A permits drug
migration to the surrounding tear or tear film fluid. Core 264 also
includes channels 264C. Channels 264C extend to exposed surface
264. Channels 264C are large enough that tear or tear film fluid
can enter the channels and therefore increase the surface area of
core 264 that is in contact with tear or tear film fluid. The
surface area of the core that is exposed to the surrounding fluid
tear or tear film fluid includes the inner surfaces 264P of core
262 that define channels 264C. With this increase in exposed
surface area, channels 264C increase migration of the therapeutic
agent from core 264 into the tear or tear film fluid and target
treatment area. Thus, the total exposed surface area of core 264
includes exposed surface 264A that is directly exposed to the tear
or tear film fluid and internal surface 264P that is exposed to the
tear or tear film fluids via connection of channels 262C with
exposed surface 264A and the tear or tear film fluid.
[0555] FIG. 2I shows a perspective view of a sustained release
implant 256 with a drug core 266 comprising a convex exposed
surface 266A, according to an embodiment of the present invention.
Drug core 266 is partially covered with a sheath body 276 that
extends at least partially over drug core 266 to define convex
exposed surface 266A. Sheath body 276 comprises a shaft portion
276S. Convex exposed surface 266A provides an increased exposed
surface area above the sheath body. A cross sectional area of
convex exposed surface 266A is larger than a cross sectional area
of shaft portion 276S of sheath body 276. In addition to the larger
cross sectional area, convex exposed surface 266A has a larger
surface area due to the convex shape which extends outward from the
core. Sheath body 276 comprises several fingers 276F that support
drug core 266 in the sheath body and provide support to the drug
core to hold drug core 266 in place in sheath body 276. Fingers
276F are spaced apart to permit drug migration from the core to the
tear or tear film fluid between the fingers. Protrusions 276P
extend outward on sheath body 276. Protrusions 276P can be pressed
inward to eject drug core 266 from sheath body 276. Drug core 266
can be replaced with another drug core after an appropriate time,
for example after drug core 266 has released most of the
therapeutic agent.
[0556] FIG. 2J shows a side view of a sustained release implant 258
with a core 268 comprising an exposed surface area with several
soft brush-like members 268F, according to an embodiment of the
present invention. Drug core 268 is partially covered with a sheath
body 278 that extends at least partially over drug core 268 to
define exposed surface 268A. Sheath body 278 comprises a shaft
portion 278S. Soft brush-like members 268F extend outward from drug
core 268 and provide an increased exposed surface area to drug core
268. Soft brush-like members 268F are also soft and resilient and
easily deflected such that these members do not cause irritation to
neighboring tissue. Although drug core 268 can be made of many
materials as explained above, silicone is a suitable material for
the manufacture of drug core 268 also comprises soft brush like
members 268F. Exposed surface 268A of drug core 268 also includes
an indentation 268I such that at least a portion of exposed surface
268A is concave.
[0557] FIG. 2K shows a side view of a sustained release implant 259
with a drug core 269 comprising a convex exposed surface 269A,
according to an embodiment of the present invention. Drug core 269
is partially covered with a sheath body 279 that extends at least
partially over drug core 269 to define convex exposed surface 269A.
Sheath body 279 comprises a shaft portion 279S. Convex exposed
surface 269 provides an increased exposed surface area above the
sheath body. A cross sectional area of convex exposed surface 269A
is larger than a cross sectional area of shaft portion 279S of
sheath body 279. In addition to the larger cross sectional area,
convex exposed surface 269A has a larger surface area due to the
convex shape that extends outward on the core. A retention
structure 289 can be attached to sheath body 279. Retention
structure 289 can comprise any of the retention structures as
describe herein, for example a coil comprising a super elastic
shape memory alloy such as Nitinol.TM.. Retention structure 289 can
be dip coated to make retention structure 289 biocompatible.
[0558] FIG. 2L shows a side view of a sustained release implant 230
with a drug core 232 comprising a concave indented surface 232A to
increase exposed surface area of the core, according to an
embodiment of the present invention. A sheath body 234 extends at
least partially over drug core 232. Concave indented surface 232A
is formed on an exposed end of drug core 232 to provide an
increased exposed surface area of the drug core.
[0559] FIG. 2M shows a side view of a sustained release implant 240
with a drug core 242 comprising a concave surface 242A with a
channel 242C formed therein to increase an exposed surface area of
the core, according to an embodiment of the present invention. A
sheath body 244 extends at least partially over drug core 242.
Concave indented surface 242A is formed on an exposed end of drug
core 232 to provide an increased exposed surface area of the drug
core. Channel 242C formed in drug core 242 to provide an increased
exposed surface area of the drug core. Channel 242C can extend to
concave indented surface 242A such that channel 242C and provide an
increase in surface area of the core exposed to the tear or tear
film.
[0560] Referring now to FIGS. 3A and 3B an implant, for example a
punctal plug 300, is shown which comprises a silicone body 310, a
drug core 320 and a retention structures 330, according to
embodiments of the present invention. Body 310 comprises a proximal
channel 314 sized to receive drug core insert 320. Body 310
comprises a distal channel 318. Distal channel 318 can be sized to
receive a hydrogel rod 332. A partition 319 may separate the
proximal channel from the distal channel. A filament 334 can be
embedded in body 310 and wrapped around hydrogel rod 332 to affix
hydrogel rod 332 to body 310.
[0561] Drug core insert 320 may comprise a sheath 322, which is
substantially impermeable to the drug so as to direct the drug
toward an exposed surface 326 of the drug core. Drug core 320 may
comprises a silicone matrix 328 with inclusions 324 of the drug
encapsulated therein. The drug core insert and manufacture of the
drug core insert are described in U.S. application Ser. Nos.
11/695,537 and 11/695,545, the full disclosures of which are
incorporated herein by reference. In some embodiments, body 310 may
comprise an annular rim 315 near exposed surface 326, that extends
into proximal channel 314 and presses on sheath body 322 so as to
indent the sheath body and decrease the exposed surface area of the
drug core near the proximal end of the body. In some embodiments,
optional annular rim 315 may press on the sheath body to retain the
drug core in the channel without indentation of the sheath
body.
[0562] Retention structures 330 may comprise hydrogel rod 332,
hydrogel coating 336, protrusions 312 and protrusion 316. Hydrogel
rod 332 can be inserted through the punctum into a canalicular
lumen in a narrow profile configuration. After insertion into the
lumen hydrogel rod 332 and hydrogel coating 336 can hydrate and
expand to a wide profile configuration. Protrusions 312 and
protrusion 316 can retain and/or stabilize implant 300 in the
lumen, for example while the hydrogel coating and rod expand.
[0563] FIG. 3C shows insertion of punctal plug 300 as in FIG. 3A
into an upper canaliculus of an eye. Punctal plug 300 can be
oriented with hydrogel rod 332 aligned for placement in the upper
canaliculus. Punctal plug 300 can be advanced into vertical portion
10V of the canaliculus such that the exposed surface of the drug
core and proximal end of the implant are substantially aligned with
the exterior of the punctal opening.
[0564] FIG. 3D shows a punctal plug as in FIG. 3A in an expanded
profile configuration following implantation in the canaliculus of
the eye. Hydrogel rod 332 and hydrogel coating 336 are shown in an
expanded profile configuration.
[0565] FIG. 4 shows a drug core insert 400 suitable for use with an
implant, according to embodiments of the present invention. Drug
core insert comprises a first proximal end 402 and a distal end
404. Drug core insert 400 comprises a sheath body 410, for example
a polyimide tube. Sheath body 410 can comprise a material that is
substantially impermeable to the therapeutic agent such that flow
of the therapeutic agent can be inhibited by the sheath body.
Examples of materials that can be substantially impermeable to the
therapeutic agent include polyimide, polymethylmethacrylate (PMMA)
and polyethylene terephthalate (PET). Sheath body 410 comprises a
first proximal end 412 and a second distal end 414. Drug core
insert 400 comprises a drug core 420 comprising inclusions 424
encapsulated in a matrix material 426. An exposed surface 422
comprising an area on the proximal end of the drug core is capable
of sustained release of the therapeutic agent at therapeutic
levels, for example quantities. In many embodiments, the
therapeutic agent is at least partially soluble in the matrix
material 426 such that the therapeutic agent from the inclusions
can penetrate the matrix material, for example via diffusion, and
be released from matrix material into a tissue surface and/or
bodily fluid in contact with exposed surface 422. A material 430
comprises distal end 404 of the drug core insert. In many
embodiments, the polyimide tube comprises a cut length of tube in
which the both ends of the tube have been cut to expose the drug
core. Material 430 can be adhered on the distal end of the drug
core inserted to inhibit flow of the therapeutic agent. In many
embodiments, material 430 comprises an adhesive material that is
substantially impermeable to the therapeutic agent, for example
acrylic, cyanoacrylate, epoxy, urethane, hot melt adhesives and
Loctite.TM. with UV curing.
[0566] Sheath body 410 is sized to fit within a channel of an
implant. The distal end of drug core insert 404 can be inserted
into the implant such that exposed surface 422 remains exposed when
the drug core insert is inserted into the implant.
[0567] FIG. 4B shows an example of implant 450 suitable for use
with a drug core insert 400 as in FIG. 4A, according to embodiments
of the present invention. Implant 450 comprises a proximal 452 and
a distal end 454. Implant 450 comprises a retention structure 460
that includes an indentation to retain implant 450 in the punctum
of the eye. Implant 450 comprises a channel 456 that extends from
within the implant to an opening formed proximal end 452. Channel
456 can be sized to receive drug core insert 400. Drug core insert
400 can be inserted into channel 456 such that distal end 404 of
drug core insert 400 is embedded within implant 450 while proximal
end 402 comprising surface 422 is exposed. When implant 450 is
placed in the punctum, surface 422 is exposed to the tear fluid of
the eye such that the therapeutic agent can be delivered to the
eye. In many embodiments, the punctual plug has a length of about 2
mm and a width of about 1 mm.
[0568] Many implants can be used with drug core insert 400. Some
embodiments can employ a commercially available implant, for
example the Soft Plug silicone punctum plug commercially Oasis
Medical of Glendora Calif., the Tear Pool Punctal Plug commercially
available form Medtronic, the "Parasol Punctal Occluder System"
available from Odyssey of Memphis, Tenn., and/or the Eagle Vision
Plug available from Eagle Vision of Memphis, Tenn. In some
embodiments, the punctual plug may comprise a custom punctual plug,
for example sized custom plugs that are selected in response to
patient measurements. In some embodiments, the implant used with
the drug core insert may comprise implants as described in U.S.
application Ser. No. 11/695,537, filed on Apr. 2, 2007, entitled
"DRUG DELIVERY METHODS, STRUCTURES, AND COMPOSITIONS FOR
NASOLACRIMAL SYSTEM", published as U.S. patent Application
Publication No. 2007/0269487 on Nov. 22, 2007; Ser. No. 11/695,545,
filed on Apr. 2, 2007, entitled "NASOLACRIMAL DRAINAGE SYSTEM
IMPLANTS FOR DRUG THERAPY", which issued as U.S. Pat. No. 7,998,497
on Aug. 16, 2011; 60/871,867, filed on Dec. 26, 2006, entitled
"DRUG DELIVERY IMPLANTS FOR INHIBITION OF OPTICAL DEFECTS", the
priority of which was claimed in PCT Application No.
PCT/US2007/088701, which published as WO 2008/083118 on Jul. 10,
2008; and 10/825,047, filed Apr. 15, 2004, entitled "DRUG DELIVERY
VIA PUNCTAL PLUG," published as U.S. Patent Application Publication
No. 2005/0232972 on Oct. 20, 2005; the full disclosures of which
are all incorporated herein by reference.
[0569] In some embodiments, such as shown in FIG. 36 and discussed
in U.S. patent application Ser. No. 12/231,989, filed Sep. 8, 2008,
entitled "LACRIMAL IMPLANTS AND RELATED METHODS", and published as
U.S. Patent Application Publication No. 2009/0104248 on Apr. 23,
2009, the implant can be insertable through a lacrimal punctum and
into the associated canaliculus. The insertion of the implant
through the lacrimal punctum and into the associated canaliculus
can allow for one or more of: inhibition or blockage of tear flow
therethrough (e.g., to treat dry eyes) or the sustained delivery of
a drug or other therapeutic agent to an eye (e.g., to treat an
infection, inflammation, glaucoma or other ocular disease or
disorder), a nasal passage (e.g., to treat a sinus or allergy
disorder) or an inner ear system (e.g., to treat dizziness or a
migraine). The implant can comprise an implant body including first
and second portions, and can extend from a proximal end of the
first portion to a distal end of the second portion. In various
examples, the proximal end can define a longitudinal proximal axis
and the distal end can define a longitudinal distal axis. The
implant body can be configured such that, when implanted within the
lacrimal punctum and associated canaliculus, an at least 45 degree
angled intersection exists between the proximal axis and the distal
axis for biasing at least a portion of the implant body against at
least a portion of a lacrimal canaliculus located at or more distal
to a canaliculus curvature. In some examples, the implant body can
be configured such that the angled intersection is between about 45
degrees and about 135 degrees. In this example, the implant body is
configured such that the angled intersection is about 90 degrees
(i.e., the intersection is about perpendicular). In various
examples, a distal end of the first portion can be integral with
the second portion at or near a proximal end of the second
portion.
[0570] In certain examples, the implant body can include angularly
disposed cylindrical-like structures comprising one or both of a
first cavity disposed near the proximal end or a second cavity
disposed near the distal end. In this example, the first cavity
extends inward from the proximal end of the first portion, and the
second cavity extends inward from the distal end of the second
portion. A first drug-releasing or other agent-releasing drug core
insert can be disposed in the first cavity to provide a sustained
drug or other therapeutic agent release to an eye, while a second
drug core insert can be disposed in the second cavity to provide a
sustained drug or other therapeutic agent release to a nasal
passage or inner ear system, for example. An implant body septum
can be positioned between the first cavity and the second cavity,
and can be used to inhibit or prevent communication of a material
(e.g., agent) between the first drug core insert and the second
drug core insert. In some examples, the implant body is solid and
does not include one or more cavities or other voids.
[0571] FIG. 4C shows an annular drug core insert 470 suitable for
use with an implant for systemic delivery of a therapeutic agent.
Drug core insert 470 comprises a sheath body 472 which is
substantially impermeable to the therapeutic agent so as to inhibit
flow of the therapeutic agent through the sheath body. Drug core
insert 470 comprises a solid drug core 474. Drug core 474 comprises
a matrix material with inclusions of the therapeutic agent
dispersed therein, as described above. Drug core 474 comprises an
exposed surface 478. Drug core 474 comprises a generally annular
shape with a channel 476 formed therein, such that exposed surface
478 is inwardly directed and exposed to bodily fluids in the
channel, for example the tear liquid when implanted in the channel.
Therapeutic quantities, or levels, of the therapeutic agent can be
released from inner exposed surface 478 to the bodily fluid within
the channel.
[0572] FIG. 4D shows an of implant 480 suitable for use with a drug
core insert as in FIG. 4C. Implant 480 comprises a body 484, for
example a molded silicone body, and retention structures 482. A
channel 486 within body 484 is sized to receive drug core insert
470. Implant 480 may comprise a hydrogel coating 488 on the
outside. Hydrogel coating 488 may be located near retention
structure 488. In some embodiments, hydrogel coating 488 may be
located away from the ends of implant 480, such that the hydrogel
does not inhibit flow through channel 476 of the drug core insert
when implanted in the patient. In some embodiments, the retention
structure may comprise an expandable coil or stent like structure
with a proximal portion embedded in body 484 and an exposed distal
portion that expands to permit flow through the coil between the
punctum and lacrimal sac, for example a shape memory capable of
expansion to anchor the implant in the canaliculus.
[0573] FIGS. 4E and 4F show a side cross-sectional view and an end
view, respectively, of a drug core insert 490 comprising a first
drug core 494 and a second drug core 496. First drug core 494
comprises inclusions 494I of a first therapeutic agent, and second
drug core 496 comprises inclusions 4961 of a second therapeutic
agent. Therapeutic quantities of the first therapeutic agent are
released through an exposed surface 494S of first drug core 494,
and therapeutic quantities of a second therapeutic agent are
released through an exposed surface 496S of second drug core
496.
[0574] Insert 490 comprises an outer sheath body 492 around drug
core 496 and an inner sheath body 498 disposed between drug core
494 and drug core 496, so as to inhibit release of one drug core to
the other drug core. The sheath body 492 and sheath body 498 may
comprise materials substantially impermeable to the therapeutic
agent, so as to inhibit release of the therapeutic agent away from
the exposed surfaces. In some embodiments, the sheath bodies may
comprise thin walled tubes.
[0575] In some embodiments, the drug core insert can be used with
an implant for insertion in tissues in or near the eye, for example
the sclera, the conjunctiva, the cul-de-sac of the eyelid, the
trabecular meshwork, the ciliary body, the cornea, the choroid, the
suprachoroidal space, the sclera, the vitreous humor, aqueous humor
and retina.
[0576] In some embodiments, the drug core insert can be
manufactured with a structure to facilitate removal of the drug
core insert, for example a filament as described in U.S.
Application Ser. Nos. 60/970,696, filed on Sep. 7, 2007, and
60/974,367 filed on Sep. 21, 2007 entitled "EXPANDABLE NASOLACRIMAL
DRAINAGE SYSTEM IMPLANTS", the priorities of which are claimed in
U.S. patent application Ser. No. 12/231,989, filed Sep. 8, 2008,
entitled "LACRIMAL IMPLANTS AND RELATED METHODS", and published as
U.S. Patent Application Publication No. 2009/0104248 on Apr. 23,
2009; the full disclosures of which are all incorporated herein by
reference.
[0577] FIGS. 5A to 5C schematically illustrate replacement of a
drug core 510 and a sheath body 520, according to an embodiment of
the present invention. An implant 500 comprises drug core 510,
sheath body 520 and a retention structure 530. Implant 500 can
include an occlusive element support by and movable with retention
structure 530. Often retention structure 530 can assume a first
small profile configuration prior to implantation and a second
large profile configuration while implanted. Retention structure
530 is shown in the large profile configuration and implanted in
the canalicular lumen. Sheath body 520 includes extension 525A and
extension 525B to attach the sheath body and drug core to retention
structure 530 so that the sheath body and drug core are retained by
retention structure 530. Drug core 510 and sheath body 520 can be
removed together by drawing drug core 510 proximally as shown by
arrow 530. Retention structure 530 can remain implanted in the
canalicular tissue after drug core 510 and sheath body 520 have
been removed as shown in FIG. 5B. A replacement core 560 and
replacement sheath body 570 can be inserted together as shown in
FIG. 5C. Such replacement can be desirable after drug core 510 has
released effective amounts of therapeutic agent such that the
supply of therapeutic agent in the drug core has diminished and the
rate of therapeutic agent released is near the minimum effective
level. Replacement sheath body 570 includes extension 575A and
extension 575B. Replacement drug core 560 and replacement sheath
body 570 can be advanced distally as shown by arrow 590 to insert
replacement drug core 560 and replacement sheath body 570 into
retention structure 530. Retention structure 530 remains at
substantially the same location while replacement drug core 560 and
replacement sheath body 570 are inserted into resilient member
530.
[0578] FIGS. 5D and 5E show an implant comprising 800 a filament
810 that extends from a drug core insert 808 for removal drug core
insert 808 from implant 800, according to embodiments of the
present invention. Implant 800 comprises a body 805 and expandable
retention structure 820, as described above. Body 810 comprises a
proximal end 802 and a distal end 803. Implant 800 extends from
proximal end 802 to a distal end 804 of retention structure 820.
Implant 800 comprises a channel to receive the drug core insert, as
described above. Filament 810 extends from a proximal end of the
drug core insert to a distal end of the drug core insert. Filament
810 can be molded into the drug core insert. Filament 840 may
comprise many of the filaments described above, for example a
suture, a thermoset polymer, a shape memory alloy, and the
like.
[0579] FIG. 5F shows an implant 830 comprising a filament 840 that
extends along a drug core insert 831 bonded to a distal end of the
drug core insert for removal of the drug core insert from a body
832 of the implant, according to embodiments of the present
invention. Implant 830 comprises a proximal end 833. Filament 840
may be bonded to the distal end of drug core insert 831 with an
adhesive 842. Filament 840 can be bonded to the distal end of drug
core insert 831 in many ways, for example with cyanoacrylate,
acrylic, epoxy, urethane and hot melt adhesives and the like.
Sheath Body
[0580] The sheath body comprises appropriate shapes and materials
to control migration of the therapeutic agent from the drug core.
The sheath body houses the core and can fit snugly against the
core. The sheath body is made from a material that is substantially
impermeable to the therapeutic agent so that the rate of migration
of the therapeutic agent may be largely controlled by the exposed
surface area of the drug core that is not covered by the sheath
body. In many embodiments, migration of the therapeutic agent
through the sheath body can be about one tenth of the migration of
the therapeutic agent through the exposed surface of the drug core,
or less, often being one hundredth or less. In other words, the
migration of the therapeutic agent through the sheath body is at
least about an order of magnitude less that the migration of the
therapeutic agent through the exposed surface of the drug core.
Suitable sheath body materials include polyimide, polyethylene
terephthalate" (hereinafter "PET"), polymethylmethacrylate
("PMMA"), stainless steel (for example, type 316 stainless steel,
tubing size 25XX), or titanium. The sheath body has a wall
thickness from about 0.00025'' to about 0.0015''. In some
embodiments, the wall thickness can be defined as the distance from
the sheath surface adjacent the core to the opposing sheath surface
away from the core. The total diameter of the sheath that extends
across the core ranges from about 0.2 mm to about 1.2 mm. The core
may be formed by dip coating the core in the sheath material.
Alternatively or in combination, the sheath body can comprise a
tube and the core introduced into the sheath, for example as a
liquid or solid that can be slid, injected and/or extruded into the
sheath body tube. The sheath body can also be dip coated around the
core, for example dip coated around a pre-formed core.
[0581] The sheath body can be provided with additional features to
facilitate clinical use of the implant. For example, the sheath may
receive a drug core that is exchangeable while the retention
structure and sheath body remain implanted in the patient. The
sheath body may be rigidly attached to the retention structure as
described above, and the core is exchangeable while the retention
structure retains the sheath body. In specific embodiments, the
sheath body can be provided with external protrusions that apply
force to the sheath body when squeezed and eject the core from the
sheath body. Another drug core can then be positioned in the sheath
body. In many embodiments, the sheath body and/or retention
structure may have a distinguishing feature, for example a
distinguishing color, to show placement such that the placement of
the sheath body and/or retention structure in the canaliculus or
other body tissue structure can be readily detected by the patient.
The retention element and/or sheath body may comprise at least one
mark to indicate the depth of placement in the canaliculus such
that the retention element and/or sheath body can be positioned to
a desired depth in the canaliculus based on the at least one
mark.
Retention Structure
[0582] The retention structure comprises an appropriate material
that is sized and shaped so that the implant can be easily
positioned in the desired tissue location, for example the
canaliculus. The retention structure is mechanically deployable and
typically expands to a desired cross sectional shape, for example
with the retention structure comprising a super elastic shape
memory alloy such as Nitinol.TM.. Other materials in addition to
Nitinol.TM. can be used, for example resilient metals or polymers,
plastically deformable metals or polymers, shape memory polymers,
and the like, to provide the desired expansion. In some embodiments
polymers and coated fibers available from Biogeneral, Inc. of San
Diego, Calif. may be used. Many metals such as stainless steels and
non-shape memory alloys can be used and provide the desired
expansion. This expansion capability permits the implant to fit in
hollow tissue structures of varying sizes, for example canaliculae
ranging from 0.3 min to 1.2 mm (i.e. one size fits all). Although a
single retention structure can be made to fit canaliculae from 0.3
to 1.2 mm across, a plurality of alternatively selectable retention
structures can be used to fit this range if desired, for example a
first retention structure for canaliculae from 0.3 to about 0.9 mm
and a second retention structure for canaliculae from about 0.9 to
1.2 mm. The retention structure has a length appropriate to the
anatomical structure to which the retention structure attaches, for
example a length of about 3 mm for a retention structure positioned
near the punctum of the canaliculus. For different anatomical
structures, the length can be appropriate to provide adequate
retention force, e.g. 1 mm to 15 mm lengths as appropriate.
[0583] Although the sheath body and drug core can be attached to
one end of the retention structure as described above, in many
embodiments the other end of retention structure is not attached to
drug core and sheath body so that the retention structure can slide
over the sheath body and drug core while the retention structure
expands. This sliding capability on one end is desirable as the
retention structure may shrink in length as the retention structure
expands in width to assume the desired cross sectional width.
However, it should be noted that many embodiments may employ a
sheath body that does not slide in relative to the core.
[0584] In many embodiments, the retention structure can be
retrieved from tissue. A protrusion, for example a hook, a loop, or
a ring, can extend from the retention structure to facilitate
removal of the retention structure.
Occlusive Element
[0585] The occlusive element comprises an appropriate material that
is sized and shaped so that the implant can at least partially
inhibit, even block, the flow of fluid through the hollow tissue
structure, for example lacrimal fluid through the canaliculus. The
occlusive material shown is a thin walled membrane of a
biocompatible material, for example silicone, that can expand and
contract with the retention structure. The occlusive element is
formed as a separate thin tube of material that is slid over the
end of the retention structure and anchored to one end of the
retention structure as described above. Alternatively, the
occlusive element can be formed by dip coating the retention
structure in a biocompatible polymer, for example silicone polymer.
The thickness of the occlusive element can be in a range from about
0.01 mm to about 0.15 mm, and often from about 0.05 mm to 0.1
mm.
Therapeutic Agents
[0586] A "therapeutic agent" can comprise a drug and may be any of
the following or their equivalents, derivatives or analogs,
including, anti-glaucoma medications, (e.g. adrenergic agonists,
adrenergic antagonists (beta blockers), carbonic anhydrase
inhibitors (CAIs, systemic and topical), parasympathomimetics,
prostaglandins, prostaglandin analogs, and hypotensive lipids, and
combinations thereof), antimicrobial agent (e.g., antibiotic,
antiviral, antiparacytic, antifungal, etc.), a corticosteroid or
other anti-inflammatory such as olopatadine (e.g., an NSAID), a
decongestant (e.g., vasoconstrictor), an agent that prevents of
modifies an allergic response (e.g., cyclosporine, an
antihistamine, cytokine inhibitor, leucotriene inhibitor, IgE
inhibitor, immunomodulator), a mast cell stabilizer, cycloplegic or
the like. Examples of conditions that may be treated with the
therapeutic agent(s) include but are not limited to glaucoma, pre
and post surgical treatments, dry eye and allergies. In some
embodiments, the therapeutic agent may be a lubricant or a
surfactant, for example a lubricant to treat dry eye.
[0587] Exemplary therapeutic agents include, but are not limited
to, thrombin inhibitors; antithrombogenic agents; thrombolytic
agents; fibrinolytic agents; vasospasm inhibitors; vasodilators;
antihypertensive agents; antimicrobial agents, such as antibiotics
(such as tetracycline, chlortetracycline, bacitracin, neomycin,
polymyxin, gramicidin, cephalexin, oxytetracycline,
chloramphenicol, rifampicin, ciprofloxacin, tobramycin, gentamycin,
erythromycin, penicillin, sulfonamides, sulfadiazine,
sulfacetamide, sulfamethizole, sulfisoxazole, nitrofurazone, sodium
propionate), antifungals (such as amphotericin B and miconazole),
and antivirals (such as idoxuridine trifluorothymidine, acyclovir,
gancyclovir, interferon); inhibitors of surface glycoprotein
receptors; antiplatelet agents; antimitotics; microtubule
inhibitors; anti-secretory agents; active inhibitors; remodeling
inhibitors; antisense nucleotides; anti-metabolites;
antiproliferatives (including antiangiogenesis agents); anticancer
chemotherapeutic agents; anti-inflammatories (such as
hydrocortisone, hydrocortisone acetate, dexamethasone 21-phosphate,
fluocinolone, medrysone, methylprednisolone, prednisolone
21-phosphate, prednisolone acetate, fluoromethalone, betamethasone,
triamcinolone, triamcinolone acetonide); non steroidal
anti-inflammatories (NSAIDs) (such as salicylate, indomethacin,
ibuprofen, diclofenac, flurbiprofen, piroxicam indomethacin,
ibuprofen, naxopren, piroxicam and nabumetone). Such anti
inflammatory steroids contemplated for use in the methodology of
the present invention, include triamcinolone acetonide (generic
name) and corticosteroids that include, for example, triamcinolone,
dexamethasone, fluocinolone, cortisone, prednisolone, flumetholone,
and derivatives thereof.); antiallergenics (such as sodium
chromoglycate, antazoline, methapyriline, chlorpheniramine,
cetrizine, pyrilamine, prophenpyridamine); anti proliferative
agents (such as 1,3-cis retinoic acid, 5-fluorouracil, taxol,
rapamycin, mitomycin C and cisplatin); decongestants (such as
phenylephrine, naphazoline, tetrahydrazoline); miotics and
anti-cholinesterase (such as pilocarpine, salicylate, carbachol,
acetylcholine chloride, physostigmine, eserine, diisopropyl
fluorophosphate, phospholine iodine, demecarium bromide);
antineoplastics (such as carmustine, cisplatin, fluorouracil3;
immunological drugs (such as vaccines and immune stimulants);
hormonal agents (such as estrogens,--estradiol, progestational,
progesterone, insulin, calcitonin, parathyroid hormone, peptide and
vasopressin hypothalamus releasing factor); immunosuppressive
agents such as cyclosporine, growth hormone antagonists, growth
factors (such as epidermal growth factor, fibroblast growth factor,
platelet derived growth factor, transforming growth factor beta,
somatotrapin, fibronectin); inhibitors of angiogenesis (such as
angiostatin, anecortave acetate, thrombospondin, anti-VEGF
antibody); dopamine agonists; radiotherapeutic agents; peptides;
proteins; enzymes; extracellular matrix; components; ACE
inhibitors; free radical scavengers; chelators; antioxidants; anti
polymerases; photodynainic therapy agents; gene therapy agents; and
other therapeutic agents such as prostaglandins, antiprostaglandin,
prostaglandin precursors, including antiglaucoma drugs including
beta-blockers such as Timolol, betaxolol, levobunolol, atenolol,
and prostaglandin analogues such as Bimatoprost, travoprost,
Latanoprost etc; carbonic anhydrase inhibitors such as
acetazolamide, dorzolamide, brinzolamide, methazolamide,
dichlorphenamide, diamox; and neuroprotectants such as lubezole,
nimodipine and related compounds; and parasympathomimetrics such as
pilocarpine, carbachol, physostigmine and the like.
[0588] For use in ophthalmic applications, some specific
therapeutic agents that can be used include glaucoma medications
(muscarinics, beta blockers, alpha agonists, carbonic anhydrase
inhibitors, prostaglandins and their analogs), antiinflammatories
(steroids, soft steroids, NSAIDs), anti infectives including
antibiotics such as beta lactams, fluoro quinolones, etc.),
antivirals, and antimicotics, dry eye medications (CsA,
delmulcents, sodium hyaluronate), or combinations thereof.
[0589] The amount of drug associated with the drug-delivery device
may vary depending on the particular agent, the desired therapeutic
benefit and the time during which the device is intended to deliver
the therapy. Since the devices of the present invention present a
variety of shapes, sizes and delivery mechanisms, the amount of
drug associated with the device will depend on the particular
disease or condition to be treated, and the dosage and duration
that is desired to achieve the therapeutic effect. Generally, the
amount of drug is at least the amount of drug that upon release
from the device, is effective to achieve the desired physiological
or pharmacological effects.
[0590] Embodiments of the drug delivery devices of the present
invention can be adapted to provide delivery of drug at a daily
rate that is substantially below the therapeutically effective drop
form of treatment so as to provide a large therapeutic range with a
wide safety margin. For example, many embodiments treat the eye
with therapeutic levels for extended periods that are no more than
5 or 10 percent of the daily drop dosage. Consequently, during an
initial period of about seven days, more typically of about one to
three days, the implant can elute the therapeutic agent at a rate
that is substantially higher than the sustained release levels but
still below the daily drop form dosage. For example, with an
average sustained release level of 100 ng per day, and an initial
release rate of 1000 to 1500 ng per day, the amount of drug
initially released is less than the 2500 ng of drug that may be
present in a drop of drug delivered to the eye. This use of
sustained release levels substantially below the amount of drug in
a drop and/or drops administered daily allows the device to release
a therapeutically beneficial amount of drug to achieve the desired
therapeutic benefit with a wide safety margin, while avoiding an
inadequate or excessive amount of drug at the intended site or
region.
[0591] An extended period of time may mean a relatively short
period of time, for example minutes or hours (such as with the use
of an anesthetic), through days or weeks (such as the use of
pre-surgical or post-surgical antibiotics, steroids, or NSAIDs and
the like), or longer (such as in the case of glaucoma treatments),
for example months or years (on a recurring basis of use of the
device).
[0592] For example, drug such as Timolol maleate, a beta1 and beta2
(non-selective) adrenergic receptor blocking agent can be used in
the device for a release over an extended period of time such as 3
months. Three months is a relatively typical elapsed time between
physician visits for a glaucoma patient undergoing topical drop
therapy with a glaucoma drug, although the device could provide
treatment for longer or shorter durations. In the three month
example, a 0.25% concentration of Timolol translates to from 2.5 to
5 mg/1000 .mu.L, typically being 2.5 mg/1000 .mu.L. A drop of
Timolol for topical application is usually in the range of 40-60
.mu.L, typically being 50 .mu.L. Thus, there may be 0.08-0.15 mg,
typically being 0.125 mg of Timolol in a drop. There may be
approximately 8% (e.g. 6-10%) of the drop left in the eye after 5
minutes, so about 10 .mu.g of the drug is available at that time.
Timolol may have a bioavailability of 30-50%, which means that from
1.5 to 7.5 .mu.g, for example 4 .mu.g of the drug is available to
the eye. Timolol is generally applied twice a day, so 8 (or 3-15)
.mu.g is available to the eye each day. Therefore, a delivery
device might contain from 270 to 1350 .mu.g, for example 720 .mu.g,
of the drug for a 90 day, or 3 month, extended release. The drug
would be contained within the device and eluted based on the design
of the device, including the polymers used and the surface area
available for drug elution. The drug can be similarly contained on
the device and eluted for olopatadine hydrochloride (Patanol.RTM.)
and other drugs in a manner similar to Timolol.
[0593] Commercially available solutions of Timolol maleate are
available in 0.25% and 0.5% preparations, and the initial dosage
can be 1 drop twice per day of 0.25% solution. A 0.25%
concentration of Timolol is equivalent to 2.5 mg per 1000 .mu.L. A
sustained release quantity of Timolol released each day from the
drug core can be from about 3 to 15 .mu.g each day. Although the
sustained release quantity delivered each day from the device may
vary, a sustained release delivery of about 8 .mu.g per day
corresponds to about 3.2% of the 0.250 mg of Timolol applied with
two drops of a 0.25% solution.
[0594] For example, in the case of Latanoprost (Xalatan), a
prostaglandin F2.alpha. analogue, this glaucoma medication has
concentrations that are about 1/50th that of Timolol. Therefore,
the amount of drug on the implantable device, depending on the
bioavailability, would be significantly less--approximately 5-135
.mu.g and typically 10-50 .mu.g--for Latanoprost and other
prostaglandin analogues. This also translates to a device that can
either be smaller than one required for a beta blocker delivery or
can house more drug for a longer release period.
[0595] A drop of Xalatan contains about 2.5 .mu.g of Latanoprost,
assuming a 50 .mu.L drop volume. Therefore, assuming that about 8%
of 2.5 .mu.g is present 5 minutes after instillation, only about
200 ng of drug remains on the eye. Based on the Latanoprost
clinical trials, this amount is effective in lowering IOP for at
least 24 hours. Pfizer/Pharmacia conducted several dose-response
studies in support of the NDA for Xalatan. The doses ranged from
12.5 .mu.g/mL to 115 .mu.g/mL of Latanoprost. The current dose of
Latanoprost, 50 .mu.g/mL, given once per day, was shown to be
optimal. However, even the lowest doses of 12.5 .mu.g/mL QD or 15
.mu.g/mL BID consistently gave about 60-75% of the IOP reduction of
the 50 .mu.g/mL QD dose. Based on the assumptions above, a 12.5
.mu.g/mL concentration provides 0.625 .mu.g of Latanoprost in a 50
.mu.L drop, which results in only about 50 ng (8%) of drug
remaining in the eye after 5 minutes.
[0596] In many embodiments, the concentrations of Latanoprost are
about 1/100th, or 1 percent, that of Timolol, and in specific
embodiments the concentrations of Latanoprost may be about 1/50th,
or 2 percent, that of Timolol. For example, commercially available
solution preparations of Latanoprost are available at
concentrations 0.005%, often delivered with one drop per day. In
many embodiments, the therapeutically effective concentration of
drug released from the device per day can be about 1/100th of
Timolol, about 30 to 150 ng per day, for example about 80 ng,
assuming tear washout and bioavailability similar to Timolol. For
example, the amount of drug on the implantable device, can be
significantly less--approximately 1% to 2% of Timolol, for example
2.7 to 13.5 .mu.g, and can also be about 3 to 20 .mu.g, for
Latanoprost and other prostaglandin analogues. Although the
sustained release amount of Latanoprost released each day can vary,
a sustained release of 80 ng per day corresponds to about 3.2% of
the 2.5 .mu.g of Latanoprost applied with a single drop of a 0.005%
solution.
[0597] For example, in the case of Bimatoprost (Lumigan), a
synthetic prostamide prostaglandin analogue, this glaucoma
medication may have concentrations that are 1/20th or less than
that of Timolol. Therefore, the amount of drug loaded on the
extended release device for a 3 to 6 month extended release,
depending on the bioavailability, can be significantly less,
approximately 5-30 .mu.g and typically 10-20 .mu.g--for Bimatoprost
and analogues and derivatives thereof. In many embodiments, the
implant can house more drug for a longer sustained release period,
for example 20-40 .mu.g for a sustained release period of 6 to 12
months with Bimatoprost and its derivatives. This decrease in drug
concentration can also translate to a device that can be smaller
than one required for a beta blocker delivery.
[0598] Commercially available solution concentrations of
Bimatoprost are 0.03% by weight, often delivered once per day.
Although the sustained release amount of Bimatoprost released each
day can vary, a sustained release of 300 ng per day corresponds to
about 2% of the 15 .mu.g of Bimatoprost applied with a single drop
of a 0.03% solution. Work in relation with the present invention
suggests that even lower sustained release doses of Bimatoprost can
provide at least some reduction in intraocular pressure, for
example 20 to 200 ng of Bimatoprost and daily sustained release
dosages of 0.2 to 2% of the daily drop dosage.
[0599] For example, in the case of Travoprost (Travatan), a
prostaglandin F2.alpha. analogue, this glaucoma medication may have
concentrations that are 2% or less than that of Timolol. For
example, commercially available solution concentrations are 0.004%,
often delivered once per day. In many embodiments, the
therapeutically effective concentration of drug released from the
device per day can be about 65 ng, assuming tear washout and
bioavailability similar to Timolol. Therefore, the amount of drug
on the implantable device, depending on the bioavailability, would
be significantly less. This also translates to a device that can
either be smaller than one required for a beta blocker delivery or
can house more drug for a longer release period. For example, the
amount of drug on the implantable device, can be significantly
less--approximately 1/100 of Timolol, for example 2.7 to 13.5
.mu.g, and typically about 3 to 20 .mu.g, for Travoprost,
Latanoprost and other prostaglandin F2.alpha. analogues. Although
the sustained release amount of Latanoprost released each day can
vary, a sustained release of 65 ng per day corresponds to about
3.2% of the 2.0 .mu.g of Travoprost applied with a single drop of a
0.004% solution.
[0600] In some embodiments, the therapeutic agent may comprise a
corticosteriod, for example fluocinolone acetonide, to treat a
target ocular tissue. In specific embodiments, fluocinolone
acetonide can be released from the canaliculus and delivered to the
retina as a treatment for diabetic macular edema (DME).
[0601] It is also within the scope of this invention to modify or
adapt the devices to deliver a high release rate, a low release
rate, a bolus release, a burst release, or combinations thereof. A
bolus of the drug may be released by the formation of an erodable
polymer cap that is immediately dissolved in the tear or tear film.
As the polymer cap comes in contact with the tear or tear film, the
solubility properties of the polymer enable the cap to erode and
the drug is released all at once. A burst release of a drug can be
performed using a polymer that also erodes in the tear or tear film
based on the polymer solubility. In this example, the drug and
polymer may be stratified along the length of the device so that as
the outer polymer layer dissolves, the drug is immediately
released. A high or low release rate of the drug could be
accomplished by changing the solubility of the erodable polymer
layer so that the drug layer released quickly or slowly. Other
methods to release the drug could be achieved through porous
membranes, soluble gels (such as those in typical ophthalmic
solutions), microparticle encapsulations of the drug, or
nanoparticle encapsulation, depending on the size of the drug
molecule.
Drug Core
[0602] The drug core comprises the therapeutic agent and matrix
materials to provide sustained release of the therapeutic agent.
The matrix material can include a polymer, such as silicone or
polyurethane. The therapeutic agent migrates from the drug core to
the target tissue, for example the ciliary body of the eye. The
therapeutic agent may optionally be only slightly soluble in the
matrix so that a small amount of therapeutic agent is dissolved in
the matrix and available for release from the surface of drug core
110, additional agent being present in the form of inclusions,
which can be in a solid or a liquid physical state within the
matrix. As the therapeutic agent diffuses from the exposed surface
of the core to the tear or tear film, the rate of migration from
the core to the tear or tear film can be related to the
concentration of therapeutic agent dissolved in the matrix. In
addition or in combination, the rate of migration of therapeutic
agent from the core to the tear or tear film can be related to
properties of the matrix in which the therapeutic agent dissolves.
In specific embodiments, the rate of migration from the drug core
to the tear or tear film can be based on a silicone formulation. In
some embodiments, the concentration of therapeutic agent dissolved
in the drug core may be controlled to provide the desired rate of
release of the therapeutic agent. The therapeutic agent included in
the core can include liquid, solid, solid gel, solid crystalline,
solid amorphous, solid particulate, and/or dissolved forms of the
therapeutic agent. In an embodiment, the drug core comprises a
silicone matrix containing the therapeutic agent. The therapeutic
agent may comprise liquid or solid inclusions, for example liquid
latanoprost droplets or solid bimatoprost particles, respectively,
dispersed in the silicone matrix. The average diameter, and the
distribution of diameters throughout the population of droplets or
particles, can be used to control the elution rate of the agent
from the drug core into, for example, tear liquid in the eye.
[0603] In another embodiment, the therapeutic agent can be soluble
at relatively high levels in the matrix, such that inclusions are
not formed when the agent is present at therapeutically useful
concentrations. For example, cyclosporine can be dissolved in a
polyurethane matrix at high concentrations, and the cyclosporine is
dispersed throughout the polyurethane matrix at molecular levels,
i.e., a "solid solution" of the cyclosporine in the polyurethane
matrix can be achieved.
[0604] When the inclusion is solid, various comminuted forms of the
solid material can be used to achieve a particular average particle
diameter and size distribution of dimeters. Such solid powders can
be obtained by any suitable method known in the art. See, for
example, machines manufactured for the pharmaceutical industry by
Glatt GmbH, at http://www.glatt.com/e/00_home/00.htm. In the
milling process a range of sizes can be generated. Fluidized beds
and coaters can be used to increase particle size to a desired
dimension. Particle size will influence surface area and may affect
dissolution. Inclusion size and associated size distribution can be
used to control an elution rate of the agent from the drug core,
both in the situation where the inclusions are solid, such as
bimatoprost, and where the inclusions are liquid, such as
latanoprost oil.
[0605] The drug core can comprise one or more biocompatible
materials capable of providing a sustained release of the
therapeutic agent. Although the drug core is described above with
respect to an embodiment comprising a matrix with a substantially
non-biodegradable silicone matrix with inclusions of the drug
located therein that dissolve, the drug core can include structures
that provide sustained release of the therapeutic agent, for
example a biodegradable matrix, a porous drug core, liquid drug
cores and solid drug cores. A matrix that contains the therapeutic
agent can be formed from either biodegradable or non-biodegradable
polymers. A non-biodegradable drug core can include silicone,
acrylates, polyethylenes, polyurethane, polyurethane, hydrogel,
polyester (e.g., DACRON.RTM. from E. I. Du Pont de Nemours and
Company, Wilmington, Del.), polypropylene, polytetrafluoroethylene
(PTFE), expanded PTFE (ePTFE), polyether ether ketone (PEEK),
nylon, extruded collagen, polymer foam, silicone rubber,
polyethylene terephthalate, ultra high molecular weight
polyethylene, polycarbonate urethane, polyurethane, polyimides,
stainless steel, nickel-titanium alloy (e.g., Nitinol), titanium,
stainless steel, cobalt-chrome alloy (e.g., ELGILOY.RTM. m Elgin
Specialty Metals, Elgin, Ill.; CONICHROME.RTM. from Carpenter
Metals Corp., Wyomissing, Pa.). A biodegradable drug core can
comprise one or more biodegradable polymers, such as protein,
hydrogel, polyglycolic acid (PGA), polylactic acid (PLA),
poly(L-lactic acid) (PLLA), poly(L-glycolic acid) (PLGA),
polyglycolide, poly-L-lactide, poly-D-lactide, poly(amino acids),
polydioxanone, polycaprolactone, polygluconate, polylactic
acid-polyethylene oxide copolymers, modified cellulose, collagen,
polyorthoesters, polyhydroxybutyrate, polyanhydride,
polyphosphoester, poly(alpha-hydroxy acid) and combinations
thereof. In some embodiments the drug core can comprise at least
one of hydrogel polymer.
Release of Therapeutic Agent at Effective Levels
[0606] The rate of release of the therapeutic agent can be related
to the concentration of therapeutic agent in the drug core. In many
embodiments, the drug core comprises non-therapeutic agents that
are selected to provide a desired solubility of the therapeutic
agent in the drug core. The non-therapeutic agent of the drug core
can comprise polymers as described herein and additives. A polymer
of the core can be selected to provide the desired solubility
and/or dispersability of the therapeutic agent in the matrix. For
example, the core can comprise hydrogel that may promote solubility
or dispersability of hydrophilic treatment agent. In some
embodiments, functional groups can be added to the polymer to
provide the desired solubility or dispersity of the therapeutic
agent in the matrix. For example, functional groups can be attached
to silicone polymer.
[0607] In some embodiments, release rate modifying additives may be
used to control the release kinetics of therapeutic agent. For
example, the additives may be used to control the concentration of
therapeutic agent by increasing or decreasing solubility of the
therapeutic agent in the drug core so as to control the release
kinetics of the therapeutic agent. The solubility may be controlled
by providing appropriate molecules and/or substances that increase
and/or decrease the solubility of the therapeutic agent to the
matrix. The solubility of the therapeutic agent may be related to
the hydrophobic and/or hydrophilic properties of the matrix and
therapeutic agent. For example, surfactants, tinuvin, salts and
water can be added to the matrix and may increase the solubility of
hydrophilic therapeutic agent in the matrix. Salts can be water
soluble, such as sodium chloride, or water-insoluble, such as
titanium dioxide. In addition, oils and hydrophobic molecules and
can be added to the matrix and may increase the solubility of
hydrophobic treatment agent in the matrix. Alternatively, various
oligomers and polymers, for example polysaccharides such as
alginates, or proteins such as albumin, can be added. Solvents such
as glycerol can also be used to modify the rate of release of the
agent from the matrix into the tear liquid.
[0608] Instead of or in addition to controlling the rate of
migration based on the concentration of therapeutic agent dissolved
in the matrix, the surface area of the drug core can also be
controlled to attain the desired rate of drug migration from the
core to the target site. For example, a larger exposed surface area
of the core will increase the rate of migration of the treatment
agent from the drug core to the target site, and a smaller exposed
surface area of the drug core will decrease the rate of migration
of the therapeutic agent from the drug core to the target site. The
exposed surface area of the drug core can be increased in any
number of ways, for example by any of castellation of the exposed
surface, a surface having exposed channels connected with the tear
or tear film, indentation of the exposed surface, protrusion of the
exposed surface. The exposed surface can be increased by the
addition of salts that dissolve and leave cavities once the salt
dissolves. Hydrogels may also be used, and can swell in size to
provide a larger exposed surface area.
[0609] In addition, drug impregnated porous materials, such as
meshes, may be used such as those disclosed in U.S. Patent
Application Publication No. 2002/0055701 or layering of biostable
polymers as described in U.S. Patent Application Publication No.
2005/0129731. Certain polymer processes may be used to incorporate
drug into the devices of the present invention such as, so-called
"self-delivering drugs" or PolymerDrugs (Polymerix Corporation,
Piscataway, N.J.) are designed to degrade only into therapeutically
useful compounds and physiologically inert linker molecules,
further detailed in US Patent Publication No. 2005/0048121 (East),
hereby incorporated by reference in its entirety. Such delivery
polymers may be employed in the devices of the present invention to
provide a release rate that is equal to the rate of polymer erosion
and degradation and is constant throughout the course of therapy.
Such delivery polymers may be used as device coatings or in the
form of microspheres for a drug depot injectable (such as a
reservoir of the present invention). A further polymer delivery
technology may also be adapted to the devices of the present
invention such as that described in U.S. Patent Application
Publication No. 2004/0170685 (Carpenter), and technologies
available from Medivas (San Diego, Calif.).
[0610] In specific embodiments, the drug core matrix comprises a
solid material, for example silicone, that encapsulates inclusions
of the drug. The drug comprises molecules which are very insoluble
in water and slightly soluble in the encapsulating drug core
matrix. The inclusions encapsulated by the drug core can be
micro-particles having dimensions from about 1 .mu.m to about 100
.mu.m across. The drug inclusions can comprise crystals, for
example bimatoprost crystals, and/or droplets of oil, for example
with latanoprost oil. The drug inclusions can dissolve into the
solid drug core matrix and substantially saturate the drug core
matrix with the drug, for example dissolution of latanoprost oil
into the solid drug core matrix. The drug dissolved in the drug
core matrix is transported, often by diffusion, from the exposed
surface of the drug core into the tear film. As the drug core is
substantially saturated with the drug, in many embodiments the rate
limiting step of drug delivery is transport of the drug from the
surface of the drug core matrix exposed to the tear film. As the
drug core matrix is substantially saturated with the drug,
gradients in drug concentration within the matrix are minimal and
do not contribute significantly to the rate of drug delivery. As
surface area of the drug core exposed to the tear film is nearly
constant, the rate of drug transport from the drug core into the
tear film can be substantially constant. Work in relation with the
present invention suggests that the solubility of the therapeutic
agent in water and molecular weight of the drug can effect
transport of the drug from the solid matrix to the tear. In many
embodiments, the therapeutic agent is nearly insoluble in water and
has a solubility in water of about 0.03% to 0.002% by weight and a
molecular weight from about 400 grams/mol. to about 1200
grams/mol.
[0611] In many embodiments the therapeutic agent has a very low
solubility in water, for example from about 0.03% by weight to
about 0.002% by weight, a molecular weight from about 400 grams per
mole (g/mol.) to about 1200 g/mol and is readily soluble in an
organic solvent. Cyclosporin A (CsA) is a solid with an aqueous
solubility of 27.67 .mu.g/mL at 25.degree. C., or about 0.0027% by
weight, and a molecular weight (M.W.) of 1202.6 g/mol. Latanoprost
(Xalatan) is a prostaglandin F2.alpha. analogue, a liquid oil at
room temperature, and has an aqueous solubility of 50 .mu.g/mL in
water at 25.degree. C., or about 0.005% by weight and a M.W. of
432.6 g/mol.
[0612] Bimatoprost (Lumigan) is a synthetic prostamide analogue, a
solid at room temperature solubility in water of 300 .mu.g/mL in
water at 25.degree. C., or 0.03% by weight, and has a M.W. of 415.6
g/mol.
[0613] Work in relation with the present invention indicates that
naturally occurring surfactants in the tear film, for example
surfactant D and phospholipids, may effect transport of the drug
dissolved in the solid matrix from the core to the tear film. The
drug core can be adapted in response to the surfactant in the tear
film to provide sustained delivery of the drug into the tear film
at therapeutic levels. For example, empirical data can be generated
from a patient population, for example 10 patients whose tears are
collected and analyzed for surfactant content. Elution profiles in
the collected tears for a drug that is sparingly soluble in water,
for example cyclosporine, can also be measured and compared with
elution profiles in buffer and surfactant such that an in vitro
model of tear surfactant is developed. An in vitro solution with
surfactant based on this empirical data can be used to adjust the
drug core in response to the surfactant of the tear film.
[0614] The drug cores may also be modified to utilize carrier
vehicles such as nanoparticles or microparticles depending on the
size of the molecule to be delivered such as latent-reactive
nanofiber compositions for composites and nanotextured surfaces
(Innovative Surface Technologies, LLC, St. Paul, Minn.),
nanostructured porous silicon, known as BioSilicon.RTM., including
micron sized particles, membranes, woven fivers or micromachined
implant devices (pSividia, Limited, UK) and protein nanocage
systems that target selective cells to deliver a drug
(Chimeracore).
[0615] In many embodiments, the drug insert comprises of a
thin-walled polyimide tube sheath with a drug core comprising
latanoprost dispersed in Nusil 6385 (MAF 970), a medical grade
solid silicone that serves as the matrix for drug delivery. The
distal end of the drug insert is sealed with a cured film of solid
Loctite 4305 medical grade adhesive. The drug insert may be placed
within the bore of the punctum plug, the Loctite 4305 adhesive does
not come into contact with either tissue or the tear film. The
inner diameter of the drug insert can be 0.32 mm; and the length
can be 0.95 mm. Three Latanoprost concentrations in the finished
drug product can be tested clinically: Drug cores can comprise 3.5,
7 or 14 .mu.g latanoprost, with percent by weight concentrations of
5, 10 and 20% respectively. Assuming an overall elution rate of
approximately 100 ng/day, the drug core comprising 14 .mu.g of
latanoprost is adapted to deliver drug for approximately at least
100 days, for example 120 days. The overall weight of the drug
core, including latanoprost, can be .about.70 .mu.g. The weight of
the drug insert including the polyimide sleeve can be approximately
100 .mu.g.
[0616] In many embodiments, the drug core may elute with an initial
elevated level of therapeutic agent followed by substantially
constant elution of the therapeutic agent. In many instances, an
amount of therapeutic agent released daily from the core may be
below the levels found in drops and still provide a benefit to the
patient. An elevated level of eluted therapeutic agent can result
in a residual amount of therapeutic agent and/or residual effect of
the therapeutic agent to provide relief to the patient. In
embodiments where therapeutic level is about 80 ng per day, the
device may deliver about 100 ng per day for an initial delivery
period. The extra 20 ng delivered per day can have a beneficial
immediate effect. As the amount of drug delivered can be precisely
controlled, an initial elevated dose may not result in
complications and/or adverse events to the patient.
[0617] Further, an implant may be used that includes the ability to
release two or more drugs in combination, such as the structure
disclosed in U.S. Pat. No. 4,281,654 (Shell). For example, in the
case of glaucoma treatment, it may be desirable to treat a patient
with multiple prostaglandins or a prostaglandin and a cholinergic
agent or an adrenergic antagonist (beta blocker), such as
Alphagan.RTM., or prostaglandin and a carbonic anhydrase
inhibitor.
[0618] In various embodiments, the implant may have at least one
surface and release a therapeutic quantity of two therapeutic
agents into tear or tear film fluid of the eye throughout a time
period of at least one week when the implant is implanted with the
at least one surface exposed to the tear or tear film fluid. For
example, the implant can be adapted to release the therapeutic
agents in therapeutic amounts over a period of time from about one
to twelve months. The release rate of each of the therapeutic
agents may be the same or each of the therapeutic agents may have
different release rates.
[0619] In some embodiments, the implant comprise a single drug core
with two therapeutic agents mixed within a matrix. In other
embodiments, the implant comprise two drug cores, each with a
single therapeutic agent.
[0620] In specific embodiments, at least a portion of the implant
may be bioerodable, and the therapeutic agents can be released
while the a portion of the implant erodes.
[0621] In some embodiments, the second therapeutic agent may
comprise a counteractive agent to avoid a side effect of the first
therapeutic agent. In one example, the second therapeutic agent may
comprise at least one of an anti-glaucoma drug or a miotic drug.
The anti-glaucoma drug may comprise at least one of a
sympathomimetic, a parasympathomimetic, a beta blocking agent, a
carbonic anhydrase inhibitor, or prostaglandin analogue. In another
example, the first therapeutic agent may be steroids and the second
therapeutic agent may be antibiotics, where the steroids compromise
the immune response, but the antibiotics provides coverage for
infection. In another example, the first therapeutic agent may be
pilocarpine and the second therapeutic agent may be non-steroidal
anti-inflammatory drug (NSAID). An analgesic may be a good
compliment for the treatment.
[0622] In some embodiments the therapeutic agents can be released
with a profile that corresponds to a kinetic order of therapeutic
agents release and the order can be within a range from about zero
to about one. In specific embodiments, the range is from about zero
to about one half, for example from about zero to about one
quarter. The therapeutic agents may be released with a profile that
corresponds to a kinetic order of therapeutic agents release and
the order is within a range from about zero to about one half for
at least about a month after the structure is inserted, for example
the order can be within the range at least about 3 months after the
structure is inserted.
[0623] Referring now to FIG. 17, an implant, for example a punctal
plug 1700, is shown which comprises a silicone body 1710, a drug
core 1720 and a retention structures 1730, according to embodiments
of the present invention. Body 1710 comprises a proximal channel
1714 sized to receive drug core insert 1720. A filament 1734 can be
embedded in body 1710 and wrapped around hydrogel rod 1732 to affix
hydrogel rod 1732 to body 1710. The drug core insert and
manufacture of the drug core insert are described in U.S.
application Ser. Nos. 11/695,537 and 11/695,545, the full
disclosures of which are incorporated herein by reference. Although
a drug core insert is shown, some embodiments may comprises a drug
reservoir, a semi-permeable membrane, a drug coating or the like,
as described in U.S. Pat. No. 6,196,993 (Cohan) and U.S.
application Ser. No. 10/899,416 (Prescott); Ser. No. 10/899,417
(Prescott); Ser. No. 10/762,421 (Ashton); Ser. No. 10/762,439
(Ashton); Ser. No. 11/571,147 (Lazar) and Ser. No. 10/825,047
(Odrich), the full disclosures of which are herein incorporated by
reference for all purposes. In some embodiments, the implant
comprises a punctal plug without drug carried on the implant, for
example an implant similar to punctal plug 1700 without channel
1714 and drug core insert 1720.
[0624] Retention structures 1730 may comprise hydrogel rod,
hydrogel coating, and protrusions. Hydrogel rod 1732 can be
inserted through the punctum into a canalicular lumen in a narrow
profile configuration. After insertion into the lumen the hydrogel
rod, hydrogel coating, or both, can hydrate expand to a wide
profile configuration.
[0625] FIG. 18A shows a cross sectional view of a sustained release
implant 1800 having two therapeutic agents to treat an eye,
according to embodiments of the present invention Implant 1800 has
a proximal end 1812 in which the therapeutic agents are released
and a distal end 1814. Implant 1800 includes two concentric drug
cores 1810, 1815. First drug core 1810 is a cylindrical shaped
structure with a central opening that includes a first therapeutic
agent, and second drug core 1815 is a cylindrical shaped structure
that includes a second therapeutic agent. Second drug core 1815 is
configured to fit within the central opening of first drug core
1810, as shown in the figures. First drug core 1810 comprises a
first matrix 1870 that contains first inclusions 1860 of the first
therapeutic agent, and second drug core 1815 comprises a second
matrix 1875 that contains second inclusions 1865 of the second
therapeutic agent. First and second inclusions 1860, 1865 will
often comprise a concentrated form of the first and second
therapeutic agents, for example a liquid or solid form of the
therapeutic agents, and the therapeutic agents may over time
dissolve into first matrix 1870 of first drug core 1810 and second
matrix 1875 of second drug core 1815. First and second matrixes
1870, 1875 can comprise a silicone matrix or the like, and the
mixture of therapeutic agents within matrixes can be
non-homogeneous. In many embodiments, the non-homogenous mixture
comprises a silicone matrix portion that is saturated with the
therapeutic agents and an inclusions portion comprising inclusions
of the therapeutic agents, such that the non-homogenous mixture
comprises a multiphase non-homogenous mixture. The first matrix may
differ from the second matrix, including, for example, an exposed
surface area, a surfactant, a cross-linking, an additive, and/or
matrix materials including formulation and/or solubility. In some
embodiments, first and second inclusions 1860, 1865 comprise
droplets of an oil of the therapeutic agent, for example
Latanoprost oil. In some embodiments, first and second inclusions
1860, 1865 may comprise particles of the therapeutic agents, for
example solid bimatoprost particles. In many embodiments, first
matrix 1870 contains first inclusions 1860 and second matrix 1875
contains second inclusions 1865. First and second inclusions 1860,
1865 may comprise microparticles having dimensions from about 0.1
.mu.m to about 100 .mu.m, or 200 .mu.m. The contained inclusions at
least partially dissolve into the surrounding solid matrix, for
example silicone, that contains the micro particles such that first
and second matrixes 1870, 1875 are substantially saturated with the
therapeutic agent while the therapeutic agent is released from the
core.
[0626] First and second drug cores 1810, 1815 are surrounded by a
sheath body 1820, except at an exposed surface where the
therapeutic agents are released, in this case at the proximal end
1812. Sheath body 1820 is substantially impermeable to the
therapeutic agents, so that the therapeutic agents are released
from the exposed surface on the open end of first and second drug
cores 1810, 1815 that are not covered with sheath body 1820. In
some embodiments, the implant may be incorporated into a different
structure, such as a punctal plug.
[0627] FIG. 18B shows a side cross sectional view of the sustained
release implant of FIG. 18A. First drug core 1810 with a first
therapeutic agent is a cylindrical shaped structure and shown with
a circular cross-section with an open center. Second drug core 1815
with a second therapeutic agent is a cylindrical shaped structure
and shown with a circular cross-section and is configured to fit
within first drug core 1810, as shown in the figures. Sheath body
1820 comprises an annular portion disposed on first drug core
310.
[0628] FIG. 19A shows a cross sectional view of a sustained release
implant 1900 having therapeutic agents to treat an eye, according
to embodiments of the present invention. Implant 1900 has a
proximal end 1912 in which the therapeutic agents are released and
a distal end 1914. Implant 1900 includes first and second drug
cores 1910, 1915 that are positioned in a side by side
configuration. First drug core 1910 is a cylindrical shaped
structure that includes the first therapeutic agent and second drug
core 1915 is a cylindrical shaped structure that includes the
second therapeutic agent. First and second drug cores 1910 and 1915
are placed adjacent to each other and may have the same length, or
different lengths, such as shown in the figure. First drug core
1910 comprises a first matrix 1970 that contains first inclusions
1960 of the first therapeutic agent and second drug core 415
comprises a second matrix 1975 that contains second inclusions 1965
of the second therapeutic agent. First and second inclusions 1960,
1965 will often comprise a concentrated form of the first and
second therapeutic agents, for example a liquid or solid form of
the therapeutic agents, and the therapeutic agents may over time
dissolve into first matrix 1970 of first drug core 1910 and second
matrix 1975 of second drug core 1915. First and second matrixes
1970, 1975 can comprise a silicone matrix or the like, and the
mixture of therapeutic agents within matrixes can be
non-homogeneous. In many embodiments, the non-homogenous mixture
comprises a silicone matrix portion that is saturated with the
therapeutic agents and an inclusions portion comprising inclusions
of the therapeutic agents, such that the non-homogenous mixture
comprises a multiphase non-homogenous mixture. The first matrix may
differ from the second matrix, including, for example, an exposed
surface area, a surfactant, a cross-linking, an additive, and/or
matrix materials including formulation and/or solubility. In some
embodiments, first and second inclusions 1960, 1965 comprise
droplets of an oil of the therapeutic agent, for example
Latanoprost oil. In some embodiments, inclusions may comprise
particles of the therapeutic agent, for example solid bimatoprost
particles. First and second inclusions 1960, 1965 may comprise
microparticles having dimensions from about 0.1 .mu.m to about 100
.mu.m, or 200 .mu.m. The contained inclusions at least partially
dissolve into the surrounding solid matrix, for example silicone,
that contains the micro particles such that first and second
matrixes 1970, 1975 are substantially saturated with the
therapeutic agent while the therapeutic agent is released from the
core.
[0629] First and second drug cores 1910, 1915 are surrounded by a
sheath body 1920, except at an exposed surface where the
therapeutic agents are released, in this case at the proximal end
1912. Sheath body 1920 is substantially impermeable to the first
and second therapeutic agents, so that the first and second
therapeutic agents are released from the exposed surface on the
open end of first and second drug cores 1910, 1915 that are not
covered with sheath body 1920. In some embodiments, the implant may
be incorporated into a different structure, such as a punctal
plug.
[0630] FIG. 19B shows a side cross sectional view of the sustained
release implant of FIG. 19A. First drug core 1910 with the first
therapeutic agent is a cylindrical shaped structure and shown with
a circular cross-section. Second drug core 1915 with the second
therapeutic agent is also a cylindrical shaped structure and shown
with a circular cross-section. First and second drug cores 1910,
1915 may have different diameters or the same diameter, as shown in
the figures. Sheath body 1920 comprises an annular portion disposed
around first and second drug cores 1910, 1915.
[0631] FIG. 20A shows a cross sectional view of a sustained release
implant 2000 having therapeutic agents to treat an eye, according
to embodiments of the present invention. Implant 2000 has a
proximal end 2012 and a distal end 2014. Implant 2000 includes two
concentric drug cores 2010, 2015 with hollow centers to allow fluid
flow through the implant 2000. First drug core 2010 is a hollow
cylindrical shaped structure that includes a first therapeutic
agent and second drug core 2015 is a hollow cylindrical shaped
structure that includes a second therapeutic agent. Second drug
core 2015 is configured to fit within a central opening of first
drug core 2010, as shown in the figures. First and second drug
cores 2010, 2015 may have the same length, or different lengths, as
shown in the figures. First drug core 2010 comprises a first matrix
2070 that contains first inclusions 2060 of the first therapeutic
agent and second drug core 2015 comprises a second matrix 2075 that
contains second inclusions 2065 of the second therapeutic agent.
First and second inclusions 2060, 2065 will often comprise a
concentrated form of the first and second therapeutic agents, for
example a liquid or solid form of the therapeutic agents, and the
therapeutic agents may over time dissolve into a first matrix 2070
of first drug core 2010 and a second matrix 2075 of second drug
core 2015, respectively. First and second matrixes 2070, 2075 can
comprise a silicone matrix or the like, and the mixture of
therapeutic agents within matrixes can be non-homogeneous. In many
embodiments, the non-homogenous mixture comprises a silicone matrix
portion that is saturated with the therapeutic agents and an
inclusions portion comprising inclusions of the therapeutic agents,
such that the non-homogenous mixture comprises a multiphase
non-homogenous mixture. The first matrix may differ from the second
matrix, including, for example, an exposed surface area, a
surfactant, a cross-linking, an additive, and/or matrix materials
including formulation and/or solubility. In some embodiments, first
and second inclusions 2060, 2065 comprise droplets of an oil of the
therapeutic agent, for example latanoprost oil. In some
embodiments, inclusions may comprise particles of the therapeutic
agent, for example solid bimatoprost particles. First and second
inclusions 2060, 2065 may comprise microparticles having dimensions
from about 0.1 .mu.m to about 100 .mu.m, or about 200 .mu.m. The
contained inclusions at least partially dissolve into the
surrounding solid matrix, for example silicone, that contains the
micro particles such that first and second matrixes 2070, 2075 are
substantially saturated with the therapeutic agent while the
therapeutic agent is released from the core.
[0632] First drug core 2010 is surrounded on its outer surface by a
sheath body 2020, having first drug core 2010 with an open inner
surface 2085 and exposed proximal and distal end surfaces. Sheath
body 2020 is substantially impermeable to the first therapeutic
agents in first drug core 2010, so that the first therapeutic
agents are released from the exposed surfaces of the drug core
2010. Second drug core 2015 is surrounded on its outer surface by
first drug core 2010, with an open inner surface 2080 and exposed
proximal and distal end surfaces. The second drug core 2015 is
shorter than the first drug core 2010 so that portions of the inner
surface 2085 are exposed. First therapeutic agents are released
from the exposed surfaces of first drug core 2010 that are not
covered by the sheath body 2020 and second drug core 2015, and
second therapeutic agents are released from the exposed surfaces of
second drug core 2015 that are not covered with first drug core
2010. In some embodiments, the implant may be incorporated into a
different structure, such as a punctal plug.
[0633] FIG. 20B shows a side cross sectional view of the sustained
release implant of FIG. 20A with concentric drug cores. First drug
core 510 with the first therapeutic agent is shown with a circular
cross-section with a first open center portion. Second drug core
2015 with the second therapeutic agent is shown with a circular
cross-section with a second open center and is configured to fit
within the first open center portion of first drug core 2010, while
allowing flow through the center of the second drug core 2015, as
shown in the figures. Sheath body 2020 comprises an annular portion
disposed on first drug core 2010.
[0634] The drug cores disclosed above comprise the first and second
therapeutic agents and materials to provide sustained release of
the first and second therapeutic agents. The first and second
therapeutic agents migrate from the drug core to the target tissue,
for example ciliary body of the eye. The ocular surface could be
targeted for cyclosporine A (control inflammation) and mucin
inducers for dry eyes. The uvea could be targeted by steroids,
NSAIDs and CSA for uveitis. The first and second therapeutic agents
may optionally be only slightly soluble in the matrix so that the
release rate remains "zero order" for the lifetime of the release
of the first and second therapeutic agents when dissolved in the
matrix and available for release from the exposed surfaces of the
drug cores. As the first and second therapeutic agents differs from
the exposed surfaces of the drug cores to the tear or tear film,
the rate of migration from the drug cores to the tear or tear film
is related to the concentration of first and second therapeutic
agents dissolved in the matrixes. In some embodiments, the
concentration of first and second therapeutic agents dissolved in
the drug cores may be controlled to provide the desired rate of
release of the first and second therapeutic agents. In some
embodiments the desired rate of release of the first therapeutic
agent may be the same as the desired rate of release of the second
therapeutic agent. In some embodiments the desired rate of release
of the first therapeutic agent may be different than the desired
rate of release of the second therapeutic agent. The first and
second therapeutic agents included in the drug cores can include
liquid, solid, solid gel, solid crystalline, solid amorphous, solid
particulate, and/or dissolved forms of the therapeutic agents. In
some embodiments, the drug cores comprise a silicone matrix
containing the first and second therapeutic agents.
[0635] The drug cores can be made from any biocompatible material
capable of providing a sustained release of the therapeutic agents.
Although the drug cores are described above with respect to
embodiments comprising a matrix with a substantially
non-biodegradable silicone matrix with particles of the drugs
located therein that at least partially dissolve, the drug cores
can include any structure that provides sustained release of the
first and second therapeutic agents, for example biodegradable
matrix, a porous drug core, liquid drug cores and solid drug cores.
In some embodiments, the drug cores have the same structure, while
in other embodiments, the drugs cores have different structures.
The structures can be adapted to release the first and second
therapeutic agents in therapeutic amounts over a period of time
from about one to twelve months after the structure is inserted
into the eye. In some embodiments the release rate for the first
and second therapeutic agents may be the same or similar. In other
embodiments the release rate for the first and second therapeutic
agents may be different, with one therapeutic agent being released
at a higher rate than the other therapeutic agent. A matrix that
contains the first and second therapeutic agents can be formed from
either biodegradable or non-biodegradable polymers. Examples of
biodegradable polymers may include poly(L,-lactic acid) (PLLA),
poly(L-glycolic acid) (PLGA), polyglycolide, poly-L-lactide,
poly-D-lactide, poly(amino acids), polydioxanone, polycaprolactone,
polygluconate, polylactic acid-polyethylene oxide copolymers,
modified cellulose, collagen, polyorthoesters, polyhydroxybutyrate,
polyanhydride, polyphosphoester, poly(alpha-hydroxy acid), collagen
matrices and combinations thereof. The devices of the present
invention may be fully or partially biodegradable or
non-biodegradable. Examples of non-biodegradable materials are
various commercially available biocompatible polymers including but
not limited to silicone, polyethylene terephthalate, acrylates,
polyethylenes, polyolefins, including ultra high molecular weight
polyethylene, expanded polytetrafloroethylene, polypropylene,
polycarbonate urethane, polyurethanes, polyamides, sheathed
collagen. Additional examples of polymers may include
cyclodextrans, chitans, hyaluronic acid, chrondroitin sulfate and
any cross limited derivatives of these polymers. In some
embodiments the drug cores may comprise a hydrogel polymer, either
degradable or non-degradable. In some embodiments, the therapeutic
agents can be comprised in a drug eluting material used as a
coating, such as those commercially available from Surmodics of
Eden Prairie, Minn., and Angiotech Pharmaceuticals of British
Columbia, Canada, and the like.
[0636] The first and second therapeutic agents can comprise any
substance, for example a drug, that effects the eye. In some
embodiments, the first and second therapeutic agents work together
in treating the eye. In other embodiments, the first therapeutic
agent can counteract possible side effects of the second
therapeutic agent. The additional counteractive therapeutic agent
can be comprised within the core that releases the therapeutic
agent that treats the eye, such as shown in FIG. 2A, or separate
drug cores can be provided to separately release the additional
counteractive therapeutic agent, such as shown in FIGS. 3A, 4A and
5A.
[0637] For example, one possible side effect of a cycloplegic
therapeutic agent is pupil dilation that can result in photophobia.
Therefore, a miotic therapeutic agent is released into the eye to
counteract the pupil dilation caused by the cycloplegic.
Cycloplegic therapeutic agents may include atropine,
cyclopentolate, succinylcholine, homatropine, scopolamine, and
tropicamide. Miotic therapeutic agents may include echothiophate,
pilocarpine, physostigmine salicylate, diisopropylfluorophosphate,
carbachol, methacholine, bethanechol, epinephrine, dipivefrin,
neostigmine, echothiopateiodide and demecium bromide. Other
suitable therapeutic agents include mydriatics such as
hydroxyamphetamine, ephedrine, cocaine, tropicamide, phenylephrine,
cyclopentolate, oxyphenonium and eucatropine. In addition,
anti-cholinergics may be employed such as, pirenzepine. Examples of
applicable therapeutic agents may be found in U.S. Patent
Application Publication Nos. 2006/0188576 and 2003/0096831, hereby
incorporated by reference in their entirety.
[0638] Another potential side effect of cycloplegic therapeutic
agents is glaucoma, possibly related to the dilation of the pupil.
Therefore, the second therapeutic agent is an anti-glaucoma agent
released to counteract a possible glaucoma inducing side effect of
the first therapeutic agent used to treat the eye. Suitable
anti-glaucoma therapeutic agents include: sympathomimetics such as
Apraclonidine, Brimonidine, Clonidine, Dipivefrine, and
Epinephrine; parasympathomimetics such as Aceclidine,
Acetylcholine, Carbachol, Demecarium, Echothiophate, Fluostigmine,
Neostigmine, Paraoxon, Physostigmine, and Pilocarpine; carbonic
anhydrase inhibitors such as Acetazolamide, Brinzolamide,
Diclofenamide, Dorzolamide, and Methazolamide, beta blocking agents
such as Befunolol, Betaxolol, Carteolol, Levobunolol, Metipranolol,
and Timolol; prostaglandin analogues such as Bimatoprost,
Latanoprost, Travoprost, and Unoprostone; and other agents such as
Dapiprazole, and Guanethidine. In a preferred embodiment, atropine
is released as a first therapeutic agent to treat developmental
myopia in children, and bimatoprost and/or latanoprost is released
as a second therapeutic agent for anti-glaucoma treatment.
[0639] Other non-limiting examples of the active agents or
medications which are appropriate for use with the invention
include, for example only: topical prostaglandin derivatives such
as latanoprost, travaprost and bimatoprost used for the topical
treatment of glaucoma. Also a treatment for corneal infections is
appropriate using ciprofloxacin, moxifloxacin or gatifloxacin.
Systemic medications useful for this invention are those used for
hypertension such as atenolol, nifedipine or hydrochlorothiazide.
Any other chronic disease requiring chronic medication could be
used. The active agents or medications may by antiinfective agents.
For example for bacteria use fluoroquinolones, .beta. lactan,
aminoglycosides or cephalasporins. For antiviral agents use
antimycotics. For anti-inflammatory agents use gluco corticoid
steroid, NSAIDs and other analgesics.
[0640] The treatment of allergic conjunctivitis and rhinitis are
also applications for the invention, e.g. using antihistamine and
anti-allergy medication such as olopatadine and cromalyn sodium in
or on the implant.
[0641] This list of active agents is not comprehensive in that many
other agents can be used with the present invention. For example, a
treatment for dry eye by topical cyclosporin is particularly
interesting for administration by the present invention, in which a
therapeutic amount of cyclosporin may be delivered each day that is
less than the daily drop administered quantity, for example, the
therapeutic amount may be 5 to 10% of the drop administered
quantity of cyclosporin or Restasis.RTM., commercially available
from Allergan. There are many other active agents can also be
administered using the method and apparatus of the invention. The
active agents may be lubricants and emollients like PVA, PVP,
modified cellulose molecules like carboxymethyl cellulose and
hydroxypropyl methyl cellulose, also Hyaluronic acid and mucin
stiulators.
[0642] It should be noted that some therapeutic agents will have
more than one effect on the eye. For example, anti-glaucoma
therapeutic agents can also cause pupil constriction. Thus in some
embodiments, the second therapeutic agent can counteract more than
one side effect of the first therapeutic agent that is released to
treat the eye.
[0643] The first and second therapeutic agents are released at
therapeutic levels to provide a desired treatment response when the
implants disclosed above are implanted in a tissue or near the eye.
The first and second therapeutic agents are preferably released at
a uniform rate, for example a rate that corresponds to zero order
kinetics, although the therapeutic agents can be released at rates
that correspond to other orders of reaction kinetics, for example
first order. In many embodiments, the kinetic order of the reaction
will vary from zero order to first order as the first and second
therapeutic agents are released. Thus, the first and second
therapeutic agents are released with a profile that corresponds to
a range of kinetic orders that varies from about zero to about one.
Ideally, the drug cores are removed before the rate at which the
first and second therapeutic agents are released changes
significantly so as to provide uniform delivery of the first and
second therapeutic agents. As a uniform rate of delivery is
desired, it may be desirable to remove and/or replace the drug
cores before the reaction kinetics transition entirely to first
order. In other embodiments, first or higher order release kinetics
may be desirable during some or all of the treatment, so long as
the first and second therapeutic agents release profile remains
within a safe and effective range. In some embodiments the drug
cores may release first and second therapeutic agents at an
effective rate for the period of 1 week to 5 years, more
particularly in the range of 3-24 months. As pointed out above, in
some embodiments it may be desirable for the drugs cores to have
similar release rates for the first and second therapeutic agents.
In other embodiments, it may be desirable for the drug cores to
have different release rates for the first and second therapeutic
agents, depending on the therapeutic agents used.
[0644] The rate of release of the first and second therapeutic
agents can be related to the concentration of first and second
therapeutic agents dissolved in the drug cores. In many
embodiments, the drug cores comprise additional non-therapeutic
agents that are selected to provide a desired solubility of the
first and second therapeutic agents in the drug cores. The
non-therapeutic agent of the drug cores can comprise polymers as
described above and additives. A polymer of the drug core can be
selected to provide the desired solubility of the first and second
therapeutic agents in the matrix. For example, the drug core can
comprise hydrogel that may promote solubility of hydrophilic
treatment agents. In some embodiments, functional groups can be
added to the polymer to modulate the release kinetics of one or
both of the therapeutic agents. For example, functional groups can
be attached to silicone polymer. In some embodiments different ions
may generate different salts with different solubility.
[0645] In some embodiments, additives may be used to control the
concentration of the first and second therapeutic agents by
increasing or decreasing solubility of the therapeutic agents in
the drug cores. The solubility may be controlled by providing
appropriate molecules and/or substances that increase and/or
decrease the solubility of the dissolved form of the therapeutic
agents to the matrixes. The solubility of the dissolved form of the
therapeutic agents may be related to the hydrophobic and/or
hydrophilic properties of the matrix and therapeutic agents. For
example, surfactants, salts, hydrophilic polymers can be added to
the matrix to modulate the release kinetics. In addition, oils and
hydrophobic molecules can be added to the matrix to modulate the
release kinetics of the matrix.
[0646] Instead of or in addition to controlling the rate of
migration based on the concentration of the first and second
therapeutic agents dissolved in the matrix, the surface area of the
drug cores can also be controlled to attain the desired rate of
drug migration from the core to the target site. For example, a
larger exposed surface area of the drug cores will increase the
rate of migration of the first and second therapeutic agents from
the drug core to the target site, and a smaller exposed surface
area of the drug core will decrease the rate of migration of the
first and second therapeutic agents from the drug core to the
target site. The exposed surface area of the drug cores can be
increased in any number of ways, for example by making the exposed
surface tortuous or porous, thereby increasing the surface area
available to the drug cores.
[0647] The sheath body of the implants disclosed above comprise
appropriate shapes and materials to control migration of the first
and second therapeutic agents from the drug cores. The sheath body
houses the drug cores and can fit snugly against the cores. The
sheath body is made from a material that is substantially
impermeable to the therapeutic agents so that the rate of migration
of the therapeutic agents may be largely controlled by the exposed
surface area of the drug cores that are not covered by the sheath
body. Typically, migration of the therapeutic agents through the
sheath body will be about one tenth of the migration of the
therapeutic agents through the exposed surface of the drug cores,
or less, often being one hundredth or less. In other words, the
migration of the therapeutic agents through the sheath body is at
least about an order of magnitude less that the migration of the
therapeutic agents through the exposed surface areas of the drug
cores. Suitable sheath body materials include polyimide,
polyethylene terephthalate" (hereinafter "PET"). The sheath body
has a wall thickness from about 0.00025'' to about 0.0015''. The
total diameter of the sheath that extends across the drug cores
range from about 0.2 mm to about 1.2 mm. The drug cores may be
formed by dip coating the drugs cores in the sheath material.
Alternatively, the sheath body can be a tube and the drug cores
introduced into the sheath as a liquid or slid into the sheath body
tube.
[0648] The sheath body can be provided with additional features to
facilitate clinical use of the implant. For example, the sheath may
replaceable receive drug cores that are exchangeable while the
retention element and sheath body remain implanted in the patient.
The sheath body is often rigidly attached to the retention element
as described above, and the drugs cores are exchangeable while the
retention element retains the sheath body. For example, the sheath
body can be provided with external protrusions that apply force to
the sheath body when squeezed and eject the drug cores from the
sheath body. Another drug core can then be positioned in the sheath
body.
[0649] In another embodiment, the therapeutic implant includes an
implantable body that is sized and shaped for insertion into the
patient body. The implantable body has a first receptacle and a
second receptacle. The first receptacle includes a first
therapeutic agent and a first surface for releasing the first
therapeutic agent. The second receptacle includes a second
therapeutic agent and a second surface for releasing the second
therapeutic agent. The first and second therapeutic agents may be
any therapeutic agent described herein. The first and second
therapeutic agents may be released at therapeutic levels through
the first and second surfaces of the first and second receptacles
over a sustained period when the implant is implanted for use. As
disclosed herein, the release rate and/or the release period of the
first and second therapeutic agents may be the same or different.
In other embodiments, the first and second receptacles be shaped
and positioned within the sustained release implants and
therapeutic implants described in the present application.
[0650] FIG. 21 schematically illustrates one embodiment of a
lacrimal insert in the shape of a punctal plug 2100 for use in a
therapeutic implant configured to hold a sustained release implant
with at least one drug core containing first and second therapeutic
agents. The punctal plug 2100 includes a collarette 2110 at a
proximal end which rests on the exterior of the punctum 11, 13 (see
FIG. 34), a bulb 2120 with a tapered portion 2125 terminating in a
tip 2135 at a distal end that blockingly projects into the
canaliculus 10, 12 (see FIG. 34), and a body portion 2130
connecting the collarette 2110 and the bulb 2120. The punctal plug
2100 is approximately 2.0 mm in length. The bulb 2120 is designed
to prevent the punctal plug 2100 from being easily dislodged from
the canaliculus 10, 12, and may be tapered for ease of insertion
into the punctum 11, 13. The collarette 2110 is designed to have a
diameter to prevent the punctal plug 2100 from completely entering
the canaliculus 10, 12, and is preferably smooth to minimize
irritation of the eye. The body portions 2130 of the punctual plug
2100 is essentially a non-functional connection between the
collarette 2110 and the bulb 2120 portions. The collarette 2110
includes an aperture 2140 extending into the body portion 2130 into
which an implant 2145 is placed. The size of the aperture 2140 is
selected to hold the implant in place during treatment. In some
embodiments, a sheath body of the implant may be omitted and the
drug core(s) may be inserted directly into the aperture 2140 of the
punctal plug 2100. In some embodiments, the tip 2135 is closed, in
other embodiments, an opening 2150 in the tip 2135 at the distal
end allows access to the aperture 2140, allowing fluid flow through
the punctal plug. In some embodiments, an optional non-porous head
2115 is provided over the collarette 2110 to enclose the aperture
2140. In accord with one aspect of the invention, the body 2110 and
head 2115 are made of different materials, with the body 2110 may
be molded or otherwise formed from a flexible material, such as
silicone, that is impermeable to the therapeutic agents, and the
head 2115 being made from a biocompatible, preferably soft and
flexible second material which is permeable to the medication. When
the punctal plug 2100 is in place, the therapeutic agents are
deployed from the drug core(s) into the tears of the lacrimal lake
where the therapeutic agents mix, as eye drops do, with the tears
and penetrates the eye to have the intended pharmacological effect.
The size of the aperture 2140 is selected to hold the implant in
place during treatment.
[0651] FIGS. 22-25 show different embodiments of therapeutic
implants having a structure, such as a punctual plug 2100. Other
structures suitable for incorporation with the present invention
are described in U.S. Pat. App. Pub. Nos. 2006/0020253, entitled
"Implantable device having controlled release of medication and
method of manufacturing the same", published in the name of
Prescott on Jan. 26, 2006; and U.S. Pat. No. 7,117,870, entitled
"Lacrimal insert having reservoir with controlled release of
medication and method of manufacturing the same", issued on Oct.
10, 2006 in the name of Prescott, the full disclosures of which are
incorporated herein by reference. The reservoir can include any of
the therapeutic agents described herein to treat the eye, for
example medications to treat optical defects of the eye.
[0652] FIG. 22 schematically illustrates one embodiment of a
therapeutic implant 2200 having a punctal plug 2100 and a sustained
release implant containing first and second therapeutic agents. In
the embodiment shown, the sustained release implant is sustained
release implant 2200 discussed above having drug core 2210 with
first inclusions 2260 of a first therapeutic agent and second
inclusions 2265 of a second therapeutic agent. This embodiment of
the therapeutic implant 2200 further includes the optional head
2115 at a proximal end that is permeable to the first and second
therapeutic agents. When the therapeutic implant 2200 is in place,
the first and second therapeutic agents are deployed from proximal
end of the drug core through the permeable head into the tears of
the lacrimal lake where the first and second therapeutic agents
mix, as eye drops do, with the tears and penetrates the eye to have
the intended pharmacological effect. The size of the aperture 2240
is selected to hold the sustained release implant in place during
treatment. In the embodiment shown, the sheath body is also within
the aperture 2140. In other embodiments, the sheath body 2220 may
be omitted and the drug core 2210 may be inserted directly into the
aperture 2140 of the punctal plug 2100.
[0653] FIG. 23 schematically illustrates one embodiment of a
therapeutic implant 2300 having a punctal plug 2100 and a sustained
release implant having first and second concentric drug cores with
first and second therapeutic agents. In the embodiment shown, the
sustained release implant is sustained release implant 2300 having
an outer first drug core 2310 with first inclusions 2360 of a first
therapeutic agent and an inner second drug core 2315 with second
inclusions 2365 of a second therapeutic agent. When the therapeutic
implant 2300 is in place, the first and second therapeutic agents
are deployed from the drug cores at the exposed or proximal end and
into the tears of the lacrimal lake where the first and second
therapeutic agents mix, as eye drops do, with the tears and
penetrates the eye to have the intended pharmacological effect. The
size of the aperture 2140 is selected to hold the sustained release
implant in place during treatment. In some embodiments, the sheath
body 2320 of the implant 2300 may be omitted and the first and
second drug cores 2310, 2315 may be inserted directly into the
aperture 2140 of the punctal plug 2100. Optionally, a head 2115 may
be used that is permeable to the first and second therapeutic
agents, wherein first and second therapeutic agents are deployed
from first and second drug cores 2310, 2315 through permeable head
2115.
[0654] FIG. 24 schematically illustrates one embodiment of a
therapeutic implant 2400 having a punctal plug 2100 and a sustained
release implant having first and second drug cores containing first
and second therapeutic agents. In the embodiment shown, the
sustained release implant is sustained release implant 2400 having
a first drug core 2410 with first inclusions 2460 of a first
therapeutic agent next to a second drug core 2415 with second
inclusions 2465 of a second therapeutic agent. When the therapeutic
implant 2400 is in place, the first and second therapeutic agents
are deployed from the drug cores at the exposed or proximal ends
and into the tears of the lacrimal lake where the first and second
therapeutic agents mix, as eye drops do, with the tears and
penetrates the eye to have the intended pharmacological effect. The
size of the aperture 2140 is selected to hold the implant 2400 in
place during treatment. In some embodiments, the sheath body 2420
of the implant 400 may be omitted and the first and second drug
cores 2410, 2415 may be inserted directly into the aperture 2140 of
the punctal plug 2100. Optionally, a head 2115 may be used that is
permeable to the first and second therapeutic agents, wherein first
and second therapeutic agents are deployed from the first and
second drug cores 2410, 2415 through the permeable head 2115.
[0655] FIG. 25 schematically illustrates one embodiment of a
therapeutic implant 2500 having a punctal plug 2100 and a sustained
release implant having first and second concentric drug cores in a
flow-through configuration, with each drug core containing a
therapeutic agent. In the embodiment shown, the sustained release
implant is sustained release implant 2500 having an outer first
drug core 2510 with first inclusions 2560 of a first therapeutic
agent and an inner second drug core 2515 with second inclusions
2565 of a second therapeutic agent. In the embodiment shown, the
punctal plug 2100 includes an opening 2150 in the tip 2135 at the
distal end allowing fluid flow through the body of the punctal plug
2100 from the proximal end to the distal end and through first and
second drug cores 2510, 2515. When the therapeutic implant 2500 is
in place, the first and second therapeutic agents are deployed from
the drug cores 2510, 2515 at the exposed ends and exposed inner
surfaces 2585, 2580 as the fluid flows through. The size of the
aperture 2140 of the punctal plug 2100 is selected to hold the
implant in place during treatment and the opening 2150 is sized to
allow sufficient flow through the implant 2100 and first and second
drug cores 2510, 2515. In some embodiments, the sheath body of the
implant may be omitted and first and second drug cores 510, 2515
may be inserted directly into the aperture 2140 of the punctal plug
2100. Optionally, a head 2115 may be used that is permeable to the
first and second therapeutic agents. Other flow-through structures
suitable for incorporation with the present invention are described
in U.S. patent application Ser. No. 11/695,545, entitled
"Nasolacrimal Drainage System Implants for Drug Therapy, filed Apr.
2, 2007, and issued as U.S. Pat. No. 7,998,497 on Aug. 16, 2011,
the full disclosure of which is incorporated herein by
reference.
[0656] FIGS. 26A-26C show therapeutic implants 2600, 2600', 2600''
that encompass punctual plugs and structures that release first and
second therapeutic agents, according to an embodiment of the
present invention. Structures suitable for incorporation with the
present invention are described in U.S. Pat. No. 3,949,750,
entitled "Punctum plug and method for treating keratoconjunctivitis
sicca and other ophthalmic aliments using same", issued in the name
of Freeman on Apr. 13, 1976, the full disclosure of which is
incorporated herein by reference. The head portion can include any
two of the therapeutic agents described herein to treat the
eye.
[0657] In the treatment of ophthalmic ailments where it is desired
to prevent or decrease the drainage of lacrimal fluid and/or
medication from the eye, the punctal aperture in one or both of the
upper and lower lids are to be blocked by therapeutic implants, two
respective embodiments of which are shown in FIGS. 26A and 26B.
Referring initially to the embodiment of FIG. 26A, the therapeutic
implant 2600 has a blunted tip or barb portion 2620 at a distal
end, a middle neck or waist portion 26130 of somewhat smaller
diameter than the tip, and a smooth disc-like head portion 2610 at
a proximal end of relatively larger diameter. The therapeutic
implant 2600' of FIG. 26B is of generally similar dimensions to the
first-described embodiment with a blunted tip or barb portion
2620', a cylindrical middle portion 2630' of substantially the same
dimension, and a dome-shaped head portion 2610' of somewhat smaller
diameter than its counterpart in the embodiment of FIG. 26A. The
head portion 2610, 2610' of both embodiments may be provided, if
desired as an alternative to grasping it with forceps, with a
central bore opening 2640, 2640' adapted to receive the projecting
tip of an inserter tool to provide a releasable grip on the
therapeutic implant as it is manipulated for insertion, as
hereinafter described.
[0658] FIG. 26C shows a hollow therapeutic implant 2600'' that is
of generally similar dimensions to the first-described embodiment
having a blunted tip or barb portion 2620'', a middle neck or waist
portion 2630'' of somewhat smaller diameter than the tip, a smooth
disc-like head portion 2610'' of relatively larger diameter and a
central bore 2640'' extending through the plug. The central bore
2640'' allows fluid flow from a proximal end to distal end of the
therapeutic implant 2600''.
[0659] In some embodiments of the invention, the two therapeutic
agents as described herein are incorporated in a punctal plug as
described in U.S. App. Pub. No. 2005/0197614, the full disclosure
of which is incorporated herein by reference. A gel can be used to
form the therapeutic implant 2600, 2600', 2600'' and the gel can
swell from a first diameter to a second diameter in which the
second diameter is about 50% greater than the first diameter. The
gel can be used to entrap the first and second therapeutic agents,
for example within a microporous structure in which the agents are
uniformly dispersed, and the gel can slowly elute the first and
second therapeutic agents into the patient. Various therapeutic
agents have been describe herein and additional therapeutic agents
are described in U.S. Provisional Application No. 60/550,132,
entitled "Punctum Plugs, Materials, And Devices", the full
disclosure of which is incorporated herein by reference, and may be
combined with the gels and devices described herein.
[0660] In other embodiments of the invention, the entire body or
only portions of the therapeutic implants 2600, 2600', 2600'' may
be made of a medication-impregnable porous material such as HEMA
hydrophilic polymer, or may be otherwise adapted as with
capillaries or the like, to store and slowly dispense ophthalmic
drugs to the eye as they are leached out by the lacrimal fluids.
For example, the head portion 2610, 2610', 2610'' of each
embodiment may be medication-impregnable porous material
impregnated with first and second therapeutic agents.
[0661] FIG. 27 shows therapeutic implants containing first and
second therapeutic agents as applied to the eye. In the embodiment
shown, a therapeutic implant 2700 is designed for insertion into
the lower punctal aperture 13 of the eye 2, and along the
canaliculus 12 communicating with the aperture. The therapeutic
implant 2700 includes a collarette 2710 at a proximal end, a flared
portion 2720 at a distal end, a neck portion 2730. The collarette
2710 is designed for seating against the aperture 13. Examples of
suitable therapeutic implants 2700 containing two therapeutic
agents have been described above, and include therapeutic implants
2200, 2300, 2400, 2500, 2600, 2600' and 2600''. The therapeutic
implant 2700 may be used to block fluid flow, or may have a hollow
portion allowing fluid flow. In the embodiment shown in FIG. 27,
the therapeutic implant 2700 is shown as being a hollow like a
straw shape for the passage of tears. Examples of these include
therapeutic implants 2500 and 2600''. Unlike the tear stopping
therapeutic implants 2200, 2300, 2400, 2600 and 2600', the hollow
therapeutic implants 2500 and 2600'' provide a very different drug
administering method, scheme and structure. The hollow therapeutic
implant is particularly useful in that the active agents are
available at the inner surface or interior of the therapeutic
implant, and is uniquely structured to pass tears and thus
administer the active therapeutic agents to the tear stream in a
fashion that is controlled by the flow of tears which thus act as
the carrier for the therapeutic agents.
[0662] FIG. 27 further shows an implant 2700' containing first and
second therapeutic agents that is a substantially cylindrical in
shape that has been inserted into the upper punctum aperture 11, to
block the flow of tears to canaliculus 10, while lower punctal plug
2700 passes the tears to canaliculus 12. Examples of suitable
implants 2700' containing two therapeutic agents may be any one of
the implants disclosed herein, or it may be an occlusive plug of
some inert biocompatible material.
[0663] The therapeutic implant 2700 and implant 2700' can be used
in any desired combination, either separately or in combination
(shown in FIG. 27). For example, implant 2700' can be positioned in
the lower canaliculus and therapeutic implant 2700 can be
positioned in the upper canaliculus. Alternatively, two of the same
therapeutic implants 2700 or 2700' can be positioned in both
canaliculi.
[0664] FIGS. 28, 29A-29D, 30A, and 30B show embodiments of various
drug delivery core elements for use in a therapeutic implant that
can be tailored to each individual patient based on their needs.
The core elements of the therapeutic implant are pie slice shaped
and can be assembled into cylindrical shaped drug cores with many
different configurations with many different therapeutic agents.
Doing this can achieve therapeutic implant configurations to
maximize individual patient management. This approach can tailor
treatment to use multiple therapeutic agents for disease
management. The approach can also tailor the dose of the
therapeutic agent based on the genetic and/or physiological
condition of the patient.
[0665] FIG. 28 shows various core elements, or drug cores, that are
combinable into a, for example, cylindrical shaped drug core
according to embodiments of the present invention. The drug core
need not be cylindrical, but a cylindrical drug core is preferred
for ease of manufacture. Drug core 2810 is a blank core element
that does not contain a therapeutic agent, drug core 2820 contains
a therapeutic agent 2825 with a concentration X, drug core 2830
contains a therapeutic agent 2835 with a concentration Y, and drug
core 2840 contains a therapeutic agent 2845 with a concentration Z.
The cores and the therapeutic agents may be any of the cores and
therapeutic agents disclosed herein. While the drug cores are shown
as pie slice shaped (sectors), the drug cores are not limited to
any particular shape. Since the drug cores 2810, 2820, 2830, and
2840, or any combination thereof, together can form a right
cylindrical shape, (for example, see FIGS. 29A-D) each drug core in
this instance is a right prismatic shape with the particular
cross-section, for example, a sector cross-section. The drug cores
may have many different combinable shapes, for example square,
rectangular, oval, jig saw puzzle piece, to name a few.
[0666] Each individual drug core comprises a matrix that contains
the therapeutic agent, which can be present as a solid solution, or
can be present as inclusions. Inclusions will often comprise a
concentrated form of the therapeutic agent, for example a
crystalline form of the therapeutic agent, and the therapeutic
agent may over time dissolve into matrix of the drug core. A
certain concentration of the agent can be dissolved in the matrix
in equilibrium with the inclusions of the agent. The concentration
of dissolved agent can be a saturation concentration. The matrix
can comprise a silicone matrix, or a polyurethane matrix, or the
like. In many embodiments, the non-homogenous mixture comprises a
silicone matrix portion that is saturated with the therapeutic
agent and an inclusions portion comprising inclusions of the
therapeutic agent, such that the non-homogenous mixture comprises a
multiphase nonhomogenous mixture. The first matrix may differ from
the second matrix, including, for example, an exposed surface area,
a surfactant, a cross-linking, an additive, and/or matrix materials
including formulation and/or solubility. In some embodiments,
inclusions comprise droplets of an oil of the therapeutic agent,
for example latanoprost oil. In some embodiments, inclusions may
comprise particles of the therapeutic agent, for example solid
bimatoprost particles in crystalline form. In many embodiments,
matrix encapsulates inclusions, and inclusions may comprise
microparticles have dimensions from about 0.1 .mu.m to about 100
.mu.m, or about 200 .mu.m. The encapsulated inclusions dissolve
into the surrounding solid matrix, for example silicone, that
encapsulates the micro particles such the matrix is substantially
saturated with the therapeutic agent while the therapeutic agent is
released from the core.
[0667] FIGS. 29A-29D show different embodiments of a cylindrical
shaped drug core using the core elements of FIG. 28 surrounded by a
sheath body 2920. Sheath body 2920 is can be substantially
impermeable to the therapeutic agents, so that the therapeutic
agents are often released from an exposed surface on an end of the
cylindrical shaped drug core that is not covered with sheath body
2920. In some embodiments, the sheath body may be omitted and the
cylindrical shaped drug core be place directly into the implant,
such as placement in an aperture of a punctal plug. While only four
embodiments are shown for the cylindrical shaped drug core, any
suitable drug cores and therapeutic agents may be used.
[0668] FIG. 29A shows one embodiment of a cylindrical shaped drug
core 2900 assembled using two core elements 2810 (blank cores), one
core element 2820 and one core element 2830. The cylindrical shaped
drug core 2900 is then able to deliver therapeutic agent 2825 with
a concentration X and therapeutic agent 2835 with a concentration
Y.
[0669] FIG. 29B shows one embodiment of a cylindrical shaped drug
core 2905 assembled using one core element 2810 (blank core), one
core element 2820, one core element 2830 and one core element 2840.
The cylindrical shaped drug core 2905 is then able to deliver
therapeutic agent 2825 with a concentration X, therapeutic agent
2935 with a concentration Y and therapeutic agent 2845 with a
concentration Z.
[0670] FIG. 29C shows one embodiment of a cylindrical shaped drug
core 2910 assembled using two core elements 2810 (blank core) and
two core elements 2840. The cylindrical shaped drug core 2910 is
then able to deliver two doses therapeutic agent 2845 with a
concentration Z.
[0671] FIG. 29D shows one embodiment of a cylindrical shaped drug
core 2915 assembled using four core elements 2840. The cylindrical
shaped drug core 2915 is then able to deliver four doses
therapeutic agent 2845 with a concentration Z.
[0672] FIGS. 30A and 30B show other embodiments of a cylindrical
shaped drug core assembled from core elements of different shapes.
FIG. 30A shows a cylindrical shaped drug core 3000 made from two
core elements 3010, 3015 that are semicircular in shape surrounded
by a sheath body 3020. FIG. 30B shows a cylindrical shaped drug
core 3030 made from three core elements 3040, 3045 and 3050
surrounded by sheath body 3020. While embodiments may include a
plurality of core elements of substantially even sizes as shown,
other embodiments may include core elements of two or more
differing sizes. For example, a semicircular core element 3010 may
be combined with two 1/4 circular core elements 2830 and 2840. A
wide variety of different sizes and uneven shapes may also be
combined with a variety of geometries, with or without sheath body
material (or other material that is substantially impermeable to
one or more of the therapeutic agents) being disposed between the
adjacent drug core elements. For example, sheets of drug core
material (including matrix and an associated agent) may formed
separately and stacked or layered, and/or may be formed
sequentially by polymerizing the matrix over a substrate or
underlying drug core element sheet. The multi-layered drug core
element sheets could then be cut across the layers to a desired
drug core length and/or width. An end and/or side of the sheet
could be exposed in the implanted device, with the exposed end or
side of each layered drug core element having a surface area
dependent on a thickness of the associated drug core layer or
sheet.
[0673] FIG. 31 shows a sectional view of a sustained release
implant 3100 having a first drug core 3110 with a first therapeutic
agent 3160 and a second drug core 3115 with a second therapeutic
agent 3165 to treat an eye, the first and second drug cores being
in a stacked configuration, according to an embodiment of the
present invention.
[0674] FIG. 31 shows a cross sectional view of a sustained release
implant 3100 having two therapeutic agents to treat an eye 2,
according to embodiments of the present invention. Implant 3100 has
a proximal end 3112 in which the therapeutic agents are released
and a distal end 3114. Implant 3100 includes two drug cores 3110,
3115. First drug core 3110 is a cylindrical shaped structure that
includes a first therapeutic agent, and second drug core 3115 is a
cylindrical shaped structure that includes a second therapeutic
agent. The first drug core 3110 and the second drug core 3115 are
assembled in a stacked configuration, as shown in the figures, with
the first drug core 3110 being positioned near the proximal end
3112. First drug core 3110 comprises a first matrix 3170 that
contains first inclusions 3160 of the first therapeutic agent, and
second drug core 3115 comprises a second matrix 3175 that contains
second inclusions 3165 of the second therapeutic agent. First and
second inclusions 3160, 3165 will often comprise a concentrated
form of the first and second therapeutic agents, for example a
liquid or solid form of the therapeutic agents, and the therapeutic
agents may over time dissolve into first matrix 3170 of first drug
core 3110 and second matrix 3175 of second drug core 3115. First
and second matrixes 3170, 3175 can comprise a silicone matrix or
the like, and the mixture of therapeutic agents within matrixes can
be non-homogeneous. In many embodiments, the non-homogenous mixture
comprises a silicone matrix portion that is saturated with the
therapeutic agents and an inclusions portion comprising inclusions
of the therapeutic agents, such that the non-homogenous mixture
comprises a multiphase non-homogenous mixture. The first matrix may
differ from the second matrix, including, for example, an exposed
surface area, a surfactant, a cross-linking, an additive, and/or
matrix materials including formulation and/or solubility. In some
embodiments, first and second inclusions 3160, 3165 comprise
droplets of an oil of the therapeutic agent, for example
latanoprost oil. In some embodiments first and second inclusions
3160, 3165 may comprise particles of the therapeutic agents, for
example solid bimatoprost particles. In many embodiments, first
matrix 3170 contains first inclusions 3160 and second matrix 3175
contains second inclusions 3165. First and second inclusions 3160,
3165 may comprise microparticles having dimensions from about 0.1
.mu.m to about 100 .mu.M, or about 200 .mu.m. The contained
inclusions at least partially dissolve into the surrounding solid
matrix, for example silicone, that contain the micro particles such
that first and second matrixes 3170, 3175 are substantially
saturated with the therapeutic agent while the therapeutic agent is
released from the core.
[0675] First and second drug cores 3110, 3115 are surrounded by a
sheath body 3120, except at an, exposed surface where the
therapeutic agents are released, in this case at the proximal end
3112. Sheath body 3120 is substantially impermeable to the
therapeutic agents, so that the therapeutic agents are released
from the exposed surface on the open end of first and second drug
cores 3110, 3115 that are not covered with sheath body 3120. In
some embodiments, the sheath body is similar to sheath body 3120
disclosed above, and a retention structure and an occlusive
element, such as retention element and occlusive element as
discussed above, may be connected to the sheath body. In other
embodiments, the implant may be incorporated into a different
structure, such as a punctal plug (see FIG. 32).
[0676] FIG. 32 schematically illustrates one embodiment of a
therapeutic implant 3200 having a punctal plug and a sustained
release implant having first and second stacked drug cores with
first and second therapeutic agents. In the embodiment shown, the
sustained release implant is sustained release implant 3100 having
a proximal first drug core 3110 with first inclusions 3160 of a
first therapeutic agent and a distal second drug core 3115 with
second inclusions 3165 of a second therapeutic agent. When the
therapeutic implant 3200 is in place, the first therapeutic agent
is deployed from the proximal first drug core at the exposed or
proximal end and into the tears of the lacrimal lake where the
first therapeutic agent mixes, as eye drops do, with the tears and
penetrates the eye to have the intended pharmacological effect.
Subsequent to that, the second therapeutic agent is deployed from
the distal second drug core, through the first drug core to the
exposed or proximal end and into the tears of the lacrimal lake
where the second therapeutic agent mixes, as eye drops do, with the
tears and penetrates the eye to have the intended pharmacological
effect. The size of the aperture 2140 is selected to hold the
sustained release implant 3100 in place during treatment. In some
embodiments, the sheath body 3120 of the implant 3100 may be
omitted and the first and second drug cores 3110, 3115 may be
inserted directly into the aperture 2140 of the punctal plug 2100.
Optionally, a head 2115 may be used, such as shown in FIG. 22, that
is permeable to the first and second therapeutic agents, wherein
first and second therapeutic agents are deployed from first and
second drug cores 3110, 3115 through permeable head 3115.
[0677] In other embodiments, referring to FIG. 33, the multiple
drug delivery therapeutic implants 3310 may be implanted in other
portions of a body 3300, not just in the punctum, to treat a body
condition, as shown in FIG. 33. The therapeutic implants 3310 are
sustained release implants with at least one drug core containing
first and second therapeutic agents that is used to delivery
multiple drugs to treat other conditions or diseases other than the
eye. Therapeutic implant 3310 may include therapeutic implants
having two or more therapeutic agents released from an exposed
surface of core(s), such as the therapeutic implants described
above. The therapeutic implant may be implanted by known means.
[0678] The first and second therapeutic agents are released at
therapeutic levels to provide a desired treatment response when the
implants are implanted in a body. The first and second therapeutic
agents are preferably released at therapeutic levels over a
sustained period. In some embodiments the drug cores may release
first and second therapeutic agents at an effective rate for the
period of 1 week to 5 years, more particularly in the range of 3-24
months. In some embodiments it may be desirable for the drugs cores
to have similar release rates for the first and second therapeutic
agents. In other embodiments, it may be desirable for the drug
cores to have different release rates for the first and second
therapeutic agents, depending on the therapeutic agents used. In
some embodiments, the therapeutic level is less than a dose
administered quantity or less or 5-10% of the dose administered
quantity, typically being less than 10% and often being 5% or less
than the dose administered quantity each day for an extended period
of days. The dose administered quantity may be the oral dose or may
be an injectable dose.
[0679] In use, the therapeutic implant 3310 is implanted in the
body 3300, where a body fluid may contact the exposed surface of
the drug core(s), releasing the first and second therapeutic
agents. Depending on the implant location, any body fluid proximate
the therapeutic implant, such as blood, may contact the exposed
surface, releasing the first and second therapeutic agents from the
implant. The therapeutic implant location may include body
locations for local drug delivery to joints, such as proximate the
shoulder, knee, elbow, or a trauma location 3315, or a trauma
location 3320, other locations, such as the abdomen, for general
drug delivery. The therapeutic implant 3310 may include one or more
retention elements known in the art to retain the therapeutic
implant 3310 near a body location, such as the body locations
listed above.
[0680] In one embodiment, a therapeutic implant may be used in
oncology, where chemotherapy involves use of a cocktail that is
dependent upon the primary tumor type. Use of a local therapeutic
implant drug delivery could allow an extra benefit of treating a
tumor site post surgically, and minimizing the collateral damage to
the rest of the body. An example would be lumpectomy for breast
tumor or surgical treatment of prostate cancer, where the
therapeutic implant would be implanted near the cancer site. In
fact any solid tumor would be a target, with the therapeutic
implant being implanted near the tumor.
[0681] In another embodiment, a therapeutic implant may be used for
the delivery of multiple drugs, sometimes called cocktails, for the
treatment of HIV. In this instance, the therapeutic implant would
be treating a systemic disease. One example of the multiple drugs
in the therapeutic implant is a protease inhibitor and a nucleic
acid target.
[0682] Some treatments are contraindicated due to other disease
states. An example is diabetics where surgeries including
amputation are often required in patients where circulation and
wound healing is impaired. The use of steroids could not be used
systemically in these patients, but could be used locally. In this
embodiment, the therapeutic implant is positioned post surgically
in the body at the appropriate location for local delivery of a
steroid and another drug, such as an antiinflammatory or
anti-infective drug. In some embodiments, the steroid may be
released at therapeutic levels for 8 or more weeks and the
anti-inflammatory may be released at therapeutic levels for 2-4
weeks.
[0683] In joints, non-steroidal anti-inflammatory drugs (NSAIDs)
may be used for the treatment of such things as osteoarthritis and
rheumatoid arthritis. Delivery of NSAIDs locally would reduce the
risk associated with systemic cox II inhibitors, such as
gastrointestinal problems (problems in the stomach or intestine)
the may include stomach ulcers or bleeding, and possibly life
threatening perforations (rips or holes) in the wall of the stomach
or intestine. In this embodiment, the therapeutic implant is
positioned near the joint to deliver NSAIDs locally and may also
include the delivery of a nutritional supplement, like glucosamine,
and perhaps get a positive physiological response in local
tissue.
[0684] In another embodiment, a therapeutic implant may be used for
localized delivery of multiple drugs to a trauma site, such as
delivering an analgesic and an antiinfectives.
[0685] FIGS. 34 and 35 show anatomical tissue structures of an eye
2 suitable for treatment with implants, according to an embodiment
of the present invention. Eye 2 includes a cornea 4 and an iris 6.
A sclera 8 surrounds cornea 4 and iris 6 and appears white. A
conjunctival layer 9 is substantially transparent and disposed over
sclera 8. A crystalline lens 5 is located within the eye. A retina
7 is located near the back of eye 2 and is generally sensitive to
light. Retina 7 includes a fovea 7F that provides high visual
acuity and color vision. Cornea 4 and lens 5 refract light to form
an image on fovea 7F and retina 7. The optical power of cornea 4
and lens 5 contribute to the formation of images on fovea 7F and
retina 7. The relative locations of cornea 4, lens 5 and fovea 7F
are also important to image quality. For example, if the axial
length of eye 2 from cornea 4 to retina 7F is large, eye 2 can be
myopic. Also, during accommodation, lens 5 moves toward cornea 4 to
provide good near vision of objects proximal to the eye.
[0686] The anatomical tissue structures shown in FIG. 34 also
include the lacrimal system, which includes an upper canaliculus 10
and a lower canaliculus 12, collectively the canaliculae, and a
naso-lacrimal duct or sac 14. The upper canaliculus 10 and lower
canaliculus 12 extend from the lacrimal sac 14 and terminate in an
upper punctum 11 and a lower punctum 13, respectively, that also
referred to as punctal apertures. The punctal apertures are
situated on a slight elevation at the medial end of the lid margin
at the junction 15 of the ciliary and lacrimal portions near the
medial canthus 17. The punctal apertures are round or slightly
ovoid openings surrounded by a connective ring of tissue. Each
canaliculus extends from punctal openings 11, 13, and comprises a
vertical position 10v, 12v of the respective canaliculus before
turning horizontally to join its other canaliculus at the entrance
of a lacrimal sac 14. The canaliculae are tubular and lined by
stratified squamous epithelium surrounded by elastic tissue which
permits the canaliculus to be dilated. The upper and lower
canaliculi may each comprise an ampulla 10a, 12a, or small
dilation, in the respective canaliculus.
Manufacture of Implants
[0687] FIG. 6A shows a method 600 of manufacturing an implant,
according to embodiments of the present invention. A sub method 610
manufactures a punctal plug. A sub method 650 manufactures a drug
core insert, for example as described above. A sub method 690
assembles the components into an integrated drug delivery
system.
[0688] FIG. 6B shows a method 620 of manufacturing a hydrogel rod
for the punctal plug in accordance with method 600 of FIG. 6A. In
some embodiments, method 620 comprises a sub method, or sub-step,
of method 610. A step 622 combines 40% by weight hydrogel with an
organic solvent. In some embodiments, the percentage of hydrogel
comprises a range from about 5% to about 50% hydrogel, for example
from about 20% to about 40% hydrogel. A step 624 mixes the hydrogel
with the solvent. In some embodiments, the hydrogel may dissolve in
the organic solvent. A step 626 injects the hydrogel into a
silicone tube. In many embodiments, the silicone tube is permeable
to the organic solvent. The silicone tube comprises a mold to form
the hydrogel. A step 628 cures the hydrogel. At least one of a heat
or a pressure, in many embodiments both, can be used to drive off
the solvent, for example through the permeable mold, to cure the
hydrogel. A step 629 cuts the cured hydrogel to a desired length.
The curing can be optimized with empirical process/validation
studies with an adequate a sample size, for example 10 sample of
cured hydrogels, to determine material variability and/or process
variability over time. Process variable that can be optimized
include time, pressure and temperature of curing. Tolerance
analysis associated with the process can also be performed.
[0689] FIG. 6C shows a method 630 of molding a silicone plug body
637 in accordance with method 600 of FIG. 6A. A step 632 winds a
filament comprising a solid material, for example a coil 632C, and
heat sets the filament. A step 634 places the filament comprising
heat set coil 632C in a mold. A step 636 molds plug body 637 with
coil 632C embedded therein. The plug body may comprise sleeves,
tubes, retention structures and/or at least one chamber as
described above. The filament may comprise at least one of a heat
activated material, Nitinol, a shape memory material, a polymer,
polypropylene, polyester, nylon, natural fibers, stainless steel,
polymethylmethacrylate or polyimide. In some embodiments, the
filament may comprise an absorbable thermoplastic polymer, for
example at least one of polylactic acid (PLA), poly glycolic acid
(PGA) or poly-lactic-co-glycolic acid (PLGA). The heat setting of
the filament can be optimized by appropriately controlling the time
and/or temperature of the heat filament based on empirical data
from a sample of heat set filaments, for example 10 filaments. The
molding of the plug at step 636 can be optimized in several ways,
such as appropriate time and temperature, hard tooling of the mold,
a multiple cavity mold, and mold equipment parameters. In some
embodiments, a filament for removal of the drug core insert, as
described above, can be molded with the plug body such that the
filament is embedded in the plug body and positioned near the
channel that receives the drug core insert.
[0690] FIG. 6D shows a method 640 of assembling the punctal plug
components in accordance with method 600 of in FIG. 6A. Step 630
molds the punctal plug body 637 with a coil 632C. Step 620 molds a
hydrogel rod. A step 642 inserts the hydrogel rod component into a
channel of the plug body component. A step 644 extends windings of
coil 632C over the hydrogel rod. A step 648 dip coats the hydrogel
rod and plug body. A step 646 may prepare a hydrogel coating
solution 646 comprising for example a 5% solution of hydrogel by
weight. A needle 648N may be placed in a channel of the plug body
to hold the body while the hydrogel rod and plug body are dipped in
the solution.
[0691] FIG. 6E shows a method 650 of manufacturing a drug core
insert, in accordance with method 600 of in FIG. 6A. A step 661
prepares a syringe assembly to inject a drug matrix into a
polyimide tubing. A step 662 prepares a polyimide tubing for
injection. A step 670 prepares a drug core matrix for injection
into the tubing. A step 672 injects the drug core matrix into the
polyimide tubing. A step 680 cures the matrix inside the polyimide
tubing. A step 682 cuts the polyimide tubing and cured matrix to a
length and applies an adhesive.
[0692] Step 661 can use known commercially available syringes in
the syringe assembly. The syringe assembly may comprise a syringe
tube and cartridge assembly. The syringe tube and cartridge
assembly may comprise a tube attached to a modified needle tip that
attaches that attaches to a syringe. The syringe can be connected
to a syringe pump or other mechanism to pressurize the tube. The
syringe assembly can be used for injection of the drug core mixture
and/or material into the polyimide tubing. In some embodiments,
multiple syringes can be used, for example with the manufacture of
drug inserts that comprise two or more drug cores. In some
embodiments, the syringe assembly may comprise a manifold with two
or more injection pots that can be used to with separate syringes
in which each syringe includes a different drug core mixture.
[0693] Step 662 can prepare the polyimide tubing for injection by
attaching a 15 cm length of polyimide tubing to a luer. The luer
can be connected to the syringe for injection of the drug core
mixture and/or material. In some embodiments, the tubing connected
to the syringe may comprise PMMA and/or PET. In many embodiments
the tubing comprises a material that inhibits release of the
therapeutic agent from the drug core through the tubing, for
example a material that is substantially impermeable to the flow of
the therapeutic agent through the tubing, such that the flow of
therapeutic agent is directed toward the exposed end of the drug
core. In some embodiments, for example drug core inserts comprising
two or more concentric drug cores, the tubing may comprise
concentric tubes, for example concentric polyimide tubes, with an
outer tube arranged to receive and outer drug core mixture, and an
inner tube arranged to receive an inner drug core mixture. With an
annular drug core as described above, concentric tubes may be used
to form the annular drug core, with an inner tube that can be
removed after the drug core matrix material has solidified.
[0694] In some embodiments, a filament for removal of the drug core
insert can be embedded in the drug core. The filament may be run
through the sheath, for example tubing, and the mixture injected
into the tubing. The matrix material is then cured with the
filament embedded in the matrix.
[0695] Step 670 can prepare a drug core mixture comprising a
therapeutic agent with a matrix material, for example silicone. In
some embodiments, the therapeutic agent may comprise at least one
of latanoprost, bimatoprost or travoprost Embodiments can use
silicones that comprise dimethylsiloxane, for example Med-4011,
Med-6385 and Med-6380 each of which is commercially available from
NuSil of Lafayette, Calif. In some embodiments, two or more drug
core mixtures are prepared, each for injection for a separate drug
core, for example two mixtures one for an inner drug core and one
for an outer drug core.
[0696] In a specific embodiment, step 670 can prepare a drug core
mixture comprising inclusions of latanoprost oil in silicone. The
therapeutic agent and drug core matrix material can be prepared
prior to mixing the therapeutic agent with the drug core matrix
material.
Preparation of Therapeutic Agent:
[0697] Latanoprost oil can be provided as a 1% solution in methyl
acetate. An appropriate amount of the 1% solution can be placed in
a dish. A stream of dry nitrogen can be used to evaporate the
solution until only the latanoprost remains. The dish with
latanoprost oil can be placed under vacuum for 30 minutes. In some
embodiments, for example those which use bimatoprost available as
crystals as the therapeutic agent, the evaporation and vacuum may
not be used to prepare the therapeutic agent.
[0698] In some embodiments with solid therapeutic agent, for
example bimatoprost crystals, the therapeutic agent can be ground
and passed through a sieve, prior to mixing with the matrix
material. In some embodiments, the sieve may comprise a 120 sieve
(125 .mu.m) and/or a 170 sieve (90 .mu.m). Work in relation to
embodiments of the present invention indicates that a sieve may
remove a very small fraction of therapeutic agent and that many
embodiments will work with inclusions of therapeutic agent having a
size greater than the optional sieve. In many embodiments, the
release rate is independent of the size and/or distribution of size
of the inclusions, and the release rate can be independent of
particle size for particles from about 0.1 .mu.m to about 100
.mu.m. In some embodiments, the size and/or distribution of sizes
of the particles and/or inclusions can be characterized with at
least one of a sieve, light scatter measurements of the core, light
microscopy of the core, scanning electron microscopy of the core or
transmission electron microscopy of sections of the core. A sieve
can generally be used to create desirable particle sizes and/or
exclude undesirable particle sizes before mixing with the matrix.
The exemplary sieve comprises a fine mesh that passes only the
desired size particles or smaller, thereby limiting the therapeutic
agent to finer drug particles. This can be used to produce a more
homogenous drug core and/or drug particle size that is easier to
mix with the silicone matrix than one with excessively large
particles, although significant variations among particle sizes may
remain. A variety of sieves may be used. For example, a Sieve #120
can be used so that the largest particle diameter passed is about
0.0049 inches. Sieve #170 may pass particles of 0.0035 inch
diameter or smaller. A Sieve #70 will allow a particle size of
0.0083 inch diameter to pass through. Sieves may optionally be used
in series.
Preparation of Silicone:
[0699] Silicone, for example NuSil 6385, can be obtained from the
manufacturer in a sealed container. An appropriate amount of
silicone can be weighed based on the lot size of the build.
Combine Therapeutic Agent with Silicone:
[0700] The therapeutic agent, for example latanoprost, can be
combined with silicone, based on the intended and/or measured
percentage of therapeutic agent in the drug core matrix. The
percent of latanoprost to silicone can be determined by the total
weight of the drug matrix. The therapeutic agent, for example
latanoprost, is incorporated into the silicone by weighing out the
appropriate amount of the components. The following formula can be
used to determine the percentage of therapeutic agent in the drug
core matrix:
Percent Drug=(weight of drug)/(weight of drug+weight of
silicone).times.100
For the specific example of latanoprost in silicone the percentage
of latanoprost is silicone is given by:
(20 mg of latanoprost)/(20 mg of latanoprost+80 mg of
silicone).times.100=20%.
[0701] The therapeutic agent, for example latanoprost is combined
and mixed with the silicone using known methods and apparatus for
mixing silicones. In some embodiments, the therapeutic agent
comprising latanoprost oil may form a micro emulsion comprising
inclusions that may scatter light and appear white.
[0702] When a therapeutic agent such as latanoprost, which is in a
liquid physical state at about room temperature (22.degree. C.),
and thus is also in a liquid physical state at human body
temperature (37.degree. C.), is used, the agent and the matrix
material can be mixed by techniques that bring about a high degree
of dispersion of the liquid latanoprost droplets in the matrix
material in which it can be substantially insoluble. Mixing
techniques should provide for a dispersion of the droplet within
the matrix material, such that when curing takes place, the liquid
therapeutic agent is present as relatively small, relatively
homogeneously dispersed discrete droplets within the matrix of
solid silicone material. For example, mixing can include
sonication, i.e., the use of ultrasonic frequencies, such as are
generated by an ultrasonic probe. The probe can be put in contact
with the mixture of matrix material and liquid therapeutic agent to
prepare an intimate mixture of the two substantially immiscible
materials. See, for instance, Example 12 below.
[0703] Step 672 can inject the mixture of therapeutic agent and
silicone into the tubing. A syringe, for example a 1 ml syringe,
can be connected to the syringe tube and cartridge assembly. A drop
of catalyst appropriate for the silicone, for example MED-6385
curing agent, can be placed into the syringe and the syringe is
then filled with the uncured mixture of silicone and therapeutic
agent, or silicone drug matrix. The mixture, i.e., mixture of the
uncured silicone and agent still liquid enough to flow or pump, can
be chilled to subambient temperatures. For example, the mixture can
be chilled to temperatures of less than 20.degree. C. For example,
the mixtures can be chilled to 0.degree. C., or to -25.degree. C.
The polyimide tube is injected with the drug/matrix mixture until
the tube is filled. The tube and associated apparatus can also be
chilled to maintain the subambient temperature of the mixture
throughout the process of filling or injecting the sheath with the
mixture. In various embodiments, the polyimide tube, or sheath, is
filled with the drug matrix mixture under pressure, for example
through use of a high pressure pump. For instance, the drug/matrix
mixture, such as can be obtained in mixtures of latanoprost with
MED-6385 Part A to which amounts of catalyst Part B have been
added, can be pumped into the tube under at least about 40 psi
pressure. The tube can be filled at any suitable rate, but
preferably, at rates of less than about 0.5 linear cm/sec. It is
believed by the inventors herein that filling the tube relatively
rapidly under a relatively high head of pressure can reduce the
degree of phase separation of the substantially immiscible
latanoprost oil and silicone monomer material, such that upon
polymerization ("curing") to provide the final silicone polymeric
product, the latanoprost droplets are finely dispersed in the solid
matrix in which they are only slightly soluble.
[0704] Curing takes place in the presence of the catalyst ("Part
B") of the NuSil MED-6385, and can be carried out at temperatures
of at least about 40.degree. C., at relative humidity (RH) of at
least about 80%, or both. Curing can be initiated directly after
filling the tube and clamping the ends of the filled tube to
prevent the formation of voids and loss of the precursor material
from the tube ends.
[0705] After curing, which can be complete in about 16-24 hours at
40.degree. C. and 80% RH, the clamps can be removed from the ends
of the tubing, as the silicone is fully set up. The tubing can then
be cut into sections of suitable length for use as drug inserts,
for example, lengths of about 1 mm.
[0706] When the extrusion is carried out at subambient
temperatures, small and more uniform inclusions of the agent can
result. For example, when the agent is latanoprost, a liquid at
room temperature, extrusion at -5.degree. C. provides significantly
smaller and more uniform inclusion droplets. In an example, cold
extrusion yielded a drug core comprising a silicone matrix with
latanoprost droplets of average diameter of 6 .mu.m, with a
standard deviation of diameter of 2 .mu.m. In comparison, an
extrusion carried out at room temperature yielded a drug core
comprising a silicone matrix with latanoprost droplets of average
diameter of 19 .mu.m, with a standard deviation of droplet diameter
of 19 .mu.m. It is apparent that the cold extrusion technique
provides smaller, more uniform inclusions than does extrusion at
room temperature. This in turn results in a more uniform
concentration of drug throughout the core, or the insert containing
the core, which is desirable for medical applications as uniformity
of dose is improved.
[0707] The open end of the polyimide tube can be closed off until
the silicone begins to solidify. In some embodiments with two or
more drug cores, two or more separate mixtures can each be
separately injected from two or more syringes.
[0708] Step 680 cures the drug core matrix comprising the mixture
silicone and therapeutic agent. The silicone is allowed to cure,
for example for 12 hours. The amount of time and temperature of the
cure may be controlled, and empirical data can be generated to
determine ideal times and temperatures of the curing. Work in
relation with embodiments of the present invention indicates that
the silicone material and drug loading of the core, for example a
percentage of therapeutic agent in the core, may effect the optimal
time and temperature of the cure. In some embodiments, empirical
data can be generated for each silicone matrix material and
percentage of each therapeutic agent to determine an optimal amount
of time to cure the injected mixture. In some embodiments with two
or drug cores in a drug core insert, two or more mixtures can be
cured together to cure the drug cores of the insert.
[0709] Table 1 shows drug insert silicones that may be used and
associated cure properties, according to embodiments of the present
invention. The drug core insert matrix material can include a base
polymer comprising dimethyl siloxane, such as MED-4011, MED 6385
and MED 6380, each of which is commercially available from the
NuSil company. The base polymer can be cured with a cure system
such as a platinum-vinyl hydride cure system and/or a tin-alkoxy
cure system, both commercially available from NuSil. In many
embodiments, the cure system may comprise a known cure system
commercially available for a known material, for example a known
platinum vinyl hydride cure system with known MED-4011. In a
specific embodiment shown in Table 1, 90 parts of MED-4011 can be
combined with 10 parts of the crosslinker, such that the
crosslinker comprises 10% of the mixture. A mixture with MED-6385
may comprise 2.5% of the crosslinker, and mixtures of MED-6380 may
comprise 2.5% or 5% of the crosslinker.
TABLE-US-00001 TABLE 1 Drug Insert Silicone Selections Crosslinker
Curing Material Base Polymer Cure System Percent Properties MED-
Dimethyl Platinum 10% Curing inhibited 4011 Siloxane vinyl hydride
at high Silica filler system concentrations material of latanoprost
MED- Dimethyl Tin-Alkoxy 2.5% Very slight 6385 siloxane inhibition
of Diatomaceous curing at high earth filler concentrations material
of latanoprost MED- Dimethyl Tin-Alkoxy 2.5% to 5% Very slight 6380
siloxane inhibition of without curing at high filler material
concentrations of latanoprost
[0710] Work in relation with embodiments of the present invention
suggests that the cure system and type of silicone material can
effect the curing properties of the solid drug core insert, and may
potentially effect the yield of therapeutic agent from the drug
core matrix material. In specific embodiments, curing of MED-4011
with the platinum vinyl hydride system can be inhibited with high
concentrations of latanoprost, for example over 20% latanoprost,
such that a solid drug core may not be formed. In specific
embodiments, curing of MED-6385 and/or MED 6380 with the tin alkoxy
system can be slightly inhibited with high concentrations, e.g.
20%, of latanoprost. This slight inhibition of curing can be
compensated by increasing the time and/or temperature of the curing
process. For example, embodiments of the present invention can make
drug cores comprising 40% latanoprost and 60% MED-6385 with the tin
alkoxy system using appropriate cure times and temperatures.
Similar results can be obtained with the MED-6380 system the
tin-alkoxy system and an appropriate curing time and/or
temperature. In many embodiments, the solid drug core forms so as
to form a solid structure, for example a solid cylinder, within the
drug core that corresponds to the dimensions of the tube. Even with
the excellent results for the tin alkoxy cure system, work in
relation with embodiments of the present invention suggests that
there may be an upper limit, for example above 50% latanoprost, at
which the tin-alkoxy cure system may not produce a solid drug core.
In many embodiments, the therapeutic agent comprises the
prostaglandin analogue, for example latanoprost, in the drug solid
drug core may be at least about 5%, for example a range from about
5% to 50%, and can be from about 20% to about 40% by weight of the
drug core. In specific embodiments with moderate to high loading of
the therapeutic agent in the drug core, the drug core may comprise
from about 25% to about 50% of the therapeutic agent in the drug
core, for example 50% latanoprost oil in the drug core and/or
matrix material.
[0711] In some embodiments, the therapeutic agent may comprise a
functional group that can, at least potentially, react with the
cure system. In some embodiments, the therapeutic agent may
comprise a prostaglandin analogue such as latanoprost, bimatoprost
or travoprost, each of which may comprise an unsaturated
carbon-carbon double bond that can potentially react with the
platinum vinyl hydride cure system. These unsaturated carbon-carbon
double bonds can be similar to the vinyl group in the platinum cure
vinyl hydride system, and can potentially react with the vinyl
hydride cure system via a hydrosilation reaction. Latanoprost
comprise an unsaturated carbon-carbon double bond in one of the
side chains. Bimatoprost and travoprost each comprise two
unsaturated carbon-carbon double bonds, one in each side chain.
Work in relation with embodiments of the present invention indicate
that the hydrosilation reaction of the unsaturated double bond in
the prostaglandin analogues with in the platinum vinyl hydride cure
system does not significantly reduce the quantity of prostaglandin
analogue available for release from the drug core.
[0712] In some embodiments, the therapeutic agent may comprise a
prostaglandin analogue such as latanoprost, bimatoprost or
travoprost, each of which may comprise hydroxyl groups that can
potentially react with the tin alkoxy cure system. These hydroxyl
groups can potentially react with the alkoxy groups via an alkoxy
condensation reaction. Bimatoprost, latanoprost and travoprost each
comprise a molecule with three hydroxyl groups that can potentially
react via the alkoxy condensation reaction. Work in relation with
embodiments of the present invention indicate that the alkoxy
condensation reaction of the hydroxyl groups in the prostaglandin
analogues with in the tin alkoxy cure system does not significantly
reduce the quantity of prostaglandin analogue available for release
from the drug core. Work in relation to embodiments of the present
invention indicates that a negligible amount of therapeutic agent
is consumed by solidification or otherwise not available, as
extraction data of the therapeutic agent for solid cores shows that
at least 95%, for example 97% or more, of therapeutic agent can be
extracted from the drug core.
[0713] In some embodiments, the silicone material may comprise an
inert filler to add rigidity to the cured matrix. Work in relation
with embodiments of the present invention suggests that the filler
material may increase the rate of release of the therapeutic agent.
The MED-4011 and MED-6385 materials are commercially available with
the filler material. The MED-4011 material may comprise an inert
silica filler material to add rigidity to the cured silicone
matrix. The MED-4385 may comprise inert diatomaceous earth filler
material to add rigidity to the cured silicone matrix.
[0714] The inert filler material can increase the concentration of
drug in the silicone of the component matrix as the filler material
may not substantially absorb the therapeutic agent and the inert
filler material can reduce the fraction of silicone in the material
drug core matrix. In some embodiments, MED-4385 comprises
approximately 25% diatomaceous earth filler and approximately 75%
dimethyl siloxane. In a specific embodiment, the drug core may
comprise 40% of the therapeutic agent and 60% of the material. The
60% of material, e.g. MED-4385, corresponds to 45% dimethyl
siloxane base polymer and 15% inert diatomaceous earth filler.
Assuming that very little therapeutic agent is absorbed into the
inert filler material, the 40% of therapeutic agent is contained
within the 45% of dimethyl siloxane base polymer, such that the
concentration of therapeutic agent in the base polymer is 47% or
about 50%. Consequently, the release rate of the therapeutic agent
from the exposed surface of the silicone drug core insert can be
increased slightly as the concentration of therapeutic agent in the
silicone portion of the matrix material can be elevated due to the
presence of the filler material. In some embodiments, the drug core
may comprise a matrix material without a filler material, such that
the therapeutic agent, for example latanoprost oil, comprises
approximately 50% of the material in the cured solid drug core and
may also comprise a concentration approximately 50% in the matrix
base polymer.
[0715] In many embodiments, the size and/or distribution of sizes
of the inclusions in the core can be characterized with at least
one of light scatter measurements of the core, light microscopy of
the core, scanning electron microscopy of the core or transmission
electron microscopy of sections of the core.
[0716] Step 680 cuts the polyimide tubing with the cured solid
matrix mixture to an intended length and may apply an adhesive to
one end of the cut length of tubing. In many embodiments, the
matrix material is cured so as to form a solid drug core structure,
for example a cylindrical rod that corresponds to the shape of the
tubing, such that the exposed surface of the cut solid drug core
substantially retains its shape when implanted into the patient. In
some embodiments with two or more drug cores in a drug core insert,
the two or more drug cores can be cut together, for example the
tubes and cores of concentric drug cores can be cut together.
Cut Drug Inserts to Length:
[0717] The polyimide tubing may be inserted into a fixture and cut
to a section of the specified length. In some embodiments, the cut
sections of polyimide tubing may be placed in a vacuum for 30
minutes. The cut section polyimide tubing comprising the drug core
insert can be inspected and weighed following the vacuum and the
weight may be recorded.
Close Off End of Drug Core Insert:
[0718] An adhesive can be applied to one end of the drug core
insert. The adhesive may be applied as a liquid and cured under UV
light, for example cured under UV light for five seconds. In
specific embodiments, the adhesive may comprise Loctite 4305 UV
adhesive. In many embodiments the material applied to one end of
the drug core insert comprises a material that is substantially
impermeable to the therapeutic agent such that release of the
therapeutic agent through the covered end is inhibited. This
inhibition of release from the drug core through the covered end
can result in effective and/or efficient delivery of the drug
through the exposed surface of the drug core on the opposite end,
such that the drug is selectively released to the target tissue
and/or bodily fluid, for example to the tear liquid tear film. In
some embodiments, a filament may be bonded to the end as described
above, to facilitate removal of the drug core insert from the
implant.
[0719] In some embodiments, the end can be closed by heat welding,
pinching the tube end closed, and covering the end of the tube with
a cap comprising a material that is substantially impermeable to
the therapeutic agent to inhibit release of the therapeutic agent
through the cap. In embodiments with two or more drug cores in the
drug core insert, the covered end may cover both cores, for example
cover an inner cylindrical core and an outer annular core.
[0720] In some embodiments, with flow of the drug through the drug
core, the end of the drug core may not be closed off, or the end
may be partially closed, for example with a cap having an opening
to let fluid flow though the channel in the core while the
periphery of the cap covers an annular end of the core.
[0721] In some embodiments, the exposed end opposite the closed end
can be shaped to increase surface area of the exposed end as
described above. In some embodiments, a cone with a sharp tip,
similar to a sharp pencil tip, can be inserted into the exposed
surface to indent the exposed surface with an inverted cone shape
that increases surface area. In some embodiments, the exposed end
may be crimped to decrease the surface area.
[0722] FIG. 6F shows method 690 of final assembly in accordance
with method 600 of FIG. 6A. A step 692 inserts a drug core
component into a channel in the punctal plug. A step 694 packages
the punctal plug with the drug core insert in the channel. A step
696 sterilizes the packaged plug and drug core insert. A step 698
releases the product.
[0723] Step 692 inserts the drug core into the implant, for example
a punctual plug. The drug core can be inspected prior to insertion
and may be part of the step of insertion. The inspection can
comprise visual inspection to ensure that the sleeve comprising the
cut tubing is completely filled with no voids or foreign particles
in the silicone matrix, that the silicone is flush and the same
length as the polyimide tube, that the adhesive comprising
cyanoacrylate completely covers one end of the tube, and that the
tube is the correct length. The drug insert and implant comprising
the punctual plug can be loaded into a drug insertion tool and
holding fixture. The drug insert can be loaded into the implant
bore, or channel, using the plunger on the drug insertion tool. The
drug insert insertion tool can be removed. The implant comprising
the punctum plug can be inspected to verify that the drug core
insert is fully seated in the bore, that the drug core insert is
below the surface of the punctual plug flange, and that there is no
visible damage to the implant/drug core assembly.
[0724] Step 694 packages the punctual plug with the drug core
inserted into the channel. The punctual plug may be packaged with
known packaging and methods, for example with an inner pouch, an
outer Mylar pouch, a pouch sealer, argon gas, and an inflation
needle. In specific embodiments, two completed drug delivery
systems, each comprising the punctual plug implant with drug core
insert, are placed in the inner pouch and sealed in the inner
pouch. The sealed inner pouch is placed in an outer pouch. The
outer pouch may extend about 1/4 beyond a pouch sealer element. The
number 25 gauge needle can be inserted into the pouch and under the
sealing element with the Argon flowing. The sealer element can be
clamped and the package allowed to inflate. The argon flow needle
can be removed and the sealing operation repeated. The package can
be inspected by pressing gently on the argon filled pouch to check
for leaks. If a leak is detected, the inner pouch can be removed
and repacked in a new Mylar outer pouch.
[0725] Step 696 can sterilize the packaged plug and drug core
insert with known sterilization methods, for example with
commercially available e-beam from Nutek Corporation of Hayward,
Calif.
[0726] Step 698 can release the product in accordance with final
testing and release procedures.
[0727] It should be appreciated that the specific steps illustrated
in FIGS. 6A to 6E provide a particular method of manufacturing a
plug with a drug core insert, according to some embodiments of the
present invention. Other sequences of steps may also be performed
according to alternative embodiments. For example, alternative
embodiments of the present invention may perform the steps outlined
above in a different order. Moreover, the individual steps
illustrated in FIGS. 6A to 6E may include multiple sub-steps that
may be performed in various sequences as appropriate to the
individual step. Furthermore, additional steps may be added or
removed depending on the particular applications. One of ordinary
skill in the art would recognize many variations, modifications,
and alternatives.
EXAMPLES
Example 1
Latanoprost Drug Core Elution Data
[0728] Drug cores as described above have been fabricated with
different cross sectional sizes of 0.006 inches, 0.012 inches, and
0.025 inches, and drug concentrations of 5%, 10% and 20% in a
silicone matrix. Theses drug cores can be made with a Syringe Tube
and Cartridge Assembly, Mixing Latanoprost with Silicone, and
Injecting the mixture into a polyimide tube which is cut to desired
lengths and sealed. The length of the drug cores were approximately
0.80 to 0.95 mm, which for a diameter of 0.012 inches (0.32 mm)
corresponds to total Latanoprost content in the drug cores of
approximately 3.5 .mu.g, 7 .mu.g and 14 .mu.g for concentrations of
5%, 10% and 20%, respectively.
[0729] Syringe Tube and Cartridge Assembly. 1. Take polyimide
tubing of three different diameters 0.006 inches, 0.0125 inches and
0.025 inches. 2. Cut polyimide tubing of different diameters to
.about.15 cm length. 3. Insert Polyimide tubes into a Syringe
Adapter. 4. Adhesive bond polyimide tube into luer adapter
(Loctite, low viscosity UV cure). 5. Trim end of assembly. 6. Clean
the cartridge assembly using distilled water and then with methanol
and dry it in oven at 600 C.
[0730] Mix Latanoprost with Silicone. Prepare Latanoprost.
Latanoprost is provided as a 1% solution in methylacetate. Place
the appropriate amount of solution into a dish and using a nitrogen
stream, evaporate the solution until only the Latanoprost remains.
Place the dish with the Latanoprost oil under vacuum for 30
minutes. Combine Latanoprost with silicone. Prepare three different
concentrations of Latanoprost (5%, 10% and 20%) in silicone Nusil
6385 and inject it into tubing of different diameters (0.006 in,
0.012 in and 0.025 inches) to generate 3.times.3 matrixes. The
percent of Latanoprost to silicone is determined by the total
weight of the drug matrix. Calculation: Weight of
Latanoprost/(weight of Latanoprost+weight of
silicone).times.100=percent drug.
[0731] Inject tube. 1. Insert Cartridge and Polyimide tubes
assembly into 1 ml syringe. 2. Add one drop of catalyst, (MED-6385
Curing Agent) in the syringe. 3. Force excess catalyst out of the
polyimide tube with clean air. 4. Fill syringe with silicone drug
matrix. 5, Inject tube with drug matrix until the tube is filled or
the syringe plunger becomes too difficult to push. 6. Close off the
distal end of the polyimide tube and maintain pressure until the
silicone begins to solidify. 7. Allow to cure at room temperature
for 12 hours. 8. Place under vacuum for 30 minutes. 9. Place tube
in right size trim fixture (prepared in house to hold different
size tubing) and cut drug inserts to length (0.80-0.95 mm).
[0732] Testing. Elution study (in vitro). 1. Place 10 plugs of same
size and same concentration per centrifuge tube and add 1.5 ml of
7.4 pH buffer solution to it. 2. Change the solvent with fresh 7.4
pH buffer after appropriate time. 3. Take HPLC of the elutant at
210 nm with PDA detector 2996 using Sunfire C18, 3 mm.times.10 mm
column (Waters Corporation, Milford, Mass.). Acetonitrile and water
mixture is used for gradient elution. Calibration was done in house
before and after each analysis, using in-house standards with
precisely weighed concentration of Latanoprost. 4. Calculate the
amount of drug release per day per device for different size
tubings having different concentrations of Latanoprost. 5. Plot
elution rate vs area and concentration for day 1 and day 14.
[0733] FIGS. 7A and 7B show elution data of Latanoprost at day 1
and day 14, respectively, for the three core diameters of 0.006,
0.012 and 0.025 inches and three Latanoprost concentrations of
approximately 5%, 11% and 18%. Elution rate of the Latanoprost in
nanograms (ng) per day is plotted versus percent concentration.
These data show that the rate of elution is mildly dependent on the
concentration and strongly dependent on the exposed surface area at
both time periods. At day 1, the 0.006 inch, 0.012 inch and 0.025
inch diameter cores released about 200 ng, 400 ng and 1200 ng of
Latanoprost, respectively, showing that the quantity of Latanoprost
released increases with an increased size of the exposed surface
area of the drug core. For each tube diameter, the quantity of
Latanoprost released is compared to the concentration of drug in
the drug core with a least square regression line. For the 0.006,
0.012 and 0.025 inch drug cores the slope of the regression lines
are 11.8, 7.4 and 23.4, respectively. These values indicate that a
doubling of concentration of the Latanoprost drug in the core does
not lead to a doubling of the elution rate of the Latanoprost from
the core, consistent with droplets of Latanoprost suspended in a
drug core matrix and substantial saturation of the drug core matrix
with Latanoprost dissolved therein, as described above.
[0734] At day 14, the 0.006 inch, 0.012 inch (0.32 mm) and 0.025
inch diameter cores released about 25 ng, 100 ng and 300 ng of
Latanoprost, respectively, showing that the quantity of Latanoprost
released increases with an increased size of the exposed surface
area of the drug core at extended periods of time, and that the
quantity of Latanoprost released is mildly dependent on the
concentration of therapeutic agent in the core. For each tube
diameter, the quantity of Latanoprost released is compared to the
concentration of drug in the drug core with a least square
regression line. For the 0.006, 0.012 and 0.025 inch drug cores the
slope of the regression lines are 3.0, 4.3 and 2.2, respectively.
For the 0.012 and 0.025 inch cores, these values indicate that a
doubling of concentration of the Latanoprost drug in the core does
not lead to a doubling of the elution rate of the Latanoprost from
the core, consistent with droplets of Latanoprost suspended in a
drug core matrix and substantial saturation of the drug core matrix
with Latanoprost dissolved therein, as described above. However,
for the 0.006 inch diameter core, there is an approximately first
order relationship between the quantity of initially in the core
and the amount of drug released at day 14, which can may be caused
by depletion of Latanoprost drug droplets in the core.
[0735] FIGS. 7D and 7E show dependence of the rate of elution on
exposed surface area of the drug core for the three core diameters
and the three concentrations as in FIGS. 7A and 7B Latanoprost at
day 1 and day 14, respectively, according to embodiments of the
present invention. Elution rate of the Latanoprost in nanograms
(ng) per day is plotted versus the exposed surface area of the drug
core in mm2 as determined by the diameter of the drug core. These
data show that the rate of elution is mildly dependent on the
concentration of drug in the core and strongly dependent on the
exposed surface area at both one day and a 14 days. The exposed
surface areas of the 0.006 inch, 0.012 inch and 0.025 inch diameter
cores are approximately 0.02, 0.07, and 0.32 mm2, respectively. At
day 1, the 0.02, 0.07, and 0.32 mm2, cores released about 200 ng,
400 ng and 1200 ng of Latanoprost, respectively, showing that the
quantity of Latanoprost released increases with an increased size
of the exposed surface area of the drug core. For each
concentration of therapeutic agent in the drug core, the quantity
of Latanoprost released is compared to the exposed surface area of
the drug core with a least square regression line. For the 5.1%,
11.2%, and 17.9% drug cores the slope of the regression lines are
2837.8, 3286.1 and 3411.6, respectively, with R2 coefficients of
0.9925, 0.9701 and 1, respectively. At day 14, the 0.02, 0.07, and
0.32 mm2, cores released about 25 ng, 100 ng and 300 ng of
Latanoprost, respectively showing that the quantity of Latanoprost
released increases with an increased size of the exposed surface
area of the drug core. For the 5.1%, 11.2%, and 17.9% drug cores
the slope of the regression lines are 812.19, 1060.1 and 764.35,
respectively, with R2 coefficients of 0.9904, 0.9924 and 0.9663,
respectively. These values indicate the elution rate of the
Latanoprost from the core increases linearly with the surface area
of the drug core, consistent with a drug sheath that can control
the exposed surface area, as described above. The weak dependence
of Latanoprost elution on concentration in the drug core is
consistent with droplets of Latanoprost suspended in a drug core
matrix and substantial saturation of the drug core matrix with
Latanoprost dissolved therein, as described above.
[0736] FIG. 7C shows elution data for Latanoprost from 0.32 mm
diameter, 0.95 mm long drug cores with concentrations of 5, 10 and
20% and drug weights of 3.5, 7 and 14 .mu.g, respectively,
according to embodiments of the present invention. The drug cores
were manufactured as described above. The elution rate is plotted
in ng per day from 0 to 40 days. The 14 .mu.g core shows rates of
approximately 100 ng per day from about 10 to 40 days. The 7 .mu.g
core shows comparable rates from 10 to 20 days. These data are
consistent with droplets of Latanoprost suspended in a drug core
matrix and substantial saturation of the drug core matrix with
Latanoprost dissolved therein, as described above.
[0737] Table 2 shows the expected parameters for each drug
concentration. As shown in FIG. 7C, in vitro results in a buffered
saline elution system show that the plug initially elutes
approximately 500 ng of Latanoprost per day, dropping off rapidly
within 7-14 days to approximately 100 ng/day, depending on the
initial concentration of drug.
TABLE-US-00002 TABLE 2 Drug Elution Properties Total Latanoprost
content 14 .mu.g 7 .mu.g 3.5 .mu.g In vitro elution rate See FIG.
7C See FIG. 7C See FIG. 7C Duration ~100 days ~45 days ~25 days
[0738] In many embodiments, the duration of the drug core can be
determined based on the calculated time when .about.10% of the
original amount of drug remains in drug insert, for example where
the elution rate levels out and remains substantially constant at
approximately 100 ng/day.
Example 2
Cyclosporin Drug Core Elution Data
[0739] Drug cores as described in Example 1 were made with
cyclosporin having a concentration of 21.2%. FIG. 8A shows elution
profiles of cyclosporin from drug cores into a buffer solution
without surfactant and into a buffer solution with surfactant,
according to embodiments of the present invention. The buffer
solution was made as described above. The solution with surfactant
includes 95% buffer and 5% surfactant, UP-1005 Ultra Pure Fluid
from Dow Corning, Midland Mich. Work in relation with embodiments
of the present invention indicates that in at least some instances,
surfactants may be used in in vitro to model in situ elution from
the eye as the eye can include natural surfactants, for example
Surfactant Protein D, in the tear film. The elution profile of
cyclosporin into surfactant is approximately 50 to 100 ng per day
from 30 to 60 days. Empirical data from tears of a patient
population, for example 10 patients, can be measured and used to
refine the in vitro model with appropriate amounts of surfactant.
The drug core matrix may be modified in response to the human tear
surfactant as determined with the modified in vitro model. The drug
core can be modified in many ways in response to the human tear
film surfactant, for example with an increased exposed surface area
and/or additives to increase an amount of cyclosporine drug
dissolved in the core, as described above, to increase elution from
the core to therapeutic levels, if appropriate.
Example 3
Bimatoprost Bulk Elution Data
[0740] Bulk samples of 1% Bimatoprost having a known diameter of
0.076 cm (0.76 mm) were prepared. The height of each sample was
determined from the weight and known diameter of the sample.
TABLE-US-00003 TABLE 3 Bulk Sample Size calculated Exposed Surface
Sample wt (mg) Diameter (cm) height (cm) Area (cm{circumflex over (
)}2) 14-2-10 1.9 0.076 0.42 0.109 14-2-11 1.5 0.076 0.33 0.088
14-2-12 1.9 0.076 0.42 0.109
[0741] The calculated heights ranged from 0.33 cm to 0.42 cm. The
exposed surface area on each end of each bulk sample was
approximately 0.045 cm2, providing volumes of 0.019 cm3 and 0.015
cm3 for the 0.42 and 0.33 cm samples, respectively. The exposed an
exposed surface area of samples calculated from the height and
diameter without a drug sheath was approximately 0.1 cm2. Three
formulations were evaluated: 1) silicone 4011, 1% Bimatoprost, 0%
surfactant; 2) silicone 4011, 1% Bimatoprost, approximately 11%
surfactant; and 3) silicone 4011, 1% Bimatoprost, approximately 33%
surfactant. The elution data measured for the bulk samples with
formulation 1, 2 and 3 were normalized to ng per device per day
(ng/device/day) assuming a surface area of the bulk device is 0.1
cm2 and the surface area of the clinical device is 0.00078 cm2 (0.3
mm diameter). FIG. 9A shows normalized elution profiles in ng per
device per day over 100 days for bulk sample of silicone with 1%
Bimatoprost, assuming an exposed surface diameter of 0.3 mm on the
end of the device, according to embodiments of the present
invention. The normalized elution profile is about 10 ng per day.
The data show approximately zero order release kinetics from about
ten days to about 90 days for each of the formulations. These data
are consistent with particles of Bimatoprost suspended in a drug
core matrix and substantial saturation of the drug core matrix with
Bimatoprost dissolved therein, as described above. Similar
formulations can be used with drug core sheaths and a shaped
exposed surface of the core exposed to the tear to increase the
exposed surface area as described above and deliver the drug in
therapeutic amounts over an extended period.
[0742] In some embodiments, the core can comprise a 0.76 mm
diameter core with an exposed surface diameter of 0.76 mm,
corresponding to an exposed surface area of 0.0045 cm2. The core
can be covered with a sheath to define the exposed surface of the
core as described above The normalized elution profile for such a
device, based on the bulk sample data above, is approximately 6
times (0.0045 cm2/0.00078 cm2) the elution profile for the device
with a 0.3 mm diameter exposed surface area. Thus, a zero order
elution profile with an elution rate of about 60 ng per day can be
obtained over a period of about 90 days. If the exposed surface
area is increased to about 0.0078 cm2, for example with many of the
exposed surface shapes as described above, the zero order elution
rat is about 100 ng per day over a period of about 90 days. The
concentration can also be increased from 1%. Similar elution
profiles can be obtained with Latanoprost.
Example 4
Latanoprost Elution Data
[0743] Drug cores were manufactured as described above in Example 1
with Latanoprost and silicone 4011, 6385 and/or NaCl. Four
formulations were manufactured as follows: A) silicone 4011,
approximately 20% Latanoprost, and approximately 20% NaCL; B)
silicone 4011, approximately 20% Latanoprost, and approximately 10%
NaCl; C) silicone 4011, approximately 10% Latanoprost, and
approximately 10% NaCl; and D) silicone 6385, approximately 20%
Latanoprost. FIG. 10A shows profiles of elution of Latanoprost form
the cores for four formulations of Latanoprost, according to
embodiments of the present invention. The results show initial
rates of approximately 300 ng per device per day that decreases to
about 100 ng per device per day by 3 weeks (21 days). The results
shown are for non-sterile drug cores. Similar results have been
obtained with sterile drug cores of Latanoprost. These data are
consistent with droplets of Latanoprost suspended in a drug core
matrix and substantial saturation of the drug core matrix with
Latanoprost dissolved therein, as described above.
Example 5
Drug Release as a Function of Crosslinking
[0744] FIG. 11A shows the effect on elution of material and
crosslinking on drug cores with 20% latanoprost, according to
embodiments of the present invention. Drug cores were manufactured
as described above with manufacturing methods as in FIG. 6E and
Table 1. The drug cores comprised 4011 silicone, 6385 silicone with
2.5% crosslinker, 6380 with 2.5% crosslinker and 6380 with 5%
crosslinker. The therapeutic agent in all samples comprised
approximately 20% latanoprost. The 6380 material with 5%
crosslinker provided the lowest elution rate at all time points. As
the 6380 material with 5% crosslinker elutes at a lower rate than
the 6385 material with 2.5% crosslinker, increased crosslinker and
concomitant crosslinking appears to decrease the rate of elution.
The 6385 material with 2.5% crosslinker provides the highest
elution rates at 1, 4, 7 and 14 days. The 6380 material with 2.5%
crosslinker has slightly lower elution rate at 1, 4, 7 and 14 days
than the 6385 material. Both the 6385 and 6380 materials elute
faster than the 4011 material that does not include a filler
material. The 4011, 6380 and 6385 materials comprise dimethyl
siloxane as the base polymer. As noted above, the 6385 material
comprises diatomaceous earth filler material, and the 6380 material
comprises silica filler material, indicating, based on the above
elution rates, that the inert filler material can increase the rate
of elution.
Example 6
Effect of Drug Concentration on the Elution of Latanoprost
[0745] FIG. 11B shows the effect of drug concentration on the
elution of latanoprost, according to embodiments of the present
invention. Drug cores were manufactured as described above with
manufacturing methods as in FIG. 6E and Table 1. The drug cores
comprised 6385 material with 5, 10, 20, 30 and 40% latanoprost,
respectively. The amount of tin-alkoxy cure system was 2.5% in all
samples. The release of latanoprost is weakly dependent on the
concentration of latanoprost at all time periods with 40% the
latanoprost material eluting at the highest rate and 5% latanoprost
eluting at the lowest rate. The elution rate for all samples falls
below 500 ng per day by 7 days and continues to be released at
therapeutic levels thereafter.
Example 7
Effect of Covering One End of the Drug Core Insert
[0746] FIG. 11C shows the effect of covering one end of the drug
core insert, according to embodiments of the present invention.
Drug cores were manufactured as described above with manufacturing
methods as in FIG. 6E and Table 1. The drug cores comprised 6385
material with 20% latanoprost. The elution rate of cut tubes as
described above was measured with both ends of each cut tube open,
referred to as both ends open. The elution rate of cut tubes with
one end exposed and one end covered with uv cured Loctite, as
described above, was measured, referred to as one end open. For
comparison, the elution rate for the drug core inserts with both
ends open divided by two is shown, referred to as "both ends
open/2". The both ends open/2 values are very close to the one end
open data at all time points, indicating that covering one end of
the drug core insert with an adhesive material that is
substantially impermeable to the therapeutic agent can inhibit the
release of therapeutic agent from the drug core, such that the drug
is effectively delivered through the exposed surface of the drug
core on the open end of the tube.
Example 8
Elution of Fluorescein and the Effect of Surfactant on Fluorescein
Elution
[0747] FIG. 12A shows the elution of fluorescein and the effect of
surfactant on fluorescein elution, according to embodiments of the
present invention. The elution data for fluorescein show the
flexibility of the above drug core and manufacturing processes for
the sustained release of many therapeutic agents, including both
water soluble and water insoluble therapeutic agents, and
relatively low molecular weight and high molecular weight
therapeutic agents. Fluorescein has a molecular mass of 332.32
g/mol, is soluble in water, and can serve as a model for the
release water soluble therapeutic agents released from the eye.
Work in relation with embodiments of the present invention
indicates that molecular weight and solubility in water can each
effect the release rate of the drug from the solid drug core
matrix. For example, lower molecular weight may increase diffusion
through the solid matrix material, i.e. through silicone, such that
low molecular weight compounds may be released more quickly. Also,
solubility in water can also effect the release rate of the drug,
and in some instances increased water solubility of the drug may
increase the rate of release from the solid drug core matrix, for
example via transport from the solid matrix material to the bodily
liquid, such as tear liquid. In accordance with these embodiments,
therapeutic agents with higher molecular weight than fluorescein
and with lower water solubility than fluorescein, for example
cyclosporin and prostaglandins as shown above, may be released from
the solid core at lower rates. Surfactants may also effect the rate
of release of the therapeutic agent from the drug core into the
surrounding bodily tissue and/or fluid, for example tear film
fluid.
[0748] Each drug core tested comprised MED 4011 silicone. In one
embodiments, a drug core formulation 1210 comprised 9% surfactant
and 0.09% fluorescein. An exponential fit 1212 is shown for the
elution rate of drug core formulation 1210. In another embodiment,
a drug core formulation 1220 comprised 16.5% surfactant and 0.17%
fluorescein. An exponential fit 1222 is shown for the elution rate
of drug core formulation 1220. In another embodiment, a drug core
formulation 1230 comprised 22.85% surfactant and 0.23% fluorescein.
An exponential fit 1232 is shown for the elution rate of drug core
formulation 1230. In an embodiment without surfactant, a drug core
formulation 1240 comprised 0% surfactant and 0.3% fluorescein. An
exponential fit 1242 is shown for the elution rate of drug core
formulation 1240.
[0749] The drug cores were manufactured with key formulations
comprising: Silicone Surfactant "190 Fluid" (Dow Corning);
Surfactant Mix: "190 Fluid"+Fluorescein; Silicone (Nusil): MED 4011
Part A, MED 4011 Part B; Centrifuge Tubes; 3 mL Syringe; 20 ga.
Needle; 0.031 inch inner diameter Teflon Tube; and Buffer.
[0750] Key parameters included: Prepare a mixture of 2.5 g of
silicone surfactant and 0.025 g of fluorescein; Prepare silicone
compositions of Nusil MED 4011 containing 3.5 g Part A and 0.37 g
Part B (10:1 ratio); Prepare four (4) centrifuge tubes each with
0.5 g of silicone and varying surfactant mixture weights as
follows: A. 0.05 g surfactant mix: 9% surfactant, 0.09%
fluorescein; B. 0.1 g surfactant mix: 16.5% surfactant, 0.17%
fluorescein; C. 0.15 surfactant mix: 22.85% surfactant, 0.23%
fluorescein; D. 0.0015 g fluorescein: 0% surfactant, 0.3%
fluorescein; Inject each of the four formulations into respective
teflon tubes using the syringe and needle; Cure the injected tube
at 140.degree. C. for 45 minutes in the oven; Cut each tube into 3
pieces in length to 4 mm; and Immerse each cut piece into a
centrifuge tube containing 0.3 mL of buffer.
[0751] Data collection comprised: Collect samples at time points
24, 48, 72, 192, and 312 hours; Submit each sample for UV
spectrometry analysis; Convert each elution rate from .mu.g/mL/hr
to .mu.g/cm2/hr by using the dimensions of the teflon tube (4 mm
length, 0.031 inch inner diameter); Plot data for elution rate vs.
time to compare the rates of each surfactant mix formulation.
[0752] Analysis comprised fitting trendlines for each elution rate
to an exponential curve, as shown in Table 4.
TABLE-US-00004 TABLE 4 Trendlines for each elution rate fit to
exponential curves. Sample # % Surfactant % Fluorescein R2
Trendline Equation A 9.0 0.09 0.9497 636.66 .times. -1.1161 B 16.5
0.17 0.8785 4289.6 .times. -1.3706 C 22.85 0.23 0.9554 1762.0
.times. -1.0711 D 0 0.30 0.9478 1142.1 .times. -1.2305
[0753] The trendline equations of table 4 indicate the following:
The data fit experimental curves well with R2 values of 0.8785 to
0.9554. The trendline equations shows exponent coefficients of
-1.0711 to -1.3706. Elution rates increased with increasing
surfactant levels. Despite relatively similar amounts of
fluorescein, there is a dramatic increase in elution rates between
Samples C and D--this demonstrates that the addition of surfactant
to the silicone matrix dramatically affects the elution rate of the
water-soluble compound. The elution rate of Sample A is comparable
to that of Sample D, even though Sample A contains only one-third
the amount of fluorescein. This also demonstrates that the rate of
elution can be affected by the addition of surfactant to the
silicone matrix.
[0754] Although the trendline equation exponent coefficients of
-1.0711 to -1.3706 are consistent with first order release, the
data include an initial 48 hour period in which bolus release of
fluorescein from the core is observed. Such an initial washout
period of 2 to 3 days with high levels of the therapeutic agent
delivered followed by a period of sustained release at therapeutic
levels can be helpful in some embodiments, for example where
elevated levels for a short period of time are tolerated and can
lead to an accelerated effect on the eye. Work in relation with
embodiments of the present invention suggests that after 48 hours
the elution data can be closer to zero order, for example within a
range from about zero order to about first order. In some
embodiments, the level of release therapeutic agent can be
decreased with a decreased exposed surface area of the drug core,
for example as described above, to release the drug at therapeutic
levels for sustained periods.
Example 9
The Effect of Sterilization on Elution of Therapeutic Agent
[0755] Work in relation to embodiments of the present invention
suggests that radicals generated in the sterilization process may
crosslink the drug core matrix material so as to inhibit the
initial release rate of therapeutic agent from the drug core matrix
material. In specific embodiments with e-beam sterilization, this
cross-linking may be limited to the surface and/or near the surface
of the drug core matrix. In some embodiments, a known Mylar bag can
be penetrated with the e-beam to sterilize the surface of the drug
core. In some embodiments, other sterilization techniques that
effect sterilization can be used, for example gamma ray
sterilization, and that are not limited to the surface of the drug
core and fully and/or uniformly penetrate the drug core
material.
[0756] Drug cores were synthesized and e-beam sterilized in Mylar
packaging, as described above. FIG. 13A shows the elution of
sterilized and non-sterilized drug cores. The sterile and
non-sterile drug cores each comprised 20% latanoprost in 6385
synthesized as described above. The drug cores were e-beam
sterilized and the elution rates measured as described above. The
sterile and non-sterile drug cores show elution rates for the first
day of about 450 and 1400 ng/day, respectively. At days 4 and 7,
the sterile and non-sterile drug cores show similar elution rates
at about 400 ng/day. At 14 day the sterile and non-sterile drug
cores show elution rates of 200 and about 150 ng/day, respectively.
These data show that sterilization may decrease an initial release,
or bolus, of the therapeutic agent, and that sterilization may be
used to provide a more uniform rate of release of the therapeutic
agent, for example in combination with embodiments described
above.
Example 10
The Effect of Salt on Elution of Therapeutic Agent
[0757] Work in relation to embodiments of the present invention
suggests that known salts, for example sodium chloride can effect
the rate of elution from the drug core.
[0758] FIG. 14A shows the effect of salt on the elution of
therapeutic agent. Drug cores comprising 20% bimatoprost (BT) and
silicone drug core matrix comprising NuSil 6385 were manufactured
as described above. Drug cores were manufactured with salt
concentrations of 0%, 10% and 20%. At 1 day the drug cores showed
elution rates of about 750 ng/day, 400 ng per day and about 100 ng
per day for 20%, 10% and 0%, respectively. At all time periods
measured to two weeks, the 20% salt data showed the highest elution
rate and the 0% salt data showed the lowest elution rate. This data
shows that salt, for example many known salts such as sodium
chloride, can be added to the matrix to increase the order of the
elution rate of therapeutic agent.
Example 11
Extraction of Therapeutic Agent from Drug Cores to Determine
Therapeutic Agent Yield
[0759] Drug core inserts comprising MED-6385 and 20% and 40%
latanoprost were synthesized as described above. Each drug core was
weighed and the weight of solid drug core material determined with
correction for the weight of the drug tube and adhesive. The amount
of therapeutic agent present in each sample was determined based on
the weight of drug core material and percentage of therapeutic
agent in the drug core material as described above. The therapeutic
agent was extracted from the drug cores with 1 ml aliquots of
methyl acetate. The concentration of therapeutic agent in the
solution for each sample was measured with reverse phase gradient
HPLC with optical detection and peak integration at 210 nm.
Measurements were taken for 6 drug cores with 20% latanoprost and 4
drug cores with 40% latanoprost. For the 20% samples, the average
extraction of latanoprost was 104.8% with a standard deviation of
about 10%. For the 40% samples, the average extraction of
latanoprost was 96.8% with a standard deviation of about 13%.
Example 12
High Pressure Filling
[0760] A two part silicone formulation (MED6385, Nusil
Technologies) was used in the preparation of a composite resin
containing latanoprost, which was used to fill a section of
polyimide sheathing. The sheathing containing the polymerized
silicone incorporates discrete latanoprost domains, existing in the
form of droplets of less than about 25 .mu.m maximum diameter,
within the matrix. Several experiments were conducted.
[0761] Part A of the MED6385 silicone formulation was mixed with
0.43 .mu.L of Part B, the tin catalyst, using syringes, to bring
about partial coagulation of the polymer over 30 minutes. Then, 37
mg of that material was mixed with a premixed solution of 0.14
.mu.L additional catalyst and 13 mg latanoprost, and that mixture
could be further mixed by sonication with an ultrasonic probe. The
resulting mixture was transferred to a syringe needle connected to
a HP7.times. syringe adapter, which is connected to an EFD pump,
which is in turn connected to a compressed air system and the
delivery pressure set to 40 psi. The silicone-latanoprost mixture
is then extruded down the length (10 cm) of polyimide tubing (IWG
High Performance Conductors, Inc.). When the viscous mixture
reached the bottom of polyimide tubing, clamps were applied at the
bottom of the tubing and at the top connection with the syringe
adapter, then pressure is released and the tubing section removed.
The clamped section of tubing was placed in a humidity chamber
(Thunder Scientific) for curing at 40.degree. C. and 80% relative
humidity (RH) for approximately 16-24 hrs.
[0762] To process the filled polyimide tubing containing the
now-solid matrix containing the latanoprost into individual drug
inserts, the filled precursor sheath was then cut into 1 mm
segments with a jig and a razor blade. One end of each of the 1 mm
segments was then sealed with Loctite 4305 UV Flash cure adhesive,
and cured with a Loctite UV wand. Each of the segments at this
point was ready for insertion into a punctal plug (Quintess)
adapted to receive the insert, sealed end inward.
Results
[0763] Scanning electron micrographs of the sheath containing the
cured matrix, i.e., the filled precursor sheath, are shown in FIG.
15A-D at the magnifications indicated. The inserts were sectioned
cryogenically. FIGS. 15A and 15B, respectively, show the insert
cores wherein the extrusion was carried at 40.degree. C. (A) or
25.degree. C. (B).
Example 13
[0764] The temperature of the mixture, and of the associated
apparatus involved in filling the polyimide sheath was held at
various temperatures during the injection process. Among the
temperatures used were a slightly elevated temperature (40.degree.
C.), approximate room temperature (25.degree. C.), and subambient
temperatures, such as 0.degree. C., -5.degree. C., and -25.degree.
C. The subambient injection procedures are provided in this
Example.
Manufacture of Latanprost/Silicone Mixture
[0765] The silicone formulation (MED6385) is a two part system.
Part A contains the silicone and crosslinker while Part B contains
the tin catalyst to promote crosslinking. The two parts are
combined in a final ratio of 200:1 (Part A:Part B). The required
amounts of Latanoprost, MED6385 Part A and B are weighed onto a
glass slide and mixed for approximately 2 minutes using a plastic
mini spatula. The weight or volume of components required to
prepare 50 mg of mixture to be extruded is presented in the Table
below.
Ratio of Components
TABLE-US-00005 [0766] Strength (.mu.g latanoprost/`plug) Part A
(mg) Part B (.mu.l) Latanoprost (mg) 3.5 47.8 0.21 2.2 14 41.1 0.18
8.9 21 36.7 0.16 13.3
Extrusion into Polyimide Tubing
Preparation of Syringe Extrusion System
[0767] 15 cm sections are threaded through a plastic luer adaptor
and glued in place using Loctite 4304 UV flash cure adhesive (FIG.
2). A 1 mL syringe (Henke Sass Wolf NORMJect) is modified by
cutting the tip of the plunger flush. The previously assembled
tubing/adaptor piece is inserted into the syringe barrel and
threaded through the luer outlet and fitted in place.
Extrusion
[0768] After the silicone/latanoprost mixing is complete, the
mixture is loaded in the barrel of the syringe extrusion system.
The plunger is inserted and excess air is removed. The syringe is
then ready to be loaded into the chilled extrusion apparatus. The
apparatus is an all stainless steel jacketed tube in a tube
sanitary welded heat exchanger and includes a gas purge that is
internally cooled by coiling inside the coolant side of the heat
exchanger. The operating temperature setpoint of the cooling system
shall be -10.degree. C. The temperature inside the heat exchanger
shall be uniform +/-2.5.degree. C. over the useable length of the
polyimide tubing. The steady state temperature of the cooling
system is to be verified prior to insertion of syringe and
tubing.
[0769] After setup, the EFD is activated and a silicone latanoprost
mixture is extruded down the length of the polyimide tubing. Once
the mixture reaches the bottom of the tubing, it can be visually
detected. The syringe including tubing is quickly removed from the
cooling system. The syringe is removed by cutting the tubing with a
razor blade; then the tubing is clamped on both ends.
Curing
[0770] The clamped section of tubing is placed in a humidity
chamber (Thunder Scientific) to be cured at 40.degree. C. and 80%
RH for approximately 16-24 hours.
Results
[0771] Scanning electron micrographs of the sheath containing the
cured matrix, i.e., the filled precursor sheath, are shown in FIG.
15A-D at the magnifications indicated. The inserts were sectioned
cryogenically. FIGS. 15C and 15D show the results of extrusions
carried out at 0.degree. C. and -25.degree. C. respectively. They
can be compared with FIGS. 15A and 15B that were carried out at
ambient temperature (25.degree. C.) or above (40.degree. C.).
[0772] Measurements of average inclusion diameters, and standard
deviation thereof, are as shown:
[0773] Cold extrusion (-5.degree. C.): 0.006.+-.0.002 mm (n=40
inclusion)
[0774] Room temp (22.degree. C.): 0.019.+-.0.019 mm (n=40
inclusion)
[0775] Measurements of average latanoprost content (.mu.g) per 1 mm
section (core) divided (razor blade) from a filled precursor tube
are as shown:
[0776] Cold extrusion (-5.degree. C.): 20.9.+-.0.5 (Average ISD)
RSD=2.4
[0777] Room temperature (22.degree. C.): 20.2.+-.1.9
(Average.+-.SD) RSD=9.4
Further Embodiments
[0778] While described above primarily with reference to treatment
of an eye, embodiments of the drug release structures described
herein may also find applications for treatment of a wide variety
of tissues to treat a range of differing disease states. In some
embodiments, these structures may be used for systemic and/or (more
commonly) localized elution of a therapeutic agent to treat cancer.
In embodiments used for chemotherapy, the matrix may be configured
to release of a therapeutic cocktail that is dependent upon the
primary tumor type. Use of a local delivery may be particularly
beneficial for treating a tumor site post-surgically, and may help
minimizing side effects and collateral damage to healthy tissues of
the body. In some embodiments, a lumpectomy for breast tumor and/or
or surgical treatment of prostate cancer can be treated. In many
embodiments, a tumor is targeted with positioning of the matrix
within and/or adjacent the targeted tumor. In some embodiments, the
implant may comprise a radioactive agent to treat the tumor in
combination with the therapeutic agent.
[0779] Still further alternative embodiments may facilitate elution
of a therapeutic agent into a tissue of an ear, into a mouth, into
a urethra, into a skin, into a knee joint (or other joint) of a
patient, or the like. Conditions of joints that can be treated
include arthritis and other joint diseases, and the therapeutic
agents that may be used may comprise (for example) at least one COX
II inhibitor, NSAIDs, and/or the like. Such localized use of NSAIDs
and COX II inhibitors may reduce the risks associated with systemic
use of these compounds. In some embodiments, the matrix may
comprise nutritional supplements like glucosamine to effect a
positive physiological response in local tissue of and/or near the
joint. Implants for elution of therapeutic agents into or adjacent
an intervertebral joint may be particularly advantageous. Similar
(or other) pain relievers, antibiotics, antimicrobials, and/or the
like may also be included in an implant for elution of one or more
therapeutic agent into a localized trauma. Implants (optionally
implants having structures derived from the punctual implants
described above may allow elution of one or more therapeutic agent
into a nasal cavity. Modifications or differences between such
nasal implants and the punctual implants described above may
include providing a passage for controlled release of medicated
tear fluid through the canilicular lumen. Alternative nasal tissue
structures may be quite different in overall form, optionally
including any of a variety of known nasal cavity drug release
shapes, but optionally taking advantage of one or more aspects of
the drug cores or other drug release structures described above for
long term release of one or more appropriate therapeutic
agents.
[0780] Still further alternative embodiments find application in
cosmetic uses. For example, these uses include administration of a
prostaglandin to enhance eye lash growth.
[0781] While the exemplary embodiments have been described in some
detail, by way of example and for clarity of understanding, those
of skill in the art will recognize that a variety of modification,
adaptations, and changes may be employed. For example, multiple
delivery mechanisms may be employed, and each device embodiment may
be adapted to include features or materials of the other, and
further multiple features or multiple materials may be employed in
a single device. Hence, the scope of the present invention may be
limited solely by the appending claims.
* * * * *
References